Entry of feline infectious peritonitis virus
in blood monocytes

Evelien Van Hamme

Thesis for obtaining the degree of
Doctor in Veterinary Sciences (Ph. D.), 2009

Promotor
Prof. Dr. Hans Nauwynck

Co-promotor
Dr. ir. Hannah Dewerchin
© 2009 by Laboratory of Virology, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium

The author and promotor give the authorization to consult and copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author.

Evelien Van Hamme was supported by a doctoral grant from the Special Research Fund (Bijzonder Onderzoeksfonds, BOF) of Ghent University (01D29005).
TABLE OF CONTENTS

List of abbreviations 7

Chapter 1: Introduction 11
  1.1 The feline infectious peritonitis virus 12
    1.1.1 Introduction - taxonomy 12
    1.1.2 Pathogenesis of the feline coronaviruses 13
    1.1.3 Structure of the virion 16
    1.1.4 Replication cycle 20
    1.1.5 Prevention and treatment 26
  1.2 Virus entry 28
    1.2.1 Introduction 28
    1.2.2 Receptors important for group 1 coronaviruses 28
    1.2.3 Receptor use by different coronaviruses 31
    1.2.4 Virus internalization 36
    1.2.5 Internalization of coronaviruses 48
  1.3 References 52

Chapter 2: Aims 73

Chapter 3: Kinetic analysis of attachment and internalization of feline infectious peritonitis virus 77

Chapter 4: Intriguing interplay between aminopeptidase N and DC-SIGN in feline infectious peritonitis virus type II entry in primary feline monocytes 99

Chapter 5: The mechanism of feline infectious peritonitis virus type II internalization in monocytes 121

Chapter 6: Genome release after endocytosis of feline infectious peritonitis virus type II in primary monocytes 145

Chapter 7: General discussion 159
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 8: Summary - Samenvatting</td>
<td>179</td>
</tr>
<tr>
<td>Curriculum vitae</td>
<td>193</td>
</tr>
<tr>
<td>Dankwoord</td>
<td>199</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>aa</td>
<td>amino acids</td>
</tr>
<tr>
<td>ACE2</td>
<td>angiotensin-converting enzyme 2</td>
</tr>
<tr>
<td>AEBSF</td>
<td>4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride</td>
</tr>
<tr>
<td>AP</td>
<td>adaptor protein</td>
</tr>
<tr>
<td>APN</td>
<td>aminopeptidase N</td>
</tr>
<tr>
<td>CALM</td>
<td>clathrin-assembly lymphoid-myeloid leukaemia</td>
</tr>
<tr>
<td>cav</td>
<td>caveolin</td>
</tr>
<tr>
<td>CCoV</td>
<td>canine coronavirus</td>
</tr>
<tr>
<td>CEACAM</td>
<td>carcinoembryonic antigen-related cell adhesion molecule</td>
</tr>
<tr>
<td>CHO (cells)</td>
<td>Chinese hamster ovary (cells)</td>
</tr>
<tr>
<td>CHO-DC-SIGN</td>
<td>CHO cells stably expressing DC-SIGN</td>
</tr>
<tr>
<td>Chol tox B</td>
<td>Cholera toxin B</td>
</tr>
<tr>
<td>c-lig</td>
<td>control ligand</td>
</tr>
<tr>
<td>CME</td>
<td>clathrin-mediated endocytosis</td>
</tr>
<tr>
<td>CPE</td>
<td>cytopathogenic effect</td>
</tr>
<tr>
<td>CrFK (cells)</td>
<td>Crandell feline kidney (cells)</td>
</tr>
<tr>
<td>DC</td>
<td>dendritic cell</td>
</tr>
<tr>
<td>DC-SIGN</td>
<td>dendritic cell-specific intercellular adhesion molecule (ICAM3) grabbing nonintegrin</td>
</tr>
<tr>
<td>DC-SIGNR</td>
<td>DC-SIGN related</td>
</tr>
<tr>
<td>dip</td>
<td>dynamin inhibitory peptide</td>
</tr>
<tr>
<td>DN</td>
<td>dominant-negative</td>
</tr>
<tr>
<td>dyn</td>
<td>dynamin</td>
</tr>
<tr>
<td>E</td>
<td>envelop (protein)</td>
</tr>
<tr>
<td>E-64</td>
<td>trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane</td>
</tr>
<tr>
<td>eFCoV</td>
<td>enteric feline coronavirus</td>
</tr>
<tr>
<td>ERGIC</td>
<td>ER tot Golgi intermediate compartment</td>
</tr>
<tr>
<td>fAPN</td>
<td>feline aminopeptidase N</td>
</tr>
<tr>
<td>FCoV</td>
<td>feline coronavirus</td>
</tr>
<tr>
<td>fDC-SIGN</td>
<td>feline DC-SIGN</td>
</tr>
<tr>
<td>FCS</td>
<td>foetal calf serum</td>
</tr>
<tr>
<td>Fcwf (cells)</td>
<td>Felis catus whole foetus</td>
</tr>
<tr>
<td>FIPV</td>
<td>feline infectious peritonitis virus</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>FIV</td>
<td>feline immunodeficiency virus</td>
</tr>
<tr>
<td>GEEC</td>
<td>GPI-anchored protein enriched endocytic compartments</td>
</tr>
<tr>
<td>GPI</td>
<td>glycosylphosphatidylinositol</td>
</tr>
<tr>
<td>hAPN</td>
<td>human aminopeptidase N</td>
</tr>
<tr>
<td>HCoV</td>
<td>human coronavirus</td>
</tr>
<tr>
<td>hDC-SIGN</td>
<td>human DC-SIGN</td>
</tr>
<tr>
<td>HIV1</td>
<td>human immunodeficiency virus 1</td>
</tr>
<tr>
<td>HR</td>
<td>heptad repeat</td>
</tr>
<tr>
<td>IBV</td>
<td>infectious bronchitis virus</td>
</tr>
<tr>
<td>IL-2R</td>
<td>interleukin-2 receptor</td>
</tr>
<tr>
<td>irr</td>
<td>irrelevant</td>
</tr>
<tr>
<td>L-SIGN</td>
<td>liver/lymph node specific ICAM3 nonintegrin</td>
</tr>
<tr>
<td>M</td>
<td>membrane (protein)</td>
</tr>
<tr>
<td>mAb</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>MDCK (cells)</td>
<td>Madin-Darby canine kidney (cells)</td>
</tr>
<tr>
<td>MHV</td>
<td>mouse hepatitis virus</td>
</tr>
<tr>
<td>moi</td>
<td>multiplicity of infection</td>
</tr>
<tr>
<td>N</td>
<td>nucleocapsid (protein)</td>
</tr>
<tr>
<td>ORF</td>
<td>open reading frame</td>
</tr>
<tr>
<td>PAK</td>
<td>p21-activated kinase</td>
</tr>
<tr>
<td>pAPN</td>
<td>porcine aminopeptidase N</td>
</tr>
<tr>
<td>PBS</td>
<td>phosphate buffered saline</td>
</tr>
<tr>
<td>PBS-G</td>
<td>PBS supplemented with gelatine</td>
</tr>
<tr>
<td>PEDV</td>
<td>porcine epidemic diarrhoea virus</td>
</tr>
<tr>
<td>PI3K</td>
<td>phosphatidylinositol 3-kinase</td>
</tr>
<tr>
<td>PRRCoV</td>
<td>porcine respiratory coronavirus</td>
</tr>
<tr>
<td>PRRSV</td>
<td>porcine reproductive and respiratory syndrome virus</td>
</tr>
<tr>
<td>RdRp</td>
<td>RNA-dependent RNA-polymerase</td>
</tr>
<tr>
<td>Rec X</td>
<td>unknown receptor ‘X’</td>
</tr>
<tr>
<td>RTC</td>
<td>replication-transcription complex</td>
</tr>
<tr>
<td>SARS</td>
<td>severe acute respiratory syndrome</td>
</tr>
<tr>
<td>TBS</td>
<td>Tris-buffered saline</td>
</tr>
<tr>
<td>TBS-GS</td>
<td>TBS supplemented with sucrose and inactivated goat serum</td>
</tr>
<tr>
<td>Tfn</td>
<td>transferrin</td>
</tr>
<tr>
<td>TGEV</td>
<td>transmissible gastroenteritis virus</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>TNF-α</td>
<td>tumour necrosis factor α</td>
</tr>
<tr>
<td>TRS</td>
<td>transcription-regulatory sequence</td>
</tr>
<tr>
<td>S</td>
<td>spike (protein)</td>
</tr>
<tr>
<td>WT</td>
<td>wild type</td>
</tr>
<tr>
<td>γc</td>
<td>common cytokine receptor γ</td>
</tr>
</tbody>
</table>
Chapter 1

INTRODUCTION
Chapter 1

1.1 THE FELINE INFECTIOUS PERITONITIS VIRUS

1.1.1 Introduction - taxonomy

Nidoviruses, members of the order *Nidovirales*, are one evolutionary lineage among the positive stranded RNA viruses. Their genome organization and the relatedness of their proteins involved in RNA replication and transcription ties them together and distinguishes them from other viruses (Siddell & Snijder, 2008). The *Nidovirales* enclose three families: the *Coronaviridae*, the *Arteriviridae* and the *Roniviridae*, found to be evolutionary distinct based on sequence analysis of their RNA-dependent RNA-polymerase (RdRp) (Gorbalenya et al., 2006). The *Coronaviridae* consist of two genera: *Coronavirus* and *Torovirus*. The coronavirus genus is further divided in three groups. Coronavirus species are grouped based on genetic and antigenic criteria (Gonzalez et al., 2003). Table 1 lists all recently accepted species of coronaviruses and situates them within one of the three groups. Further, the strains or biotypes of species often referred to in literature, are also mentioned. These coronaviruses are associated with either respiratory or enteric diseases (Siddell & Snijder, 2008).

Feline coronaviruses are found in group 1. Based on neutralization reactivity with specific antibodies, they are divided in two serotypes: I and II (Fiscus & Teramoto, 1987). Type I grows poorly in cell culture, while type II grows easily in many different cell lines (Pedersen et al., 1984). Type II has arisen from double recombination events between type I FCoVs and CCoV (Herrewegh et al., 1998). FCoV type I is the most prevalent serotype with a prevalence of approximately 85 % in Switzerland and Austria (Benetka et al., 2004; Kummrow et al., 2005).

Apart from the different serotypes, there are also two pathotypes or virulence variants. First there is the mild, mostly unapparent enteric feline coronavirus (eFCoV). Almost all Swiss cats and 17 % of the British cats are seropositive. Second, there is the systemic, highly lethal feline infectious peritonitis virus (FIPV). Approximately 5 % of the seropositive cats eventually develop FIPV (personal communication Dr Addie). This implies that 1 to 5 % of the European cat population is a potential victim of this infection.
Table 1: List of the currently known coronaviruses (adapted from Siddell & Snijder, 2008).

<table>
<thead>
<tr>
<th>CoV group</th>
<th>species</th>
<th>strains or biotypes</th>
<th>abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>Canine coronavirus</td>
<td>Canine coronavirus</td>
<td>CCoV</td>
</tr>
<tr>
<td></td>
<td>Feline coronavirus</td>
<td>(Enteric) feline coronavirus</td>
<td>(e)FCoV</td>
</tr>
<tr>
<td></td>
<td>(Feline infectious peritonitis)</td>
<td></td>
<td>FIPV</td>
</tr>
<tr>
<td></td>
<td>Human coronavirus 229E</td>
<td>Human coronavirus 229E</td>
<td>HCoV-229E</td>
</tr>
<tr>
<td></td>
<td>Porcine epidemic diarrhea virus</td>
<td>Porcine epidemic diarrhea virus</td>
<td>PEDV</td>
</tr>
<tr>
<td></td>
<td>Transmissible gastroenteritis virus</td>
<td>Transmissible gastroenteritis virus</td>
<td>TGEV</td>
</tr>
<tr>
<td></td>
<td>Bat coronavirus</td>
<td>Bat coronavirus</td>
<td>BtCoV</td>
</tr>
<tr>
<td></td>
<td>Rabbit coronavirus</td>
<td>Rabbit coronavirus</td>
<td>RbCoV</td>
</tr>
<tr>
<td>Group 2a</td>
<td>Canine respiratory coronavirus</td>
<td>Canine respiratory coronavirus 4182</td>
<td>CRCoV-4182</td>
</tr>
<tr>
<td></td>
<td>Bovine coronavirus</td>
<td>Bovine coronavirus</td>
<td>BCoV</td>
</tr>
<tr>
<td></td>
<td>Human coronavirus OC43</td>
<td>Human coronavirus OC43</td>
<td>HCoV-OC43</td>
</tr>
<tr>
<td></td>
<td>Human enteric coronavirus</td>
<td>Human enteric coronavirus</td>
<td>HECoV</td>
</tr>
<tr>
<td></td>
<td>Murine hepatitis virus</td>
<td>Murine hepatitis virus JHM</td>
<td>MHV-JHM</td>
</tr>
<tr>
<td></td>
<td>Porcine hemagglutinating</td>
<td>Porcine hemagglutinating</td>
<td>HEV</td>
</tr>
<tr>
<td></td>
<td>encephalomyelitis virus</td>
<td>encephalomyelitis virus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Puffinosis coronavirus</td>
<td>Puffinosis coronavirus</td>
<td>PCoV</td>
</tr>
<tr>
<td></td>
<td>Rat coronavirus</td>
<td>Rat coronavirus</td>
<td>RtCoV</td>
</tr>
<tr>
<td></td>
<td>Sialodacryoadenitis</td>
<td>SDAV</td>
<td></td>
</tr>
<tr>
<td>Group 2b</td>
<td>Severe acute respiratory syndrome virus</td>
<td>Severe acute respiratory syndrome virus</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td></td>
<td>Bat coronavirus</td>
<td>Bat coronavirus 133/2005</td>
<td>BtCoV-133/2005</td>
</tr>
<tr>
<td>Group 3</td>
<td>Infectious bronchitis virus</td>
<td>Infectious bronchitis virus</td>
<td>IBV</td>
</tr>
<tr>
<td></td>
<td>Pheasant coronavirus</td>
<td>Pheasant coronavirus</td>
<td>PhCoV</td>
</tr>
<tr>
<td></td>
<td>Turkey coronavirus</td>
<td>Turkey coronavirus</td>
<td>TCoV</td>
</tr>
</tbody>
</table>

1.1.2 Pathogenesis of the feline coronaviruses

Feline enteric coronavirus (eFCoV)

Feline enteric coronavirus is a ubiquitous, worldwide intestinal virus (Pedersen et al., 1981; 2004). The importance of eFCoV as a primary intestinal pathogen is however minimal as the infection is usually unapparent or manifested by a transient gastroenteritis (Pedersen et al., 1981; Hayashi et al., 1982; Pedersen et al., 2008).
The virus is spread by fecal-oral route. eFCoV has a tropism for enterocytes in the epithelium of intestinal villi (Pedersen et al., 1981). During the course of a natural infection some eFCoVs may be detected in the blood, but much less than seen with FIPV (Meli et al., 2004). Further, virus can also be detected in mesenteric lymph nodes, spleen, bone marrow, tonsils and thymus (Pedersen et al., 1984; Herrewegh et al., 1995; Gunn-Moore et al., 1998). Obviously, infection leads to systemic disease. Virus shedding occurs within a week after exposure and remains at high levels for 2 to 10 months. Then, it evolves into one of three excretion patterns: some cats shed the virus persistently, some have periods of shedding interlaced with periods of non-shedding (recurrent shedders) and some just cease shedding (Pedersen et al., 2008). Immunity generated upon infection is slow to develop, variable in strength and duration and lacks memory explaining why reinfection can occur easily (Addie et al., 2003; Pedersen et al., 2008).

The importance of eFCoV lies in its potential to mutate in vivo into a biotype that causes the highly fatal disease, feline infectious peritonitis (Poland et al., 1996; Vennema et al., 1998). Mutations that might be responsible for the FIPV biotype were identified in the 3c gene and/or to a lesser extent in the 7b gene (Vennema et al., 1998). Pedersen claims that eFCoVs and FIPVs can be discriminated based on the 3c gene (Pedersen, 2009). The acquisition of an enhanced macrophage tropism is also essential for the development of FIP. Rottier et al. showed that the C-terminal domain of the spike protein is the determinant for efficient macrophage infection and that it distinguishes eFCoV strains from FIPV strains (2005). Taken together, these results suggest that the mutational transition between eFCoV and FIPV requires mutations in both the spike and the accessory gene(s). The higher the level of eFCoV replication, the more chance a mutation occurs and the cat develops FIP. Therefore, FIPV arises mostly during primary eFCoV infection and in kittens (Pedersen et al., 2008).

**Feline infectious peritonitis virus (FIPV)**

The evolution from eFCoV to FIPV is accompanied by the acquisition of an enhanced macrophage tropism (Stoddart & Scott, 1989; Rottier et al., 2005). Circulating blood monocytes are the predominate target cells for FIPV. These are migratory cells and after infection, they may pass through the endothelium of small vessels and initiate infection in various parts of the body (Fenner et al., 1974; Weiss & Scott, 1981). Targets are the mesenteric lymph nodes, serosal surfaces of the gut and organs, and to a lesser extent the pleura, and the omentum. Some virus also appears to reach the meninges, the ependyma...
surrounding the ventricles, the spinal cord, and the uveal tract and retina of the eyes (Pedersen, 2009).

Subsequent inflammatory reactions at these locations can lead to intravascular coagulation and vasculitis (Weiss et al., 1980). Circulating immune complexes sediment in small vessels leading to complement activation. This triggers vasodilatation and the release of chemotactic mediators which attract monocytes. Therefore, inflammation is associated with expanding cycles of monocyte/macrophage infection, virus replication and release. Released virions in turn infect the attracted macrophages and the infection site expands dramatically. This reaction is centered on small venules and the result is a lesion called pyogranuloma (Pedersen & Boyle, 1980; Jacobse-Geels et al., 1980; 1982). Further, FIPV-induced vasculitis is characterized by macrophage-dominated circul ar infiltrates in small veins and focal infiltrates in larger veins. Activated monocyte attachment to endothelial cells, subsequent emigration and perivenous macrophage accumulation cause the destruction of the vascular basal lamina through the secretion of matrix metalloproteinase B. This results in vasculitis and possible leakage (Kipar et al., 2005).

There are two forms of FIPV: wet/effusive FIPV and dry/non-effusive FIPV. Wet/effusive FIPV is characterized by leakage of protein-rich fluid into the peritoneal cavity or (less frequent) the pleural or cardiac cavity. Effusion in the peritoneal cavity leads to the typical physiology of a skinny FIP cat with a swollen abdomen. Often dry FIPV eventually evolves to wet FIPV when the immune system totally collapses. When a cat develops dry FIPV, it is believed that the animal is partially protected against infection by the cellular immune system.

Virus specific antibodies fail to control or clear the infection despite the presence of high titers (Paltrinieri et al., 1998). They even seem to facilitate infection. First, this may be explained by the occurrence, at least in vitro, of antibody-dependent enhancement (ADE) of infection of macrophages (Hohdatsu et al., 1991; Olsen et al., 1992). The in vivo relevance of ADE of infection is questioned as in natural infections of seropositive animals no enhancement of infectivity seems present. Seropositive cats showed a normal FIP progression and did not die more rapidly (Addie et al., 1995). Second, antibodies mediate internalization of surface expressed viral proteins on infected cells, making the infected monocyte invisible for the immune system (Dewerchin et al., 2007; Cornelissen et al., 2007). Further, despite the presence of antibodies and complement, there is no antibody-dependent complement-mediated lyses of infected monocytes (Cornelissen et al., 2009).

The humoral immune response is obviously not capable of successfully fighting the infection. Protection or partial protection against FIPV is therefore supposed to be cell-mediated. It is
suggested that the efficacy of early T-cell responses critically determines the outcome of infection (de Groot-Mijnes et al., 2005). Nevertheless, the cell-mediated immune system is also targeted by the FIP virus. In FIPV infected cats, T-cell depletion occurs in both lymphoid tissues and in the blood (Kipar et al., 2001; Paltrinieri et al., 2003; de Groot-Mijnes et al., 2005). This T-cell depletion is caused by a soluble factor, possibly glycoprotein 7b (see further in 1.1.3.2), present in the supernatant of infected cells, through apoptosis (Haagmans et al., 1996). Much remains to be learned on cell-mediated immunity in FIPV infection. This knowledge is indispensable for a better understanding of the pathogenesis of FIPV.

1.1.3 Structure of the virion

1.1.3.1 Genomic organization

FIPV contains an extremely large positive-stranded RNA genome of 29 125 nt in length excluding the poly(A) tail, with a 5’ cap (Fig. 1) (Dye & Siddell, 2005). The replicase gene encompasses two thirds of the genome and consists of 2 open reading frames (ORFs), ORF 1a and 1b. ORF 1a encodes polyprotein pp1a, while ORF 1a and 1b together encode pp1ab through a ribosomal frameshift during translation of genomic RNA (Brierley, 1995). The polyproteins are processed by viral proteinases to 16 non-structural proteins (Ziebuhr et al., 2000). These replicase proteins assemble to form the membrane-bound replication-transcription complex (RTC) in the cytoplasm of the cell (Gosert et al., 2002). ORFs 2, 4, 5 and 6 encode the structural proteins that are incorporated in the virion. ORFs 3 and 7 encode the accessory proteins. Expression of genes 2-7 occurs from a nested set of subgenomic mRNAs with a common leader sequence (Fig. 1). mRNA synthesis is controlled by a transcription-regulatory sequence (TRS) (Haijema et al., 2007).
1.1.3.2 Viral proteins

Figure 2: Schematic representation of a FIPV virion (Dewerchin, 2008).

Spike protein
The large petal-shaped spikes determine the characteristic morphology of the coronavirus virion. These protrusions of approximately 20 nm are formed by trimers of the monomeric spike (S-) protein (Fig. 2). The nascent S polypeptide is directed to the ER by a signal peptide (Masters, 2006). During maturation in the ER, S is heavily glycosylated and the ~150-200 kDa monomers form trimers. S-trimers are incorporated in virions by associating with the membrane protein during the budding process in the ER-to-Golgi intermediate compartment (ERGIC).
The spike protein is responsible for diverse interactions that are critical for establishing and maintaining infection in the host. First, the spike protein determines host range by inducing viral entry after specific interaction with its receptor (Dye et al., 2007). Second, the spike protein contains epitopes important for antibody neutralization and on the other hand for various immune evasion processes, namely antibody-mediated enhancement of infection and antibody-induced internalization of viral proteins expressed in the plasma membrane (Hohdatsu et al., 1991; Hohdatsu et al., 1994; Dewerchin et al., 2006).

Coronavirus spike proteins are class I fusion proteins and they are primed for fusion through cleavage with furin (Bosch et al., 2003). However, the group 1 coronaviruses, including FIPV, are generally considered to carry uncleaved S-proteins. Regan et al. claim that the FCoV S-protein is cleaved by cathepsins (2008), while de Haan et al. state that cathepsin cleavage does not occur (2008). Instead, they showed that some specific group 1 coronavirus spikes carried a furin enzyme recognition motif that could be lost by a single mutation upon culture adaptation resulting in a heparin binding motif (de Haan et al., 2008).

**Envelope protein**

The envelope (E-) or small membrane protein is a small protein of approximately 10 kDa that is expressed in virions and infected cells in small amounts. E-protein is an integral membrane protein whose highly hydrophobic N-terminal two thirds region is a transmembrane domain that spans the bilayer twice (Fig. 2) (Maeda et al., 2001). The C-terminal region extends into the virion interior. Through its interaction with M-protein, E-protein is necessary for envelope formation and budding (Lim & Liu, 2001). To fulfil its task, E-protein is retained in the pre-Golgi membranes of the intermediate compartment, prior to virus budding in the ERGIC.

**Membrane protein**

The coronavirus membrane or M-protein is a protein, ranging from 20-38 kDa according to glycosylations, that spans the viral envelope three times, leaving only small parts ‘hanging out’ on either side of the membrane (Fig. 2) (Rottier et al., 1986). M is supposed to be the determinant for the intracellular budding site. It is localized in the Golgi region which correlates with the ER to Golgi intermediate compartment (ERGIC) being the budding site (Rottier & Rose, 1987). By associating with the S-protein, the M-protein retains it at the budding site and prevents transport of S to the plasma membrane (Opstelten et al., 1995). Probably the M-protein may be involved in viral entry in monocytes/macrophages as there are neutralizing antibodies against M (Kida et al., 2000). Upon addition of antibodies,
surface-expressed M-protein is internalized (like described above for S-protein), so this protein is also involved in this immune evasion process (Dewerchin et al., 2006).

Nucleocapsid protein

N-protein is a 42.7 kDa protein, highly phosphorylated on serine residues (Spaan et al., 1988). After phosphorylation in the cytoplasm, the proteins become associated with intracellular membranes (Stohlman et al., 1983). N-proteins interact with viral RNA and stabilize the helical symmetric nucleocapsid structure that is packaged into virions (Fig. 2) (Zuniga et al., 2007). Antibodies against N-protein were able to block viral RNA transcription, suggesting another potential role for N-protein in infection (Compton et al., 1987; Baric et al., 1988). This is confirmed by the co-localization of N-protein with the replication complex in the sites of RNA synthesis at early times post-infection (Denison et al., 1999). Next to its presence at the replication site, N also accumulates in the Golgi region near the budding site and co-localizes with the viral spike (Stertz et al., 2007). N-M interactions might also be important for viral structure (Sturman et al., 1980).

Accessory proteins

All coronaviruses encode a number of accessory proteins in group-specific genes, that are thought to be dispensable for replication in cell culture, but apparently provide a selective advantage in vivo (de Haan et al., 2002; Ortego et al., 2003). For FIPV 79-1146, two regions of the genome have been identified that encode putative accessory proteins. They are known as ORFs 3abc and 7ab (Fig. 1). The gene products and function of ORF 3abc remain to be identified. The predicted size of the protein encoded by ORF 7a is 11 kDa. ORF 7b is known to encode a non-structural, secretory viral glycoprotein ‘gp7b’ of 26.5 kDa (Vennema et al., 1992). This secretory factor might be responsible for the observed induction of T-cell depletion during FIPV pathogenesis (Haagmans et al., 1996). The importance of the accessory proteins in FIPV pathogenesis was illustrated by the development of a live, attenuated vaccine by deletion of the group-specific genes from FIPV 79-1146 (Haijema et al., 2004).
1.1.4 Replication cycle

1.1.4.1 Virus entry

The process of virus entry, including binding to virus receptor(s), internalization into the cell and eventually uncoating or release of the genome in the cytosol will be discussed in detail in part 1.2 (Fig. 5, step 1-3). After release of the genome, replication and transcription can start in the cytoplasm of the infected cell. Replication is the process whereby genome-sized RNA, which also functions as mRNA, is produced. Transcription is defined as the process whereby subgenome-sized mRNAs are produced (Sawicki et al., 2007).

1.1.4.2 Replication

The 16 non-structural proteins encoded in ORF 1 are directly translated upon ‘arrival’ in the cytoplasm (Fig. 3 & Fig. 5, step 4). Together with viral N-protein and, possibly, cellular proteins, they assemble into the membrane-bound replication-transcription complex (RTC). In these complexes the production or copying of the genome- or subgenomic length RNA occurs. RTCs accumulate at perinuclear regions and are associated with double-membrane vesicles (Brockway et al., 2003; Snijder et al., 2006) (Fig. 5, step 5). The non-structural proteins include proteinase, polymerase and helicase (Snijder et al., 2003). The RTC copies the genome either continuously into genome-length template or discontinuously into various subgenome-length minus-strand templates. The minus-strand genomic template is used for genome synthesis (Fig. 4) (Sawicki et al., 2007).
Translation of non-structural proteins

**Figure 3:** Translation of the non-structural proteins encoded by open reading frame (ORF) 1.

- **POL 1a**
- **S**
- **E**
- **M**
- **N**
- **3a-c**
- **7a-b**

leader sequence | slippery sequence | poly(A) tail

**ORF 1**

- **ORF 1a**
- **ORF 1b**

translation by cellular ribosomes

**pp1a**

translation stops at 1st stop codon

**pp1ab**

translation continues after ribosomal frameshift

viral proteinases

16 non-structural proteins

including proteinases, polymerase and helicase

assembly into membrane-bound replication-transcription complex

---

represents positive-strand RNA.  represents protein. pp stands for polyprotein.
Chapter 1

1.1.4.3 Transcription

Coronavirus transcription is characterized by the generation of a nested set of mRNAs, with each mRNA having the identical “leader” sequence (Fig. 1). During subgenome-length minus-strand mRNA synthesis, the nested set of mRNAs is generated through discontinuous extension (Sawicki & Sawicki, 1995). Each subgenome-length mRNA contains a 5’ leader sequence corresponding to the 5’ end of the genome. This 5’ leader is joined to a mRNA “body”, which represents sequences from the poly(A) stretch to a position that is upstream of each genomic ORF encoding a structural or accessory protein (cluster). The junction between leader and the mRNA body in each mRNA is called the transcription regulatory sequence (TRS) of about 10 nucleotides (Fig. 4) (Sawicki et al., 2007). The process of discontinuous transcription during minus-strand synthesis starts by the recruitment of the components of a functional RTC and the initiation of synthesis at the 3’ end of the genomic RNA until the first TRS is encountered. Then, some RTCs will just continue the synthesis, while a fraction will stop strand synthesis and relocate to the 5’ end of the genome to the leader. As there are 7 TRSs, there are 7 minus-strand mRNAs synthesized including the genomic mRNA template (Fig. 5, step 6). When the nested set of minus-strand subgenomic mRNAs is generated, positive-strand genomic and subgenomic mRNAs are produced as templates for translation (Fig. 4).
Figure 4: Genome replication and transcription. —— represents minus-strand RNA. —— represents positive-strand RNA.
1.1.4.4 Translation

Viral (sub)genomic mRNAs resemble host mRNAs and are recognized by the host translation machinery (Fig. 5, step 7). The initiation of translation occurs through ribosomal scanning starting at the 5’ cap structure provided by the 5’ leader to an AUG codon (Kozak, 1989). Protein synthesis then continues until a termination codon is encountered and the ribosome complex detaches from the RNA. Coronavirus mRNAs are structural polycistronic but can be both functional monocistronic as polycistronic, the latter when a coding sequence contains more than one translational active ORF.

Little is known about the regulation of translation. For functionally monocistronic RNAs, the level of protein expression depends on the amount of mRNA and therefore transcription. However, there are some indications that the leader sequence may influence translation levels (Luytjes et al., 1995). For the polycistronic mRNAs the mechanisms are more evident. The best known example is the ribosomal -1 frameshift in ORF 1 made by one third of the ribosomes on the slippery sequence AAAUUUC (Brierley et al., 1987; Bredenbeek et al., 1990).

N-proteins are expressed in the cytosol, while S, E and M are co-translationally embedded in the membranes of the rough ER.

1.1.4.5 Budding

Positive-strand genomic RNA interacts with N-protein in the cytosol to form the nucleocapsid (Fig. 5, step 7b). The viral structural proteins S, E and M migrate from the membranes of the ER to the ER-to-Golgi intermediate compartment (ERGIC). The presence of the E-protein is essential for efficient assembly (Lim & Liu, 2001). In the ERGIC, the nucleocapsid is surrounded by an envelope containing viral proteins through the interaction between M- and N-protein as the budding process proceeds (Fig. 5, step 8).

It has not been established how the virus spreads to other cells. Egress via exocytosis could occur at lower levels of virus production and leaves the infected cell intact. Replication could also result in lysis and destruction of the host cells, releasing all produced virions (Baker, 2008).
Figure 5: Replication cycle of FIPV. 1-2 Binding and internalization. 3 Release of the genome into the cytosol. 4 Translation of the 16 non-structural proteins. 5 Assembly of the RTC. 6 Genome synthesis and transcription to mRNAs. 7 Translation mRNAs to proteins. 7b Association of N proteins and genome to form nucleocapsid. 8 Accumulation of viral proteins in the ERGIC for budding into new virions. 9 Transport through the secretory pathway. 10 Release of progeny virus (Dewerchin, 2008).
1.1.5 Prevention and treatment

1.1.5.1 Prevention
Many attempts were made in the past to induce protective immunity against the development of FIP in cats through vaccination. Most of these attempts failed and even led to accelerated disease. The enhancement of disease was probably due to the induction of a humoral immune response rather than a protective, cellular immune response. The first and only commercially marketed vaccine is Primucell FIP®®, a temperature-sensitive mutant of FIPV that is applied as a modified live vaccine. It induces a strong mucosal immune response (IgA) and a cell-mediated immune response measured by lymphocyte proliferation (Gerber et al., 1990). The vaccine does not offer full protection and needs to be administered frequently. The usefulness of this vaccine is being questioned as it only works when administered to seronegative cats. Further promising results - also with a modified live FIP vaccine - were obtained by Haijema et al. through vaccination with deletion mutants of a serotype II FIPV strain lacking the group specific genes 3a-c or 7ab (2004). The mutants replicate well in cell culture and show an attenuated phenotype in cats. Vaccinated cats are protected against a lethal homologous challenge. An extension of these data with challenges with serotype I strains are being expected.

Another strategy to prevent or at least minimize FIPV infection is reducing the FCoV infection pressure in households. This can be achieved by separating seronegative from seropositive animals and applying high hygiene standards.

1.1.5.2 Treatment
As FIP is an immune-mediated disease, treatment is mostly aimed at controlling or modulating the immune response. Glucocorticoids are often used in an attempt to slow disease progression but do not provide a cure. The antiviral drug ribavirin, a nucleoside analogue, is active against FCoV in vitro but cannot be used to treat cats as it causes severe side effects when administered in vivo (Weiss et al., 1993). In cats treated with a combination of human interferon-α and Propionibacterium acnes, the mean survival time was prolonged for a couple of days (Weiss et al., 1990). The latest strategy in the search for an effective treatment is combining feline interferon-ω with glucocorticoids. While some results indicate prolonged survival, others did not (Ishida et al., 2004; Ritz et al., 2007).

Clearly, there is no effective treatment available for FIPV. When a cat is diagnosed with FIP, it will most likely die.
The development of an effective vaccine or treatment for FIP remains a huge challenge in CoV research.
1.2 VIRUS ENTRY

1.2.1 Introduction

Essential for a virus to cause infection is gaining entry into a cell. For a number of steps in the viral replication cycle, the virus relies on cellular factors and mechanisms to guide the way. Virus entry is a multistep process during which each step is pre-programmed and tightly regulated in space and time (Smith & Helenius, 2004). Virus entry starts with recognition of the target cell through cell surface receptors or attachment factors. These can vary from being abundant and ubiquitous to rare and cell specific. Receptors often determine the cell type that can be infected. They can be just binding receptors that capture the virus or they can be ‘true’ receptors that also lead the virus across the plasma membrane (Smith & Helenius, 2004). The internalization of the virus into the cell is the second step in the entry process. The viral membrane can fuse directly with the host cell plasma membrane or the virus particle can be endocytosed in a vesicle pinched off the plasma membrane. Upon direct fusion, the viral genome is delivered directly into the cytosol. Upon endocytosis, a further uncoating of the virion is necessary (Lanzrein et al., 1994). Uncoating can be triggered by a number of factors, eg interaction with an additional receptor, exposure to low pH or reimmersion into a reducing environment (Smith & Helenius, 2004). Uncoating results in release of the genome from the vesicle into the cytosol where transcription, and translation by the host cell ribosomes can start. For most RNA viruses, no transport to the nucleus is required.

1.2.2 Receptors important for group 1 coronaviruses

1.2.2.1 Aminopeptidase N

Aminopeptidase N (APN) or CD13 is a type II metalloprotease that belongs to the M1 family of the MA clan of peptidases (Rawlings & Barret, 1999). The ‘MA’ clan of peptidases is the first (‘A’) clan of metallopeptidases (‘M’). Human APN is an integral membrane protein of approximately 967 amino acids (aa) and 110 kDa (Sjöström et al., 2000). Structural studies show that it consists of 7 domains (Fig. 6). Domain I is a short cytoplasmic N-terminal domain of only 8 to 10 aa. No signalling sequences have been found in this domain, therefore it has been suggested that APN signals over the membrane via an auxiliary
membrane protein (Sjöström et al., 2000). Domain II is a single transmembrane part. The large cellular ectodomain contains a stalk region (domain III) that ‘carries’ the four globular-like domains (domain IV to VII). The Zn-dependent active catalytic site for the enzyme preferentially releases N-terminal neutral or basic residues of oligopeptides and is located between domain V and VI. In most species aminopeptidase N forms homodimers (Sjöström & Norén, 1982). The interaction between monomers is non-covalent and localized within domains V to VII. The charged C-terminal helix at domain VII might be involved in dimerisation. Dimerisation occurs before Golgi-associated processing, suggesting that this might be crucial for the transport of the intracellular high-mannose form of APN out of the ER (Danielsen, 1990a,b). In the Golgi, APN is N- and O-glycosylated (Fig. 6) (Sjöström et al., 2000).

![Diagram](image)

**Figure 6:** Model of aminopeptidase N. The monomer consists of 7 domains and is highly glycosylated. APN forms non-covalently linked homodimers.

Aminopeptidase N is both ubiquitous and multifunctional (Luan & Xu, 2007). It is present in a number of organs, tissues and cell types including endothelial and epithelial cells, and fibroblasts and leukocytes. It is, among other processes, related with tumorigenesis, trimming of antigen and the process of antigen presentation, and serves as a receptor for several pathogens. The function that APN plays, depends on the location and tissue of origin (Nocek et al., 2007). In monocytes, APN is linked with signal transduction pathways. Crosslinking of APN leads to an increase in intracellular Ca\(^{2+}\) ions and phosphorylation of mitogen-activated (MAP) kinases. Phosphatidylinositol 3 kinases (PI3K) are linked with this signalling cascade as well (Navarrete Santos et al., 2000). APN can also functionally associate with receptors for immunoglobulin G (Fc\(\gamma\)Rs) and may act as a signal regulator of Fc\(\gamma\)R function (Mina-Osorio & Ortega, 2005).
Human aminopeptidase N also mediates human cytomegalovirus infection in lung fibroblasts by binding, and possibly internalizing, virus to these susceptible cells (Söderberg et al., 1993).

Most group 1 coronaviruses can use aminopeptidase N of their natural host as receptors (see further in 1.2.3.1).

### 1.2.2.2 DC-SIGN and L-SIGN

The dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN) or CD209 and its close relative DC-SIGNR (DC-SIGN related) or L-SIGN (liver/lymph node-specific) or CD209L are type II transmembrane proteins and members of the C-type lectin family. DC-SIGN and L-SIGN consist of four domains: a cytoplasmic domain necessary for signalling with a di-leucine motif for internalization and a tri-acidic cluster for targeting to proteolytic vacuoles, a single-spanning transmembrane region, a region with a series of seven and a half repeats of 23 aa and a carbohydrate-recognition domain (CRD) (Fig. 7) (Snyder et al., 2005). The extracellular domain of each receptor is a tetramer of approximately 145 kDa stabilized by an $\alpha$-helical stalk or neck. DC-SIGN and L-SIGN recognize specifically high-mannose carbohydrates through the CRDs. The binding depends on $\text{Ca}^{2+}$ and can be inhibited by mannann, mannose and EGTA. When the CRDs are clustered in the tetrameric extracellular domain, their arrangement provides a means of amplifying specificity for multiple glycans on host molecules targeted by DC-SIGN and L-SIGN (Mitchell et al., 2001).

![Figure 7: Structure of the extracellular domains of DC-SIGN. A) Model of tetrameric DC-SIGN with the carbohydrate-recognition domain (CRD) and the $\alpha$-helical stalk. B) Predicted model based on homology modelling and sequence-based prediction of secondary structure elements showing the repeats in the $\alpha$-helical stalk (adapted from Snyder et al., 2005).](image-url)
DC-SIGN is highly expressed in monocyte- and CD34+-derived dendritic cells (DCs) and in subsets of mature and immature DCs at various sites. L-SIGN is not expressed by these cells but by endothelial cells in lymph nodes, liver and lungs. Both DC-SIGN and L-SIGN act as cell adhesion and pathogen-recognition receptors (Khoo et al., 2008). As pathogen recognition receptors, both lectins recognize a wide range of micro-organisms. DC-SIGN captures viruses like human immunodeficiency virus 1 (HIV1), Ebola virus, hepatitis C virus, Dengue virus, cytomegalovirus and severe acute respiratory syndrome coronavirus (Alvarez et al., 2002; Geijtenbeek et al., 2000; Halary et al., 2002; Lozach et al., 2003; Pöhlmann et al., 2003; Tassaneetrithep et al., 2003; Marzi et al., 2004; Jeffers et al., 2004; Yang et al., 2004). Unlike L-SIGN that seems to function solely as an adhesion receptor, DC-SIGN is thought to mediate endocytosis next to adhesion, more specifically as a recycling receptor that releases its ligand at endosomal pH (Khoo et al., 2008). Both DC- and L-SIGN might also function as antigen-capturing receptors that bind antigens at the cell surface and internalize them into a low pH endosomal compartment for release and degradation for loading onto major histocompatibility complex molecules (Khoo et al., 2008).

The interaction between DC-SIGN and some viruses is well studied. DC-SIGN captures HIV1 from the periphery to transport it via unsusceptible DCs into the secondary lymphoid organs where it is transmitted to susceptible T-cells to enhance infection in trans (Geijtenbeek et al., 2000). For hepatitis C virus, both DC-SIGN and L-SIGN function as attachment factors possibly to target virus to the site of replication. DC-SIGN might facilitate entry into DCs in cis. While binding to L-SIGN on endothelial cells in the liver, might concentrate the virus in this target organ and enhance infection in trans (Lozach et al., 2003; Pöhlmann et al., 2003).

Some group 1 coronaviruses can interact with DC-SIGN or L-SIGN (see further in 1.2.3.1).

**1.2.3 Receptor use by different coronaviruses**

**1.2.3.1 Group 1 coronaviruses**

**Feline coronaviruses (FCoV)**

Feline aminopeptidase N (fAPN) can serve as a receptor for feline coronaviruses as well as canine, porcine and human coronaviruses. This was concluded after the observation that transfection with cDNA coding for fAPN isolated from a feline cell line, led to infection of non-susceptible cells (Tresnan et al., 1996). However, the efficiency of inducing infection was different between FCoV serotype I and II strains. Later, Hohdatsu et al. explained this
difference by showing that fAPN was only a receptor for FCoV serotype II, but not serotype I (1998). This study was based on the capability of a monoclonal antibody (R-G-4) to block infection of various cell lines with type II FCoV strains, but not type I strains. Dye et al. confirmed the inability of type I feline coronavirus spike proteins to recognize aminopeptidase N as a receptor on cell lines (2007).

Different regions of fAPN are involved in the interaction with different viruses. According to Hegyi & Kolb, aa 670 to 840 are necessary for the FCoV and transmissible gastroenteritis virus (TGEV) receptor function whereas aa 135 to 297 are essential for the human coronavirus 229E (HCoV-229E) receptor function (1998). Tusell and coworkers also performed a mutational analysis to refine the knowledge on aa regions of APN that are determining viral host range (2007). Three small, discontinuous regions in fAPN determine the host ranges of FCoV, TGEV, CCoV and HCoV-229E. They are located from aa 288-290, aa 732-746 and aa 764-788. The first region from aa 288-290, is essential for HCoV-229E. TGEV requires the second region from aa 732-746, while CCoV and FCoV require both the second and the third region from aa 732-746 and from aa 764-788. The monoclonal antibody (mAb) R-G-4 produced by Dr Hohdatsu can block infection with all these different viruses (Hohdatsu et al., 1998). The antibody binds to an epitope within the region from aa 251-582 which correlates with domain V of APN (Tusell et al., 2007). This would imply that the three discontinuous regions determining the host range lie closely together on the folded protein. These studies were all performed using APN sequences obtained from a feline cell line. Rottier et al. studied the blocking effect of mAb R-G-4 on bone marrow-derived macrophage infection and saw a reduction from approximately 33 up to 3 % (2005). On the in vivo target cells, monocytes, the entry of FCoV has not been studied. Recently, Regan & Whittaker claimed that mAb R-G-4 also significantly reduced infection of monocytes (2008). Further, the expression level of fAPN is increased in macrophages of FIP cats. In vitro, replication of FIPV in macrophages leads to tumour necrosis factor α (TNF-α) production, which subsequently up regulates the expression of fAPN. Possibly this induces an enhanced susceptibility to infection. When there is ADE of FIPV infection, the expression of TNF-α and the upregulation of APN are even stronger (Takano et al., 2007).

For the FCoVs, expression of human DC-SIGN in Crandell feline kidney cells induced an increase of infection that was blocked by mannan, a competitor of DC-SIGN binding. Further infection of feline monocytes, the in vivo target cell, was strongly reduced by mannan according to Regan & Whittaker (2008).
Canine coronavirus (CCoV)
The entry of canine coronavirus is not extensively studied but it is known that CCoV binds to canine APN (Benbacer et al., 1997).

Human coronaviruses (HCoV)
Human coronavirus 229E (HCoV-229E) binds to human APN (hAPN) on human fibroblasts (Yeager et al., 1992). In human fibroblasts, APN is located in the raft fraction of the membrane (Nomura et al., 2004). After binding, receptor/virus complexes relocate to the site of internalization. Binding of HCoV-229E to hAPN may trigger conformational changes in the viral spike necessary to mediate internalization (Breslin et al., 2003). The region between amino acids 288-295 of hAPN is crucial for the HCoV-229E receptor function. Substitution of this region with a region originating from porcine APN (pAPN) and introducing an N-linked glycosylation site abolished recognition of HCoV. It is suggested that differences in glycosylation between coronavirus receptors from different species are critical for species specificity (Wentworth & Holmes, 2001). On the spike protein, the domain between aa 417-547 is probably required for binding of HCoV-229E to the hAPN receptor (Bonavia et al., 2003).

HCoV-229E can bind and probably enter cells expressing L-SIGN via this receptor but there is no uniform cytoplasmic expression of viral proteins nor release of infectious viral particles from these cells (Jeffers et al., 2006).

Human coronavirus NL63 (HCoV-NL63) is the only group 1 coronavirus that has not been linked with APN. It uses the severe acute respiratory syndrome (SARS) coronavirus receptor angiotensin-converting enzyme (ACE) 2 and possibly also DC-SIGN (Hofmann et al., 2005; 2006). NL63 S-protein has a weaker interaction with the ACE2 receptor than SARS-CoV. The ACE2 binding site is located between residues 190 and 739 in the C-terminal part of the S1 subunit of the spike protein (Hofmann et al., 2006; Mathewson et al., 2008). Lin et al. (2008) specified this information by mapping a minimal receptor-binding domain of 141 residues between aa 476-616 in the spike protein. In this region 15 critical residues were identified: C497, Y498, V499, C500, K501, R518, R530, V531, G534, G537, D538, S540, E582, W585 and T591. These critical residues are clustered in three separate regions and may represent three receptor-binding sites. In ACE2, residue 354 is crucial for NL63 binding (Li et al., 2007).
HCoV-NL63 depends on ACE2 for infectious entry, but expression of DC-SIGN or L-SIGN slightly augments infection of susceptible cells. Expression of DC-SIGN in non-susceptible cells is however not sufficient to enable entry in these cells (Hofmann et al., 2006).

**Porcine coronaviruses**

Porcine aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV. TGEV replicates selectively in differentiated enterocytes covering the villi of the small intestine (Delmas et al., 1992). Recombinant expression of APN confers infectivity to non-susceptible cells. Transfected cells are not susceptible for FCoV, nor CCoV, but porcine respiratory coronavirus (PRCoV) does use pAPN for entry into the host cells (Delmas et al., 1993). For TGEV, an additional receptor of approximately 200kDa has been described (Weingartl & Derbyshire, 1994). This receptor was not further identified, so its role in the entry process of other coronaviruses could not be examined.

pAPN also functions as a receptor for porcine epidemic diarrhoea virus (PEDV) because transfection of non-susceptible cells with pAPN, led to infection and neutralizing antibodies against pAPN blocked infection (Oh et al., 2003; Li et al., 2007).

For both bat coronavirus and rabbit coronavirus, receptor use has not been studied.

1.2.3.2 **Other important coronaviruses**

**Mouse hepatitis virus (MHV)**

Mouse hepatitis virus (MHV) is one of the best studied viruses in coronavirus group 2. The receptor for MHV-A59, a substrain of MHV, belongs to the carcinoembryonic antigen family of glycoproteins in the immunoglobulin superfamily. More specifically, the virus binds to the carcinoembryonic antigen-related cell adhesion molecule 1a (CEACAM1a) receptor on murine cells via the MHV spike protein. It is a glycoprotein with four immunoglobulinlike domains, a transmembrane domain and a short cytoplasmic tail. Transfection into non-susceptible cells, confers infectivity (Dveksler et al., 1991). Isoform CEACAM1b can also function as an MHV receptor but with 10 to 100 times less affinity (Othsuka et al., 1996). The MHV receptor is not associated with lipid rafts and virus binding does not require cholesterol (Thorp & Gallagher, 2004). The N-terminal part of CEACAM1a is essential for binding and can induce a conformational change in the spike protein upon binding (Matsuyama & Taguchi, 2002; Zelus et al., 2003; Miura et al., 2004). The induced conformational change transforms the non-fusogenic S-protein into a fusogenic form.
Infectious bronchitis virus (IBV)

Avian infectious bronchitis virus (IBV) is the prototype for group 3 coronaviruses. IBV not only attaches to α2,3-linked sialic acids on erythrocytes, but the presence of these sialic acids on target cells determines susceptibility to infection by IBV (Schultze et al., 1992; Winter et al., 2006). Probably, sialic acids mediate primary attachment and a second, unknown receptor mediates tighter binding and internalization. Infection of ciliated and goblet cells in tracheal organ cultures also depends on the presence of sialic acids, confirming the in vivo relevance of sialic acid receptors (Winter et al., 2008; Rahman et al., 2009). For a certain IBV strain, Beaudette, that has an extended host range in cell culture, heparan sulphate works together with sialic acids (Madu et al., 2007). This could be due to cell culture adaptations that are not relevant in vivo. Previously feline aminopeptidase N was also claimed to be capable of mediating IBV entry (Miguel et al., 2002). This was however countered by Chu et al., who showed that fAPN could not rescue infection by IBV strain Mass41 (2007). The alleged IBV receptor function of fAPN was explained by a low IBV susceptibility of feline cells that was however negligible compared to susceptibility of primary chick kidney cells.

Severe acute respiratory syndrome virus (SARS-CoV)

Angiotensing-converting enzyme 2 (ACE2) is a functional receptor for SARS virus (Li et al., 2003). It is a type I transmembrane protein of 805 amino acids with carboxy-metalloprotease activity. The proteolytic activity of ACE2 is however not important for SARS-CoV receptor function. This receptor is present at the primary site for SARS-CoV replication, the lungs (Kuiken et al., 2003; Li et al., 2003). The ACE2 binding site is localized in a small region in the S1 domain of the spike protein, more specifically in a region of 193 aa between residues 318 and 510 (Babcock et al., 2004; Wong et al., 2004). The presence of ACE2 in lipid rafts would be important for efficient virus receptor interactions (Glende et al., 2008; Lu et al., 2008). SARS-CoV can also interact with L-SIGN and DC-SIGN. This interaction would lead to an enhancement of infection in susceptible cells by transmission of virus to susceptible cells (Marzi et al., 2004; Yang et al., 2004). Han et al. showed that DC/L-SIGN expression could rescue SARS-CoV infection in Hela cells (2007). The interaction between SARS-CoV and DC/L-SIGN occurs through glycans on the spike protein, more specifically asparagine residues at aa positions 109, 118, 119, 158, 227, 589 and 699 (Han et al., 2007). However, it is still unknown if DC/L-SIGN mediates infectious entry in vivo.
1.2.4 Virus internalization

1.2.4.1 Direct fusion versus endocytosis

The interaction with cellular receptors is indispensable for viruses to cross the plasma membrane. There are two major routes for enveloped viruses to cross the plasma membrane and deliver viral genomes in the cytoplasm: fusion with the plasma membrane (referred to as direct fusion) or receptor-mediated endocytosis followed by fusion with an intracellular vesicle membrane (referred to as endocytosis). The virus-receptor interaction can induce a conformational change in the viral fusion protein that exposes a fusion peptide. Fusion peptides originally reside in the ectodomain of the fusion protein. Upon binding to the right receptor, they are exposed to promote hydrophobic interactions between the viral envelope and the plasma membrane of the host cell (Voyles, 2002). The viral envelop is left behind in the plasma membrane and the viral nucleocapsid is released in the cytosol (Fig. 8). The virus-receptor interaction can however also induce invagination of the plasma membrane and the formation of an intracellular vesicle that contains the virus-receptor complex. This process of receptor-mediated endocytosis can occur through a number of pathways that are shown in Figure 9. Eventually, uptake via endocytosis also leads to a fusion event as described above, this time between the viral envelope and the membrane of the intracellular vesicle.

Figure 8: Virus entry via direct fusion with the plasma membrane.
1.2.4.2 Endocytosis pathways

Endocytosis pathways can be divided into two major categories: phagocytosis (the uptake of large particles) and pinocytosis (the uptake of fluid and solutes) (Conner & Schmid, 2003). Pinocytosis can be further subdivided into macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated endocytosis or clathrin- and caveolae-independent endocytosis (Fig. 9).

![Figure 9: Overview of all possible endocytosis pathways with the main structural compounds involved and the intracellular destination (Dewerchin, 2008).](image)

Phagocytosis

Phagocytosis is an active and highly regulated process for the uptake of ‘large’ (generally > 0.5 µm) particles. It participates in several processes such as development, tissue remodelling, the immune response and inflammation (Aderem & Underhill, 1999). Phagocytosis in mammals is conducted primarily by specialized cells, such as macrophages, monocytes and neutrophils (Conner & Schmid, 2003).
Chapter 1

Formation of phagosomes
The process is initiated by binding of the ligand to specific cell-surface receptors. This triggers a signalling pathway involving activation of the Rho GTPases Cdc42 and Rac that induces actin assembly for the formation of lamellipodia. Lamellipodia are membrane extentions that zipper up around the ligand and engulf the particle into a phagosome. Another GTPase involved in the phagocytic process is dynamin. It is enriched in early phagosomes. The exact role of dynamin is unknown but blocking dynamin function arrests internalization at the stage of membrane extension around the particle (Gold et al., 1999). Phosphatidyl inositol 3-kinase (PI3K) mediates the closing of the lamellipodia and the capture in the phagosome. After internalization, actin is depolymerised from the phagosome and the vacuole membrane becomes accessible to early endosomes. Through a series of fusion and fission events, the vacuolar membrane and its contents mature, followed by fusion with late endosomes and ultimately lysosomes to form a phagolysosome (Aderem & Underhill, 1999).

Inhibition of phagocytosis
Latrunculin B that disrupts actin polymerization can be used to block phagocytosis as it will prevent the formation of lamellipodia (Spector et al., 1989). Wortmannin is a PI3K inhibitor that can be used as an inhibitor for phagocytosis (Araki et al., 1996).

Macropinocytosis
Macropinocytosis is a highly controlled and regulated process for the uptake of particles generally > 0.2 µm. Macropinocytosis fulfils diverse functions and can be induced in most cell types. For example, GTPase Rac and p21-activated kinase (PAK) are activated through platelet-derived growth factor-induced macropinocytosis and control directed cell migration (Ridley, 2001). Further, dendritic cells sample the extracellular milieu through macropinocytosis to fulfil their role in immune surveillance (Mellman & Steinman, 2001).

Formation of macropinosomes
Like for phagocytosis, Rho GTPases induce actin-rearrangements that form membrane protrusions. These protrusions are called membrane ruffles. More specifically, Rac regulates the assembly of an actin-nucleating complex at the plasma membrane where the ruffles originate from. Besides oriented actin polymerization, ruffling may also require contributions from actin-based mechanochemical enzymes, such as myosin. Cytoplasmic microtubules also appear to modulate the ruffling (Swanson & Watts, 1995). Unlike for phagocytosis, the protrusions do not zipper up along the particle but collapse onto and fuse with the plasma
membrane. In this way, large endocytic vesicles are formed, the macropinosomes, that sample large volumes of the extra-cellular milieu (Conner & Schmid, 2003). They are heterogeneous in size (generally from 0.2 up to 5 µm). During their life span of approximately 15 minutes, macropinosomes change from an early endosome-like organelle to a late endosome-like organelle, then merge completely into the lysosomal compartment (Racoosin & Swanson, 1993).

Inhibition of macropinocytosis
Latrunculin B, an inhibitor for phagocytosis also blocks macropinocytosis, as they both rely on actin polymerization (Spector et al., 1989). Further, as for phagocytosis, PI3K is involved in closure of the macropinosomes. In the presence of the inhibitor wortmannin, the formed ruffles recede into the cytoplasm (Araki et al., 1996).

Clathrin-mediated endocytosis
Clathrin-mediated endocytosis (CME) is probably the best studied internalization pathway. CME constitutively takes place in all mammalian cells. It is important for the uptake of essential nutrients such as cholesterol-laden low-density lipoprotein particles and iron-laden transferrin (Schmid, 1997; Brodsky et al., 2001). CME is also crucial for intercellular communication during tissue and organ development (Di Fiore & De Camilli, 2001; Seto et al., 2002). Further, it is also involved in serum homeostasis and neurotransmission (De Camilli & Takei, 1996; Beattie et al., 2000).

Formation of the clathrin-coated vesicle
CME is initiated by the concentration of high-affinity transmembrane receptors and their bound ligands. The ‘coated pits’ of approximately 120 nm are subsequently formed on the plasma membrane by the assembly of cytosolic coat proteins (Fig. 11, step 1 & 2). The coat proteins consist of clathrin and the assembly proteins. Clathrin is the main assembly unit. It is a tree-legged structure formed by three clathrin heavy chains, each with a tightly associated light chain (Brodsky et al., 2001). This structure is called a ‘triskelion’ (Fig. 10). There are two structurally and functionally different classes of assembly proteins: the monomeric assembly protein AP180 (in neuronal cells) or its isoform CALM (clathrin-assembly lymphoid-myeloid leukaemia) and heterotetrameric adaptor protein (AP) complexes, AP1 to AP4. However, only AP2, composed of α-, β2-, µ2- and σ2-subunits, is involved in endocytic clathrin-coated vesicle formation (Fig. 10). Clathrin triskelions spontaneously self-assemble into lattices. AP2s direct clathrin assembly into curved lattices
to the site where cargo is recruited and where ligated receptors are concentrated through a direct interaction of AP2 with the receptors (Fig. 11, step 2) (Brodsky et al., 2001). The exact role for AP180/CALM is not known but in the absence of this protein fewer vesicles are formed and they are less uniform in size (Tebar et al., 1999). Eps15 binds directly to AP2 and indirectly via epsin to clathrin. Thus, the coat proteins clathrin, AP2, AP180/CALM and Eps15 encode all the functions necessary to select cargo and form a vesicle. After the formation of the ‘coated pit’, the vesicle is pinched off the membrane and the receptor-ligand complexes are transported into the cell (Fig. 11, step 3).

Figure 10: Structure of the main components of clathrin-coated pits: clathrin triskelions and adaptor complex 2 (AP2) (clathrin triskelion adapted from http://www.bio.indiana.edu/~ybelab/research.html).
Figure 11: Clathrin-mediated internalization. 1 Binding of ligands to receptors. 2 AP2 associates with the receptors through the µ2 subunit. The β subunit interacts with clathrin. 3 Internalized clathrin-coated vesicle. 4-5 Uncoating of the vesicle by dissociation of clathrin and AP2. 6 Sorting of the uncoated vesicle.
‘Pinching off’ the vesicle
The ‘pinching off’ is attributed to the GTPase dynamin. Dynamin forms rings at the neck of invaginated clathrin-coated pits and a conformational change in the ring that correlates with GTP hydrolysis, is essential for vesicle fission (De Camilli et al., 1995). The dynamin-2 isomer is expressed ubiquitously. It interacts with itself to form oligomers, predominantly tetramers, to form rings (Hinshaw & Schmid, 1995). Next to the GTPase domain, dynamin also contains domains to interact with several binding partners that stimulate the GTPase activity or target dynamin to the plasma membrane (Hinshaw, 2000). The GTPase activity stimulating domain is the ‘GTPase effector domain’. Targeting to the plasma membrane occurs through interaction with the ‘pleckstrin homology (PH) domain’ of dynamin with phosphoinositides (Salim et al., 1996). Further, the ‘proline-rich domain’ at the C-terminus of dynamin interacts with SH3 domains of profilin and cortactin that interact with the actin cytoskeleton (Simpson et al., 1999). Another important binding partner for dynamin are amphiphysines. They not only bind dynamin but often also clathrin and AP2 to stabilize the clathrin-coated vesicle (Slepnev et al., 2000). Together with amphiphysine, dynamin binds endophilin and actin tails through pacsin/syndapin, to pinch-off the vesicle from the membrane.

Intracellular fate of the internalized vesicle
The uncoating of the internalized vesicle is initiated through auxilin that binds Hsc70-ATP (Lemmon, 2001). Hydrolization to Hsc70-ADP induces a conformational change in clathrin that is released from the vesicle and binds to Hsc70-ADP (Fig. 11, step 4). Dissociation of AP2 is induced by synaptojanin and after release from the vesicle AP2 is phosphorylated to prevent it from binding again to clathrin (Fig. 11, step 5) (Wilde & Brodsky, 1996; Cremona et al., 1999). The uncoated vesicle can subsequently fuse with other intracellular vesicle and/or continue its intracellular journey (Fig. 11, step 6).

Inhibition of clathrin-mediated endocytosis (CME)
Amantadine stabilizes the structure of clathrin-coated vesicles in purified pig brain (Phonphok & Rosenthal, 1991). Another, perhaps more specific inhibitor of CME, is chlorpromazine. It causes clathrin lattices to assemble on endosomal membranes and at the same time prevents coated pit assembly at the plasma membrane (Wang et al., 1993). It was also shown that the extraction of cholesterol with methyl-β-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles (Rodal et al., 1999). Each protein involved in CME can also be targeted. Dynamin is often used as a target for blocking several endocytosis pathways, including CME.
Caveolae-mediated endocytosis
Caveolae are approximately 60 nm, flask-shaped invaginations of the plasma membrane that occur on many cells and demarcate cholesterol and sphingolipid-rich microdomains of the plasma membrane. Most cell types contain some caveolae, while they are really abundantly present in other cells, like eg adipocytes. Some cells completely lack caveolae, such as lymphocytes and neuronal cells from the central nervous system. Caveolae-mediated endocytosis is important for intracellular cholesterol trafficking and intracellular cholesterol homeostasis. Further, it plays an organismal role in lipid homeostasis in adipocytes and it mediates transcellular transport in endothelial cells (Conner & Schmid, 2003).

Figure 12: (a) Membrane topology of caveolin. (b) Different domains on caveolin (Williams & Lisanti, 2004).

The nature of caveolae
Unlike clathrin-coated vesicles, caveolae are not induced by binding of a ligand to its receptor but they are stationary and held in place by the cortical actin cytoskeleton underlying the plasma membrane (Fig. 13, step 1) (Pelkmans et al., 2001; Thomsen et al., 2002). Only upon specific signals they will detach from the membrane as an endocytic vesicle. Caveolae have a protein coat, though not as dense as the clathrin coat, that consists
mainly of caveolin-1 (caveolin-3 in muscle cells) (Rothberg et al., 1992). Caveolins are integral membrane proteins with both N- and C-terminal ends directed into the cytosol and one transmembrane region that does not span the membrane (Fig. 12) (Dupree et al., 1993; Monier et al., 1995). They are located in the membrane in lipid raft-like domains. Lipid rafts are more rigid domains ‘floating’ in the plasma membrane, enriched in cholesterol and sphingolipids (glycosphingolipids and sphingomyelin). The presence of caveolins discriminates caveolae from the ‘ordinary’ rafts and is due to the high affinity of caveolin for sphingolipids and especially cholesterol (Murata et al., 1995). In caveolae, every 14-16 caveolin monomers oligomerize to form the coat of the vesicle.

**Induction of internalization**

The internalization of Simian virus 40 (SV40), a DNA virus (Papovaviridae, polyomavirinae) of approximately 50 nm, is intensively studied and occurs via caveolae-mediated endocytosis. Based on the findings concerning the internalization of SV40, a model for caveolae-mediated endocytosis was proposed (Pelkmans & Helenius, 2002). After binding of a ligand to its receptor, this complex can diffuse laterally along the membrane until it is trapped in a caveola (Fig. 13, step 2) (Pelkmans et al., 2001). The caveolae are linked to the cortical actin that needs to depolymerise to enable internalization. This occurs via tyrosine phosphorylation in proteins associated with the caveolae (Pelkmans et al., 2002). *In vivo* Src phosphorylates caveolin but it is not known if this is necessary and/or sufficient to depolymerise the actin (Parton et al., 1994). The released actin monomers assemble into a small actin patch surrounding the vesicle. This is followed by peaks of actin polymerization that result in the formation of actin tails that function as propellers to direct the vesicle into the cytosol (Fig. 13, step 3). Next to actin rearrangements, also dynamin is strictly necessary to enable vesicle closure and detachment from the plasma membrane (Pelkmans et al., 2002). Once the vesicle is released, the actin tail is no longer necessary (Fig. 13, step 4) (Pelkmans & Helenius, 2002).
Figure 13: Caveolae-mediated internalization. 1 Caveolae are not induced but stationary present in the plasma membrane. 2 Binding of ligand to receptor and diffusion of the complex along the membrane. 3 Dynamin recruitment and actin rearrangements to induce internalization. 4 Released vesicle. 5 Fusion with the caveosome. 6 A caveolin-free vesicle is split off the caveosome and sorted to the ER (adapted from Pelkmans & Helenius, 2003).
Intracellular fate of the internalized vesicle

The vesicles released in the cytosol transfer their cargo to larger ‘caveosomes’ by membrane fusion (Fig. 13, step 5) (Pelkmans et al., 2001). Just like caveolae, membranes of caveosomes contain caveolin-1, cholesterol and sphingolipids. Their pH is neutral and they are consistently present and distributed throughout the cytosol. After fusion of several caveolae into the caveosome, its structure becomes more dynamic and caveolin-free vesicles are split off and cargo is sorted to the ER via transport over the microtubules (Fig. 13, step 6).

Inhibition of caveolae-mediated internalization

Caveolae-mediated internalization is often indirectly blocked by disrupting lipid rafts. This is done by sterol-binding or -extracting drugs like filipin and nystatin or methyl-β-cyclodextrin (Schnitzer et al., 1994). Although not specific, this approach is very effective. Again, all proteins involved in the cascade described above can be used as targets. For example, blocking tyrosine kinases by inhibitors like genistein blocks internalization through caveolae (Parton et al., 1994; Parton & Richards, 2003).

Clathrin- and caveolae-independent endocytosis

Little is known about the mechanisms underlying clathrin- and caveolae-independent pathways. However, probably they fulfil unique functions and the internalization is tightly regulated, as is the intracellular destination of the internalized ligands (Conner & Schmid, 2003). In what follows, the independent pathways will be described based on some selected examples. The independent pathways are identified based on characteristics like (i) the dependency on dynamin, (ii) the association with lipid rafts and (iii) the dependency on Rho GTPases. Most likely, as these pathways are further characterized, more characteristics will be necessary to differentiate between independent pathways.

Dynamin-dependent and cholesterol depletion sensitive pathway

Both the β-subunit of the IL-2 receptor (IL-2R) and the common cytokine receptor γ (γc) are internalized through a clathrin- and caveolae-independent pathway that depends on dynamin and is associated with lipid rafts (Kirkham & Parton, 2005). Binding of IL-2 to the IL-2R increases the association between the receptor and rafts. The internalization is regulated by the Rho GTPases RhoA and Rac1 (Lamaze et al., 2001). The γc receptor is a subunit shared by several cytokine receptors, namely IL-2, -4, -7, -9, -15 and -21 receptors (Schluns & Lefrancois, 2003). The internalization of the γc cytokine receptor is further characterized by
recruitment and polymerization of actin and activity of the Rho GTPase RhoA (Sauvonnet et al., 2005).

A dynamin-dependent and cholesterol depletion sensitive pathway is also (mis)used by rotavirus (Reoviridae) to gain entry into an epithelial cell line. It is not known if this pathway is regulated by Rho GTPases (Sanchez-San Martin et al., 2004).

Dynamin-independent and cholesterol depletion sensitive pathway
Endocytosis of the glycosylphosphatidylinositol (GPI)-anchored folate receptor can occur via clathrin-mediated internalization. But this is not sufficient for effective cytoplasmic folate delivery (Ritter et al., 1995). Efficient folate delivery results from internalization via a clathrin- and caveolae-independent pathway that does not rely on dynamin (Sabharanjak & Mayor, 2004). Further, the pathway is associated with lipid rafts via the GPI-anchor. After a couple of minutes, endocytosed proteins are detected in GPI-anchored protein enriched endocytic compartments (GEECs). Formation of these GEECs is regulated by the Rho GTPase Cdc42 (Sabharanjak et al., 2002). The final destination of the compounds inside the GEECs is cell type dependent and varies from recycling compartments to late endosomes.

In cell lines that lack caveolae and in embryonic fibroblasts, SV40 is taken up by a clathrin- and caveolae-independent pathway that depends on cholesterol but not on dynamin (Damm et al., 2005).

Dynamin-dependent and cholesterol depletion insensitive pathway
A possible example of a dynamin-dependent clathrin- and caveolae-independent pathway that does not depend on cholesterol is influenza virus entry in Hela cells. It is definitely a cholesterol-independent, clathrin- and caveolae-independent pathway but the dependency on dynamin has not been studied yet and was only suggested in 2002 by Sieczkarski & Whittaker based on dependency on dynamin of influenza virus in another cell type, Mv-1 lung cells (Roy et al., 2000). However, numerous viruses have been shown to use different pathways to enter different cell types, or even use different pathways in one cell. Therefore, dependency on dynamin should be further investigated before any conclusions can be made.

Dynamin-independent and cholesterol depletion insensitive pathway
The entry of murine polyomavirus strain RA in fibroblasts and kidney epithelial cells occurs via a clathrin- and caveolae-independent pathway that is independent from dynamin and cholesterol (Gilbert & Benjamin, 2000). A rearrangement of the actin microfilaments is
necessary for internalization. For intracellular transport to the nucleus, the virus relies on microtubules (Gilbert et al., 2003).

Recently, it was shown that the antibody-induced internalization of surface-expressed antigens in FIPV-infected monocytes are internalized via a clathrin- and caveolae-independent pathway that does not require dynamin or rafts. Further, this pathway is independent of actin and Rho GTPases, and phosphatases and tyrosine kinases. It did however depend on serine/threonine kinases (Dewerchin et al., 2008).

1.2.5 Internalization of coronaviruses

1.2.5.1 Group 1 coronaviruses

**Feline coronaviruses (FCoV)**

Together with the question whether FCoVs enter cells via direct fusion at the plasma membrane or fusion with the endosomal membranes after endocytosis, it is also questioned if uncoating of FCoV particles depends on low pH. Without resolving the first question and eliminating the possibility of direct fusion, Takano et al. claimed that acidification of the endosome is necessary for FIPV infection of monocytes (2008). However, Regan et al. claim that the pH drop in the endosome is necessary for infectious entry of eFCoV strain 79-1683, but not for FIPV strains 79-1146 and DF2 (2008). As such, the mystery around FCoV entry remains unresolved.

Naturally, the FCoV S-protein will fulfil an important role in the internalization process. In monocytes/macrophages, the M-protein might also be involved in some crucial interactions, as neutralizing antibodies against M-protein suggest involvement in a post-absorption step (Kida et al., 2000).

The role of proteases in FCoV entry is another point of discussion. Regan et al. reported a cathepsin-mediated cleavage of the viral spike protein (2008). For eFCoV 79-1683, both cathepsin B and L can perform this cleavage, while FIPV 79-1146 and DF2 depend on cathepsin B activity. However, de Haan et al. claim independence from cathepsins for FIPV 79-1146, but report possible furin cleavage for some serotype I strains (2008).

**Canine coronavirus (CCoV)**

The internalization of canine coronavirus is not extensively studied. The exact internalization pathway is not known. It has been suggested that CCoV enters cells via endocytosis, as replication could be inhibited by chloroquine (Savarino et al., 2003).
**Human coronaviruses (HCoV)**

HCoV-229E binds to APN in lipid rafts in human fibroblasts. At 37 °C the receptor/virus complexes redistribute to caveolae for virus entry through caveolae-mediated internalization (Nomura et al., 2004). This was shown by co-localization studies between the virus and caveolins, disruption of the rafts by cholesterol depleting drugs and caveolin knockdown by RNA interference. Kawase *et al.* showed that also in Hela cells, HCoV-229E enters via endocytosis through an endosomal pathway (2009). Infection was profoundly blocked by lysosomotropic agents as well as by protease inhibitors. Cathepsin L is involved in the fusogenic activation of HCoV-229E S-protein in endosomal infection. It is however very likely that this is not the only protease involved (Kawase *et al.*, 2009).

The mechanism of internalization has not been studied for HCoV-NL63. As this virus uses the same receptor(s) as SARS-CoV, it might be suggested that it also uses the same internalization pathway(s). This is possible but uncertain as viruses have been shown to interact in different ways with identical binding partners triggering various processes. It has already been shown that SARS-CoV and NL63 probably engage ACE2 differentially. NL63-driven entry is also less dependent on a low pH environment and activity of endosomal proteases compared to infection with SARS-CoV (Hofmann *et al.*, 2006).

**Porcine coronaviruses**

The mechanism of TGEV internalization has been studied in a cell line stably expressing porcine APN. Electron microscopic analysis showed TGEV in endocytic pits and apical vesicles so the virus clearly enters via endocytosis and not via direct fusion at the plasma membrane. Acidification of the endosome is required for infection. Thickening of the membrane below adsorbed TGEV particles, visible on electron microscopic pictures, indicates that TGEV enters cells via clathrin-mediated endocytosis (Hansen *et al.*, 1998). Based on the finding that cholesterol is important for TGEV infection, it is suggested that TGEV entry may occur via lipid rafts (Ren *et al.*, 2008). Further research is necessary to confirm this hypothesis because the effect of methyl-β-cyclodextrin is not necessarily due to raft-association of the internalization process, especially not if CME can possibly occur.

The internalization mechanisms of PRCoV and PEDV have not been studied in detail.

For both bat coronavirus and rabbit coronavirus, the internalization pathway has not been studied.
1.2.5.2 Other important coronaviruses

Mouse hepatitis virus (MHV)

Although virus binding does not depend on cholesterol and the MHV receptor is not present in lipid rafts, virus entry was reduced by cholesterol depletion (Choi et al., 2005). After virus binding independent from rafts, the virus particles shift to the raft-fraction of the membrane. This redistribution of spike proteins in the membrane and the interaction between lipid rafts and spikes may be necessary for internalization.

In the past, both endosomal and non-endosomal routes have been described for MHV entry (Nash & Buchmeier, 1997). The route of entry used, was said to depend upon the virus strain and the cell type of the host cell. Kooi et al., suggested a minor role for the endocytic pathway and showed that MHV can induce direct fusion at pH 7.4 (1991). Binding of MHV (MHV-A59 and MHV-4) to its receptor can induce a conformational change in the spike protein into a fusogenic state, possibly ready to induce direct fusion at the plasma membrane (Matsuyama & Taguchi, 2002; Zelus et al., 2003; Miura et al., 2004). On the other hand, Krzystyniak and Dupuy reported that infection by MHV-3 is sensitive to lysosomotropíc agents, suggesting virus entry via endocytosis (1984).

Recently, a novel study was set up to resolve the discussion on the route of entry of MHV strain A59. It was shown that virus uptake occurs via endocytosis (Eifart et al., 2007). This is the natural consequence of the observed requirement for the low pH in endosomes to initiate fusion of the viral spike with the host cell membranes. The low pH-triggered conformational alterations in the S-ectodomain are irreversible because low pH-treatment of virus particles in the absence of target domains causes an irreversible loss of fusion activity. Protease activity is not required for MHV entry. As chlorpromazine is an efficient inhibitor of MHV entry, the virus is probably endocytosed via clathrin-mediated internalization (Eifart et al., 2007). This is consistent with the dependency on cholesterol, as methyl-β-cyclodextrin is a potent inhibitor of CME.

Unlike for MHV-A59, endosomal protease activity is required for infection with MHV-2. Low pH activates cathepsins B and L, that are also involved in SARS-CoV infectivity, to mediate MHV-2 entry (Qiu et al., 2006). These results might confirm the statement of Nash & Buchmeier that entry pathways vary between different virus strains and their target cells (1997). Further analysis of MHV-2 entry showed the involvement of clathrin but remarkably not of Eps15, a component that until now was always involved in CME (Pu & Zhang, 2008).
**Infectious bronchitis virus (IBV)**

Avian IBV uses an endocytic pathway for entry into cells. Cell fusion occurs in a low pH-dependent manner in the endosomes without activity of endosomal proteases (Chu *et al.*, 2006). The low pH-induced conformational change is reversible, unlike the conformational change of MHV spikes.

**Severe acute respiratory syndrome virus (SARS-CoV)**

SARS-CoV infection of Vero E6 cells (and 293T and Huh-7 cells) requires acidification of endosomes, indicating that the virus enters cells via endocytosis (Simmons *et al.*, 2004; Yang *et al.*, 2004). The ACE2 receptor is located in lipid rafts that probably also function as a platform to mediate SARS-CoV entry (Lu *et al.*, 2008). In (COS7) cells that are transfected with ACE2, the endocytosis entry pathway was further characterized using inhibitors and gene silencing and appeared to be clathrin-mediated. After CME, the virus relocates to EEA1-positive early endosomes (Inoue *et al.*, 2007). Wang *et al.* also studied the pathway of SARS-CoV internalization (2008). They used HEK293E cells transfected with ACE2 and Vero E6 cells for studies with inhibitors, expression of dominant-negative proteins, gene silencing and co-localization studies. They confirmed that endocytosis was associated with lipid rafts, brought the virus in early endosomes and depended on the pH drop in late endosomes. However, the pathway appeared independent from clathrin and caveolae. Next to low pH, activity of cathepsins is also required for successful SARS-CoV entry (Huang *et al.*, 2006).

Recently, a novel mechanism of priming for the SARS-CoV S-protein has been reported. Sequential trypsin cleavage at two different sites, namely cleavage at the S1/S2 boundary and position 797 in S2, would enable the S-protein to mediate membrane fusion, presumably at the cell surface (Belouzard *et al.*, 2009).
1.3 REFERENCES


binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. *Immunity* 17, 653-664.


AIMS
Chapter 2

Feline infectious peritonitis (FIP) is the most important infectious cause of death in cats. One to 5% of the European cat population is a potential victim of this infection. At present, no means are available to heal cats. Furthermore, there is no effective vaccine available for prevention. Expanding the knowledge on FIP virus (FIPV) pathogenesis is indispensable in the search for a vaccine and treatment.

The process of viral entry is an attractive target for the development of new therapeutic agents. For example in the battle against human immunodeficiency virus 1 infections, this approach already led to the development of promising agents (Cooley & Lewin, 2003). This study was set up to unravel the process of FIPV entry and identify possible targets for drug development. At the start of this research, little was known about FIPV entry. It was even questioned whether FIPV entry is mediated via direct fusion at the plasma membrane or via fusion with endosomal membranes after endocytosis.

Viral entry consists of two major events. First, the virus binds to its receptor on the plasma membrane, leading to viral attachment. In a second step, bound virus particles pass the plasma membrane either via direct fusion or via endocytosis, which results in virus internalization. Internalization via endocytosis is followed by an extra uncoating step to release the viral RNA in the cytosol.

The first study was aimed at providing insights in how attachment and internalization are regulated in time and to quantify virus binding and internalization over time in monocytes, the target cell for FIPV in vivo. Different virus strains and different cats were included. It was also checked if cell lines were valid models to study FIPV entry. This study was set up to reveal whether FIPV enters target cells via direct fusion or via endocytosis, or a combination of both (chapter 3), and to provide basic information that was needed for the experimental set-up for the following studies that focus on attachment and internalization separately.

In chapter 4, the use of potential receptors for FIPV at different stages of the entry process was evaluated. This study was performed to provide new insights in the virus-receptor interactions upon viral contact with the host cell, the monocyte.

In a third study, the mechanism of internalization was further analysed in monocytes. Therefore, a variety of techniques was included, ranging from inhibition experiments, lentiviral transduction to express dominant-negative proteins in monocytes and co-localization studies (chapter 5). This study could identify cellular proteins that are necessary for FIPV entry in monocytes.
Finally, the release of the genome in the cytosol, necessary for genome replication, transcription and translation, was studied. A kinetical study of this process was performed to supply data on the efficiency of uncoating. Further, it was checked which triggers might induce release of the FIPV genome into the cytosol in monocytes (chapter 6).
REFERENCES

Chapter 3

KINETIC ANALYSIS OF ATTACHMENT AND INTERNALIZATION OF FELINE INFECTIOUS PERITONITIS VIRUS

Evelien Van Hamme, Hannah L. Dewerchin, Els Cornelissen & Hans J. Nauwynck

Adapted from *Journal of General Virology* (2007), 88, 2527-2532
ABSTRACT

In this study, kinetics of attachment and internalization of feline infectious peritonitis virus (FIPV) serotype I strain Black and serotype II strain 79-1146, were determined in feline monocytes from two cats and in Crandell feline kidney (CrFK) cells. Attached FIPV I (Black) particles were observed on almost all monocytes. Within 1 hour, 17 particles were bound per cell and within 1 minute, 89% of the bound particles were internalized. For FIPV II (79-1146), attachment was observed on 66% and 95% of all monocytes from the two cats. After 1 hour, respectively 5 and 20 particles were bound per cell (all cells considered). Within 1 minute, 60% of the bound particles were internalized. Internalization in monocytes was efficient and proceeded via endocytosis. In CrFK cells, attachment and internalization were less efficient, especially for FIPV I (Black), so this cell line is not suitable for studying FIPV entry.
INTRODUCTION

Feline infectious peritonitis virus (FIPV) is a coronavirus belonging to the order of the Nidovirales (Cavanagh, 1997; Cowley et al., 2000; Gorbelyana et al., 2006). Based on comparative sequence analysis, human coronavirus strain 229E (HCoV-229E), porcine transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhoea virus (PEDV), canine coronavirus (CCoV) and feline coronaviruses (FCoV) are grouped in phylogenetic group 1 (González et al., 2003; Spaan et al., 2005; Gorbelyana et al., 2006). Feline coronaviruses are divided into two serotypes: serotype I and the less prevalent serotype II (Pedersen et al., 1984; Hohdatsu et al., 1992). Type II strains are closely related to CCoV and TGEV (Pedersen et al., 1983) and are thought to be recombinants of type I strains and CCoV (Vennema et al., 1995). Unlike type I strains, type II strains grow easily in cell culture, such as Crandell feline kidney (CrFK) cells, and are therefore used frequently in FIPV studies.

To infect a target cell, a virus particle proceeds through a multistep entry process. Each step is pre-programmed and tightly regulated in time and space (Smith & Helenius, 2004). The first step in the viral entry process is the attachment of viral proteins to receptors on the surface of the target cell. Some receptors function solely as attachment receptors that recruit fitting ligands for the internalizing receptors. Others attach and internalize particles in a single step process. Attachment and internalization have not been studied in detail for most coronaviruses (Holmes & Compton, 1995). Aminopeptidase N (APN), also called CD13, is a 150 kDa class II metalloprotease. This glycoprotein serves as a receptor for several group 1 coronaviruses (Tresnan et al., 1996), including HCoV-229E (Yeager et al., 1992), porcine respiratory coronavirus (PRCoV) and TGEV (Delmas et al., 1992, 1993, 1994). For both serotype I and II FCoVs, stably expressed APN cDNA isolated from the Felis catus whole fetus (fcwf) cell line could induce susceptibility in FCoV-resistant cells. Although strains of both serotypes were able to infect these cells, the efficiency of infection was different (Tresnan et al., 1996). Hohdatsu et al. (1998) showed that only serotype II strains of FCoV use feline APN (fAPN) as a receptor for internalization into feline cell lines, like CrFK and fcwf cells. Infection of bone marrow-derived macrophages with FIPV II (79-1146) could be restricted from approximately 33 % to 3 % of the cells by a monoclonal antibody against fAPN (Rottier et al., 2005). Whether fAPN is the receptor for FIPV II on in vivo target cells, feline blood monocytes, is not known. The receptor for FIPV I has not been identified.

Viruses may enter cells via two pathways. Viral envelopes may fuse with the plasma membrane or with endosomal membranes after entering cells via endocytosis. Several group 1 coronaviruses enter cells via endocytosis. HCoV-229E enters human fibroblasts through
caveolae-mediated endocytosis (Nomura et al., 2004). TGEV causes infection in Madin-Darby canine kidney (MDCK) cells, transfected with porcine APN after receptor-mediated endocytosis (Hansen et al., 1998). CCoV also uses endocytosis to enter target cells (Savarino et al., 2003). Mouse hepatitis virus (MHV), a group 2 coronavirus, enters cells by both endosomal and non-endosomal pathways. The pathway of internalization was shown to depend upon the strain of virus and the nature of the cell being infected (Kooi et al., 1991; Nash & Buchmeier, 1997). Internalization of FIPV has not been studied in either primary cells or cell lines. Whether fusion at the plasma membrane or endocytosis occurs, is not known. In this study, kinetics of attachment and internalization were studied for FIPV in feline blood monocytes, the primary target cells, and compared with those in CrFK cells, used frequently as a model cell line for FCoV-cell interactions. In addition to the routinely used serotype II strain, 79-1146, a serotype I strain, Black, was included. Further, it was investigated whether FIPV enters monocytes and CrFK cells via fusion with the plasma membrane or via endocytosis.

**METHODS**

**Cells and virus**

Monocytes were isolated from blood collected from two FCoV-, feline leukemia virus- and feline immunodeficiency virus-negative cats as described previously (Dewerchin et al., 2005). The obtained monocytes were resuspended in RPMI 1640 (Gibco-Invitrogen) medium, supplemented with 10 % foetal bovine serum (FBS), 0.3 mg glutamine ml⁻¹, 100 U penicillin ml⁻¹, 0.1 mg streptomycin ml⁻¹, 0.1 mg kanamycin ml⁻¹, 10 U heparin ml⁻¹, 1 mM sodium pyruvate and 1 % non-essential amino acids 100x (Gibco-Invitrogen). Cells were seeded at a concentration of 2 x 10⁶ cells ml⁻¹ in 24-well dishes with cell culture coating (Nunc A/S) and cultivated at 37 °C with 5 % CO₂. The adherent cells consisted of 86 ± 7 % monocytes [assessed with monocyte marker DH59B; Veterinary Medical Research and Development (VMRD)]. Experiments were performed at 36 hours post seeding.

Type I FIPV strain Black (Black, 1980) and type II strain 79-1146 (McKeirnan et al., 1981) were kindly provided by Dr Egberink (Utrecht University, the Netherlands). FIPV strain Black was passaged on fcwf cells and FIPV strain 79-1146 on CrFK cells.
**Virus purification and biotinylation**

FIPV I (Black) infected fcwf cells and culture fluids were subjected to three freeze thaw cycles. Batches of culture fluids from FIPV II (79-1146) infected CrFK cells were collected. For both serotypes, the obtained suspensions were clarified by centrifugation at 3000 x g for 15 minutes. Purification and biotinylation were performed as described by Delputte *et al.* (2002) and Delputte & Nauwynck (2004). The supernatants were purified by ultracentrifugation with a Beckman Sw41 rotor (Beckman Coulter) on a 30 % sucrose cushion at 10^5 x g for 165 minutes. Pellets were resuspended in phosphate buffered saline (PBS) and centrifuged at 14000 x g for 30 minutes to remove cellular debris and virus aggregates. The purified virus was labelled with biotin by incubation of the virus suspension with a 10 g l^-1 solution of Sulfo-NHS-LC-Biotin (Pierce, Perbio Science) in PBS in a 20 to 1 ratio for 90 minutes at 4 °C. Tris buffer was added to a final concentration of 10 mM and 1 % FBS was used as cryoprotectant for storage at -70 °C. Experiments were performed by incubating 200 µg of purified viral particle suspension with 10^4.4 monocytes or 10^6 CrFK cells. To confirm whether the biotinylated particles were indeed virions, a co-localization assay was carried out. Two stainings were performed: viral proteins were detected using polyclonal anti-FIPV-FITC (VMRD) and biotin was visualized with streptavidin-Texas Red (Molecular Probes). The concurrence of anti-FIPV polyclonal antibodies and conjugated streptavidin was confirmed (Fig. 1). Further, it was shown that the biotinylation procedure did not influence the kinetics of attachment and internalization (data not shown).

![Figure 1: Co-localization of biotinylated particles and virions. Confocal images of monocytes incubated with biotinylated FIPV particles at 4 °C. FIPV particles are visualized by α-FIPV-FITC, biotin was visualized by streptavidin-Texas Red.](image_url)
**Quantification of biotinylated particles in suspension**

For quantification, 2 µl of virus suspension, diluted $10^{-3}$, $10^{-4}$ and $10^{-5}$ in PBS, was applied to streptavidin-coated slides (Streptavidin Cover Slips, Xenopore) and left to dry for 45 minutes. Biotinylated particles were stained with FITC-labelled streptavidin (Molecular Probes), diluted 1/500 in PBS, and incubated for 1 hour at 37 °C. The slides were washed with PBS and finally mounted on a microscope slide using glycerine-PBS in a 9 to 1 ratio with 2.5 % 1,4-diazabicyclo(2,2,2)octane (Janssen Chimica). The number of particles in the suspension was calculated after manually counting fluorescent particles.

It was shown that 200 µg of purified viral particle suspension contains $7.9 \times 10^9$ FIPV I (Black) particles and $5.0 \times 10^{10}$ FIPV II (79-1146) particles. This amount of virus suspension was applied to $10^{4.4}$ monocytes or $10^6$ CrFK cells throughout the experiments.

**Kinetics of attachment**

Cells were chilled on ice (4 °C) for 15 minutes and inoculated with biotinylated FIPV I (Black) or II (79-1146) at 4 °C. At different time points, cells were washed with PBS and fixed with 1 % formaldehyde. Attached particles were visualized using FITC-labelled streptavidin (Molecular Probes). Cell nuclei were stained with Hoechst 33342 (Molecular Probes). Finally, coverslips were mounted on microscope slides.

**Kinetics of internalization**

Cells were chilled on ice, inoculated with biotinylated FIPV I (Black) or II (79-1146) and then incubated until the maximum number of attached particles was reached. Cells were washed to remove unbound virus particles. Then, plates were transferred to 37 °C to enable virus uptake. Cells were fixed at different time points with 1 % formaldehyde. Particles attached to the outside of the cell were visualized using Texas Red-labelled streptavidin (Molecular Probes). After permeabilizing cells with 0.1 % Triton X-100, internalized particles were stained with FITC-labelled streptavidin. Finally, the cell nuclei were stained and coverslips were mounted on microscope slides.

Using ethidium monoazide bromide (EMA), cell vitality was determined for cells subjected to the manipulations described above before fixation. For the monocytes, the vitality was 99.3 % and for the CrFK cells, 97.8 %.

**Occurrence of internalization via fusion with the plasma membrane**

Stainings were performed on monocytes inoculated with FIPV I (Black) or FIPV II (79-1146) and CrFK cells inoculated with FIPV II (79-1146) to determine whether the biotinylated
Kinetic analysis of attachment and internalization of FIPV material at the plasma membrane after virus uptake via endocytosis, consisted of intact virions or viral envelopes, left behind after fusion. Cells were chilled on ice, inoculated with FIPV I (Black) and FIPV II (79-1146) and incubated at 4 °C. When attachment was completed, cells were transferred to 37 °C as described for the determination of the kinetics of internalization. Cells were fixed when maximal uptake was reached and remaining material at the plasma membrane was stained with polyclonal, FITC-labelled, anti-FIPV antibodies (VMRD). After permeabilization of the cells with 0.1 % Triton X-100, co-localization with mouse anti nucleocapsid antibodies was studied after staining with the monoclonal antibody E22-2 (kindly provided by Dr Hohdatsu, Kitasato University, Japan) and visualization with goat anti-mouse-Texas Red (Molecular Probes).

Microscopy and statistics
Analyses of virus attachment and internalization were performed by means of a DM IRB inverted microscope (Leica Microsystems). Images were obtained using a Leica TCS SP2 laser scanning spectral confocal system linked to a DM IRB inverted microscope (Leica). Argon and He/Ne lasers were used for exciting FITC and Texas Red fluorochromes, respectively. Leica confocal software was used for image acquisition. Triplicate assays were performed and compared using the Wilcoxon Signed Ranks test from the SPSS software package (version 12.0, SPSS).

RESULTS

Kinetics of attachment
Monocytes - Kinetics of attachment on monocytes from two cats were determined with both serotypes. The courses of the obtained kinetics are shown in Figure 2b. The number of particles attached at a certain time point is the average of the number of attached particles for 50 randomly chosen cells. Both cells with and without bound particles on their plasma membrane were included. For each cell, the entire plasma membrane was screened for the presence of particles.
Figure 2: Kinetics of attachment of FIPV I (Black) and FIPV II (79-1146) to monocytes of cat 1 and cat 2 and CrFK cells. Cells were inoculated with biotinylated FIPV and incubated at 4 °C. At designated timepoints virus was visualized using streptavidin-FITC. (a) Confocal images of single sections through cells. Green dots represent bound virus particles. (b) ---- courses determined in 3 independently performed experiments; —— mean course based on the 3 independently performed experiments.
**FIPV I (Black)** - After monocytes were incubated with FIPV I (Black) particles at 4 °C, bound virus was observed on the membrane of almost all monocytes (98.8 % of the monocytes for cat 1 and 99.5 % for cat 2). During the first 15 minutes of incubation, the number of attached FIPV I (Black) particles to monocytes of cat 1, gradually increased to 14 ± 1 bound particles per cell. Longer incubation times did not increase the amount of virus that bound noticeably. For cat 2, similar kinetics of attachment were obtained. A slightly slower increase persisted for 1 hour to 18 ± 7 bound particles per cell. From 1 hour on, no further increase was observed and attachment maintained at the same level.

**FIPV II (79-1146)** - Bound FIPV II (79-1146) particles were observed on the membrane of 66.2 % of the monocytes isolated from cat 1. During the first hour of incubation, the number of attached particles slowly increased to 5 ± 3 particles per cell (all cells considered). Despite longer incubation times (up to 3 hours), no more particles bound to the cell surface. In contrast, almost all monocytes of cat 2 (95.0 %) attached FIPV II (79-1146) particles at their plasma membrane. Within the first 30 minutes of incubation on ice, the number of attached particles strongly increased to 19 ± 10 bound particles per cell. From 30 minutes on, attachment maintained at the same level. Clearly, cat 2 monocytes reached a higher level of attached FIPV II (79-1146) particles than cat 1 monocytes.

**CrFK cells** - Kinetics of attachment of FIPV particles on the surface of CrFK cells are shown in Figure 2b for FIPV I (Black) and FIPV II (79-1146). The number of particles attached at different time points was determined as described for the monocytes.

**FIPV I (Black)** - Attachment of FIPV I (Black) particles was restricted to 15.4 % of the CrFK cells. After two hours of incubation on ice only 1 ± 1 particle bound per cell (all cells considered). Despite longer incubation times no further increase of this number was observed.

**FIPV II (79-1146)** - In contrast to the results for FIPV I (Black), almost all cells (99.8 %) had bound FIPV II (79-1146) particles on their plasma membrane. Also, more particles were attached, although the kinetics were slow. During 4 hours of incubation, the number of bound particles increased gradually to 49 ± 19 particles per cell. Longer incubation times increased the amount of bound virus slightly.

In Table 1, a comparison was made between the number of particles added to the cells and the resulting level of attachment for the different virus strains and cell types. Virus particles were present in excess in all experiments, therefore it might be suggested that all possible FIPV binding sites were taken. This could be confirmed by evaluating attachment after incubation with viral particle suspensions of varying concentrations.
Kinetics of internalization

Kinetics of internalization of FIPV were determined by incubating virus particles with the cells on ice until maximum attachment was reached, i.e. 1 hour for incubation of monocytes with both strains, and 2 hours and 5 hours for incubation of CrFK cells with respectively FIPV I (Black) and FIPV II (79-1146) (Fig. 2). Then, plates were transferred to 37 °C (= time point zero for the kinetics of internalization).

The kinetics of internalization of FIPV are shown in Figure 3. The percentages shown were calculated by analyzing 10 cells for the presence of particles in the cytosol and on the surface of the cell. Only cells that had attached and/or internalized particles were taken into account. For each cell, the entire cell volume was screened for particles.

**Monocytes** - The kinetics of internalization determined in monocytes are shown in Figure 3b.

*FIPV I (Black)* – The kinetics of internalization for FIPV I (Black) were similar for both cats. Almost all monocytes that bound FIPV I (Black) virions internalized virions (98.9 % of the monocytes that had bound particles for cat 1 and 98.5 % for cat 2). Remarkably, immobilization of the cells at 4 °C could not completely inhibit internalization as there were already particles internalized at time point zero. Within the first minute after the start of virus uptake, already 89 ± 6 % of the bound particles were internalized per cell. This level of internalization was roughly maintained during longer incubation times, though a slight decrease to 85 ± 13 % could be observed after one hour of incubation.

*FIPV II (79-1146)* – As for FIPV I (Black), internalization of FIPV II (79-1146) was mediated by approximately all monocytes that had bound virus particles (92.5 % of the analyzed monocytes isolated from cat 1 and all analyzed monocytes from cat 2) and kinetics were similar for both cats. After one minute, an average of 60 ± 9 % of the bound virions were internalized per cell. However, internalization further increased gradually up to 1 hour of incubation at 37 °C. Then, an average of 90 ± 7 % of the bound particles were taken up per cell.

**CrFK cells** - Kinetics of internalization of FIPV particles in CrFK cells are shown in Figure 3b.

*FIPV I (Black)* – Unlike for monocytes, uptake was restricted in CrFK cells to 20.8 % of the monocytes that had bound virus or only 3.2 % of all cells. No internalization was observed after the first minute of incubation at 37 °C, but during the first 2 hours the kinetics gradually mounted to the maximal level of internalization where 52 % of the bound particles per cell were internalized. During longer incubation times, internalization maintained at the same level. The percentage of internalized particles per cell varied between 0 and 100 % as often only 1 particle was bound to the cell, so only 1 particle could be internalized.
Figure 3: Kinetics of internalization of FIPV I (Black) and FIPV II (79-1146) in monocytes of cat 1 and cat 2 and CrFK cells. Cells were inoculated with biotinylated FIPV and incubated at 4 °C until saturation of attachment. Plates were then transferred to 37 °C. At designated timepoints virus at the plasma membrane was visualized using streptavidin-TR and - after permeabilization - internalized virus was visualized using streptavidin-FITC. (a) Confocal images of single sections through cells. Red dots represent virus particles at the cell surface, exclusively green dots internalized virus particles. (b) ---- courses determined in 3 independently performed experiments; — mean course based on the 3 independently performed experiments.
Chapter 3

FIPV II (79-1146) - All cells were capable of internalizing FIPV II (79-1146) virions. Within the first minute, no more than 3 ± 2 % of the bound particles were observed inside the cell. But, again, the percentage of internalization per cell increased gradually, and reached 67 ± 4 % after 2 hours of incubation at 37 °C. Longer incubation times only slightly increased the percentage of internalization per cell.

Table 1. Comparison of the number of FIPV particles added to the cells and the number of particles attached after incubation at 4°C until saturation

<table>
<thead>
<tr>
<th>Virus strain</th>
<th>Particles added</th>
<th>Cell type</th>
<th>Bound particles</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIPV I (Black)</td>
<td>7.9 x 10⁹</td>
<td>CrFK</td>
<td>2.00 x 10⁸</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monocytes cat 1</td>
<td>7.31 x 10⁶</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monocytes cat 2</td>
<td>7.74 x 10⁶</td>
</tr>
<tr>
<td>FIPV II (79-1146)</td>
<td>5.0 x 10¹⁰</td>
<td>CrFK</td>
<td>1.44 x 10⁸</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monocytes cat 1</td>
<td>2.58 x 10⁶</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monocytes cat 2</td>
<td>9.46 x 10⁵</td>
</tr>
</tbody>
</table>

Occurrence of internalization via fusion with the plasma membrane

The kinetics of internalization indicate that the majority of bound FIPV particles enters cells via endocytosis. But virus uptake via endocytosis did not reach 100 % in monocytes, nor in CrFK cells. A small fraction of biotinylated material remained at the outside of the cell. This could be bound virus particles, unable to enter the cell, or biotinylated envelopes that were left behind after fusion with the host cell membrane. A staining was performed to determine the nature of what was left at the plasma membrane after internalization was completed. Cells were therefore fixed after 1 hour and 2 hours of incubation at 37 °C for respectively monocytes and CrFK cells. The results are shown in Figure 4. It was obvious that all the biotinylated FIPV material at the plasma membrane co-localized with FIPV nucleocapsid proteins. Thus, the biotinylated material consisted of intact virions, unable to enter the cell. This implies that, under the present experimental conditions, both FIPV strains enter monocytes exclusively via endocytosis and so does FIPV II (79-1146) in CrFK cells. It can be stated that fusion at the plasma membrane is not involved in FIPV entry.
DISCUSSION

Feline infectious peritonitis (FIP) is a fatal viral infection. No effective treatment is commercially available as several important questions concerning the pathogenesis of FIP remain unanswered. Especially virus-cell interactions need to be studied in greater detail in order to obtain insights on possible targets for drug development. Interfering with the internalization process of viruses is a new strategy for development of antiviral compounds as has been described for e.g. human immunodeficiency virus, hepatitis C virus and dengue virus (Altmeyer, 2004; Este, 2003; Le Calvez et al., 2004). In this study, the initial steps in
FIPV infection were analyzed for the first time in the FIPV target cell by determining kinetics of attachment and internalization, using biotinylated virus. Feline blood monocytes are the target cells \textit{in vivo} for feline infectious peritonitis virus, therefore these cells were used in the experiments to approximate the natural situation as much as possible. Two virus strains were included: the FIPV serotype I strain Black and the routinely used serotype II strain 79-1146.

The kinetics of attachment for FIPV I (Black) were quite similar for both cats. However, the kinetics of attachment of FIPV II (79-1146) determined for the two cats were significantly different (Wilcoxon Signed Ranks (WSR): $p=0.025$). This difference could be the consequence of variable expression levels of one of the cellular components involved in attachment, e.g. a specific serotype II FIPV receptor, between the two cats. Another difference in kinetics of attachment was observed between FIPV I (Black) and FIPV II (79-1146) for the monocytes of cat 1 (WSR: $p=0.012$) and cat 2 (WSR: $p=0.036$). This could indicate that type I and II strains use different receptors on monocytes and that the serotype II receptor may be differentially expressed in between cats, while apparently the serotype I receptor is not. Differences in receptor use between type I and II have already been demonstrated in cell culture (Hohdatsu \textit{et al.}, 1998). As only two cats were considered, these data cannot lead to general conclusions. Further research will focus on the receptors of FIPV in monocytes, which will allow interpretation of the present findings.

Internalization in monocytes was very efficient for both serotypes. The efficiency of TGEV internalization in the MDCK cell line is evenly efficient as that of FIPV in monocytes. TGEV is another group 1 coronavirus. TGEV virions can be observed in endocytic pits and apical vesicles, by electron microscopy, after 3 to 10 minutes of incubation at 38 °C with MDCK cells, stably expressing the receptor, porcine aminopeptidase N (Hansen \textit{et al.}, 1998). For HCoV-229E, most particles are internalized in human fibroblasts within the first hour of incubation at 37 °C, but a fraction is still bound to the cell membrane upon 3 hours of incubation (Nomura \textit{et al.}, 2004). Similar results as those for FIPV are obtained for the attachment and internalization of porcine reproductive and respiratory syndrome virus (PRRSV), another member of the \textit{Nidovirales}, in macrophages (Nauwynck \textit{et al.}, 1999). Attachment of biotinylated PRRSV reaches saturation after 1 hour. After 1 minute, confocal images showed uptake of virus particles and after 1 to 2 hours the uptake was completed. The kinetics determined for FIPV led to the same conclusion (Nauwynck \textit{et al.}, 1999). PRRSV particles start to accumulate in endosomes approximately 1 or 2 hours after the start of the virus uptake. For FIPV, more intense and larger fluorescent spots were already
observed in confocal images at 15 minutes after the start of virus uptake. TGEV virions start
to accumulate in endosomes, already 10 minutes after initiation of endocytosis (Hansen et al., 1998).

Another mutual observation between PRRSV and FIPV is the decreasing number of particles
inside the cell at later time points in the kinetics: for FIPV within 1 hour (data not shown),
for PRRSV after 3 to 5 hours (Nauwynck et al., 1999). The decreasing number of particles
explains the apparent drop in internalization described for FIPV I (Black) where the
percentages of uptake per cell were higher after 1 minute than after 1 hour. The decrease in
particle number is probably the result of particle disassembly. This has also been described
for TGEV where genome penetration is situated around 1 hour after the onset of
internalization (Hansen et al., 1998).

Replication of FIPV is limited to a small fraction (less than 1 % for FIPV 79-1146) of
monocytes (Dewerchin & Cornelissen, 2005) and peritoneal macrophages (Morahan et al.,
1985; Stoddart & Scott, 1989). However, virus binding and uptake took place in almost all
monocytes. Thus, the mechanism behind the resistance of most monocytes/macrophages
must lie in an inhibition of genome release and/or genome translation. Further research will
clarify which step in virus replication is blocked in cells resistant to FIPV infection. Replication
of PRRSV in alveolar macrophages is also restricted in a step after binding and
internalization. Although bound particles and internalization were observed in almost all
alveolar macrophages, viral PRRSV antigens could be detected in only 12.3 % of the cells
(Duan et al., 1997; Nauwynck et al., 1999).

Attachment and internalization of FIPV I (Black) virions to the plasma membrane of CrFK
cells were very inefficient. It is possible that no specific mechanism is involved. Particles may
accidentally co-internalize with other compounds. The ability of FIPV I (Black) to induce
infection of CrFK cells was studied by inoculating cells with the same concentration of virus
as used for determining the kinetics, and a subsequent incubation for 12 hours at 37 °C.
Staining with polyclonal anti-FIPV antibodies revealed that only 0.003 % of the cells were
infected (data not shown). Infectivity of FIPV I (Black) in CrFK cells is the subject of
contradictory literature. According to Black (1980), FIPV strain Black is able to infect and
cause cytopathogenic effects (CPE) in CrFK cells 3 to 5 days post inoculation. Possibly
plaques are being formed at later time points post inoculation due to cell-to-cell spread of
the virus by the few primary infected cells that were observed 12 hours post inoculation. On
the other hand, Hohdatsu et al. (1998) reported that CrFK cells were not susceptible to
infection with FIPV I (Black) as no CPE, nor virus specific antigens could be detected 3 days post inoculation. It is possible that the susceptibility of CrFK cells of different laboratories may differ due to genetic changes during long term subpassaging of the cell lines.

CrFK cells are often used as a model cell line for FIPV serotype II infection studies. However, internalization of FIPV II (79-1146) was slower and less efficient than in monocytes. Thus, FIPV seems to interact differently with CrFK cells than with monocytes. This confirms earlier observations where inoculation of CrFK cells with FIPV II (79-1146) resulted in a high percentage of infected cells, but low production of newly synthesized virions. In contrast, inoculation of monocytes led to a low percentage of infected cells, but to large amounts of newly produced virions (Dewerchin et al., 2005).

Viruses may enter cells via two pathways. The envelope of the virion may directly fuse with the plasma membrane or the envelope may fuse with the endosomal membrane after entering the cell via endocytosis. The pathway used depends upon the virus strain and the nature of the cell being infected (Kooi et al., 1991; Nash & Buchmeier, 1997). Certain viruses even use both pathways in a particular cell type (Schaeffer et al., 2004). The results of this study indicate that bound FIPV particles enter target cells exclusively via endocytosis. Several other group 1 coronaviruses have also been shown to enter cells via endocytosis, e.g. HCoV-229E, TGEV and CCoV. Further research will focus on determining the characteristics of the endocytic pathway that is used by the FIPV serotype I and II virions in monocytes.

In this study, kinetics of attachment and internalization of FIPV in its primary target cell, the blood monocyte, were studied in detail for the first time. Attachment and especially internalization proceeded very efficiently for the strains of both serotypes. Bound particles entered target cells via endocytosis and not via fusion. Although infection is restricted to a small fraction of monocytes, virus uptake took place in the majority of cells, indicating that blocking of infection occurs at the level of genome release or translation/transcription. In contrast, attachment and internalization in CrFK cells were shown to proceed inefficiently, especially for FIPV I (Black) virions. It is concluded that this cell line is not suitable for studying FIPV entry into target cells.
ACKNOWLEDGEMENTS

We are grateful to Dr Hohdatsu and Dr Egberink for supplying antibodies and virus strains. E.V.H. was supported by a doctoral grant from the special research fund of Ghent University (01D29005) and H.L.D. and E.C. by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen).
REFERENCES


Chapter 4

INTRIGUING INTERPLAY BETWEEN AMINOPEPTIDASE N AND DC-SIGN IN FELINE INFECTIOUS PERITONITIS VIRUS TYPE II ENTRY IN PRIMARY FELINE MONOCYTES

Evelien Van Hamme, Hannah L. Dewerchin, Els Cornelissen & Hans J. Nauwynck

In preparation
ABSTRACT

Two potential receptors have been described for feline coronaviruses (FCoV). Feline APN (fAPN) can serve as a receptor for serotype II, but not serotype I, FCoVs in cell lines. Secondly, FCoVs can use dendritic cell-specific intercellular adhesion molecule grabbing non-integrin (DC-SIGN) for entry into host cells. In this study, the interplay between APN and DC-SIGN as receptors for FIPV was analysed in Crandell feline kidney (CrFK) cells and in monocytes. First, the effect of blocking the potential receptor(s) on attachment, internalization and infection was evaluated and secondly, the level of co-localization of FIPV and the receptors was determined. It was found that blocking fAPN completely inhibited binding to and infection of CrFKs and that FIPV co-localized with fAPN. In contrast, on monocytes, binding and infection were only reduced by 53 % and 44 % respectively and only 60 % of bound FIPV co-localized with fAPN. Transduction of human DC-SIGN was found to render CHO cells susceptible to binding and internalization of FIPV but not to infection. Blocking feline DC-SIGN (fDC-SIGN) did not influence binding and infection of monocytes and there was no co-localization. However, blocking fDC-SIGN caused a further inhibition of infection from 56 % up to 18 % infection in APN-blocked monocytes. APN is capable of binding and internalizing FIPV and APN-mediated entry leads to infection in monocytes. However, this is not the exclusive receptor for FIPV on monocytes, unlike in CrFK cells. fDC-SIGN is not directly required for attachment or internalization in monocytes, but important for infection via an alternative pathway independent of APN. Finally, this study indicates that caution should be taken when using certain cell lines for receptor and entry studies.
INTRODUCTION

Feline coronaviruses belong to coronavirus subgroup 1 and occur in two pathotypes: the often unapparent enteric feline coronavirus (eFCoV) and the deadly feline infectious peritonitis virus (FIPV). Each pathotype comprises two serotypes. Serotype I causes most natural infections, whereas serotype II is mostly used for research purposes because it grows better in culture (Pedersen et al., 1984).

The process of viral entry is an attractive target for the development of new therapeutic agents. To this end, a lot of research has been focussing on entry processes for a range of viruses (Cooley & Lewin, 2003; Timpe & McKeating, 2009). This has led to the development of a number of promising agents, for example in the treatment of HIV-1 (Cooley & Lewin, 2003). Over the last couple of years, the knowledge on the entry of feline coronaviruses in host cells has expanded. After binding to the receptor(s), the virus is internalized in monocytes through endocytosis, more specifically via a clathrin- and caveolae-independent pathway using dynamin (Van Hamme et al., 2007, 2008). According to Regan et al. (2008), subsequent escape from endosomes is mediated by cathepsin B for FIPV strains 79-1146 and DF2, while for the enteric strain 79-1683 low pH in endocytic compartments and cathepsin L need to assist cathepsin B. In contrast, de Haan et al. (2008) observed that infection with FIPV 79-1146 appears to be insensitive to cathepsin inhibitors.

Two potential receptors have been described for the feline coronaviruses. The first one is aminopeptidase N (APN), also designated CD13, a ubiquitous and multifunctional glycoprotein of approximately 110 kDa and 967 amino acids (Luan & Xu, 2007). It is a type II metalloprotease that contains seven domains (Sjöström et al., 2000). Domains V to VII can interact to form non-covalently linked homodimers (Sjöström et al., 2000). Feline APN (fAPN) serves as a receptor for feline, canine, porcine and human coronaviruses in coronavirus subgroup 1 (Tresnan et al., 1996). However, only serotype II and not serotype I FCoV strains are able to recognize fAPN (Hohdatsu et al., 1998; Dye et al., 2007). Binding of serotype II strains to fAPN from cell lines can be blocked completely by the monoclonal antibody R-G-4 that binds to a region on fAPN between aa 251 to 582, i.e. in domains V or VI (Hohdatsu et al., 1998; Tusell et al., 2007). The attachment of FIPV to fAPN was mainly studied on cell lines and by means of a fAPN cDNA clone originating from the fcwf-4 cell line. Secondly, it has been described that feline coronaviruses use dendritic cell (DC)-specific intercellular adhesion molecule (ICAM) grabbing non-integrin (DC-SIGN, CD209) for entry into Crandell feline kidney (CrFK) cells, mouse 3T3 cells transfected with DC-SIGN and monocytes (Regan & Whittaker, 2008). DC-SIGN is a C-type lectin, which implies that it
recognizes its ligands, high-mannose oligosaccharides, through $\text{Ca}^{2+}$-dependent carbohydrate-recognition domains (Drickamer, 1999). Many viruses, such as HIV, Ebola and hepatitis C, use DC-SIGN or the homologue L-SIGN, expressed in liver and lymph nodes, to augment infection (Geijtenbeek et al., 2000; Alvarez et al., 2002; Lozach et al., 2003; Pöhlmann et al., 2003). Some coronaviruses also interact with these lectins. For SARS-CoV, DC-SIGN and L-SIGN can enhance infection of cells that co-express the major SARS receptor, ACE2 (Marzi et al., 2004; Jeffers et al., 2004; Yang et al., 2004). DC-SIGN, but not L-SIGN, can similarly augment infection with human coronavirus (HCoV) NL63, that also relies on ACE2 for infectious entry (Hofmann et al., 2006). Further, L-SIGN expressed in non-susceptible cells can bind HCoV-229E (Jeffers et al., 2006). For the feline coronaviruses, expression of human DC-SIGN in CrFK cells induced an increase of infection that was blocked by mannan, a competitor of DC-SIGN binding. Further, infection of feline monocytes, the in vivo target cell, was strongly reduced by mannan (Regan & Whittaker, 2008).

In this study, the role of the candidate receptors was determined in the distinct steps of the multi-step entry process in primary target cells, blood monocytes. The effects of blocking fAPN and fDC-SIGN in monocytes were studied for the processes of attachment, internalization and infection by FIPV 79-1146. In addition, co-localization studies were performed between FIPV and these potential receptors. The aim of this study was to understand how FIPV interacts with its receptors on the primary FIPV target cells in vivo, the blood monocytes.

**METHODS**

**Cells and virus**

Feline blood monocytes were isolated from blood collected from a feline coronavirus-, feline leukaemia virus- and feline immunodeficiency virus-negative cat and cultured as described before (Dewerchin et al., 2005). CrFK cells were purchased from the ATCC. CHO control cells and CHO transfectants stably expressing wild-type human DC-SIGN (de Witte et al., 2006) were a gift of Dr Geijtenbeek (Department of Molecular Cell Biology and Immunology, VU University Medical Centre Amsterdam, Amsterdam, The Netherlands). FIPV serotype II strain WSU 79-1146 (FIPV II) was a kind gift of Dr Egberink (Department of Infectious Diseases and Immunology, Utrecht, The Netherlands) and passaged on CrFK cells (McKeirnan et al., 1981).
Antibodies

The monoclonal antibody R-G-4 (mAb R-G-4) directed against feline aminopeptidase N (fAPN) (Hohdatsu et al., 1998) was a kind gift of Dr Hohdatsu (Department of Veterinary Infectious Diseases, Towada, Japan). The monoclonal antibody 25-2B against fAPN, also designated CD13, was purchased from Veterinary Medical Research and Development (VMRD, Pullman, USA). A polyclonal mouse antibody raised against full-length human DC-SIGN, also designated CD209, was purchased from Abnova (Taipei, Taiwan). mAb DH59B (VMRD) was used to stain CD172a in the plasma membrane of monocytes. Immunoglobulin G1 13D12 against pseudorabies virus gD was produced in the laboratory (Nauwynck & Pensaert, 1995) and was used as an irrelevant isotype-matched control antibody. Polyclonal anti-FIPV antibodies against FIPV serotype II strain WSU 79-1146 were a kind gift of Dr Rottier (Department of Infectious Diseases and Immunology, Utrecht, The Netherlands).

Inhibition assays

The experimental design to study attachment and internalization separately and the time points used to evaluate the potency to inhibit these processes, were determined based on data obtained earlier on the kinetics of attachment and internalization of FIPV (Van Hamme et al., 2007).

Attachment inhibition assay. Cells were washed at 68 h post-seeding and pre-incubated at 4 °C for 60 minutes with mAb R-G-4 (25 mg/ml) and/or mannan (50 mg/ml), or an irrelevant isotype-matched mAb. After pre-treatment, FIPV was added to the cells at a multiplicity of infection (moi) of 1 (resulting concentrations: 8 mg/ml antibody and/or 16 mg/ml mannan). Cells and virus were incubated further at 4 °C for 1.5 h (monocytes) or 3 h (CrFK and CHO cells). Then, cells were washed with ice-cold RPMI 1640 and fixed with formaldehyde (1 %). Bound particles were stained with anti-FIPV-biotin, followed by streptavidin-FITC (Molecular Probes-Invitrogen, Merelbeke, Belgium). After mounting of the coverslips, attachment was quantified per cell by counting the number of bound particles for at least 20 cells.

Entry inhibition assay. Cells were washed at 68 h post-seeding and pre-incubated at 37 °C for 60 minutes with mAb R-G-4 and/or mannan, or an irrelevant isotype-matched mAb. After pre-treatment, FIPV was added to the cells at an moi of 1. Cells and virus were incubated at 37 °C for 10 minutes (monocytes) or 1 h (CrFK and CHO cells). Then, cells were washed with ice-cold RPMI 1640 and fixed with formaldehyde (1 %). Bound particles were
stained with anti-FIPV-biotin, followed by streptavidin-Texas Red (Molecular Probes-Invitrogen, Merelbeke, Belgium). After permeabilization with Triton X-100 (0.1 %), internalized particles were stained with anti-FIPV-biotin, followed by streptavidin-FITC. After mounting of the coverslips, internalization was quantified per cell as the ratio of internalized virus particles to the total number of cell associated particles. At least ten cells were analyzed and all particles over the entire volume of the cell were monitored.

**Infection inhibition assay.** At 56 h post-seeding, cells were washed with RPMI 1640 and pre-incubated for 1 h at 37 °C with mAb R-G-4 and/or mannan, or an irrelevant isotype-matched mAb. After pre-treatment, FIPV was added to the cells at an moi of 1. Then, after 1 h the inoculum was replaced by medium supplemented with the antibodies or mannan, at the same concentrations as for pre-treatment. The cells were incubated for another 11 h at 37 °C. Finally, cells were washed, fixed and permeabilized. Permeabilization was followed by 1 h of incubation at 37 °C with anti-FIPV-FITC and 10 minutes with Hoechst 33342 (Molecular Probes). Coverslips were mounted onto microscope slides and analyzed by confocal microscopy. Cells with cytoplasmic expression of viral proteins were scored as infected cells. All cells on the coverslips were evaluated.

**Co-localization assays**
Monocytes, CrFK cells and CHO cells were washed at 68 h post-seeding and chilled at 4 °C for 20 minutes. Then, cells were inoculated with FIPV at an moi of 1. Cells and virus were incubated further at 4 °C for 1.5 h. Then, cells were washed with ice-cold RPMI 1640 and fixed with formaldehyde (1 %). Bound particles were stained with anti-FIPV-biotin, followed by streptavidin-FITC (Molecular Probes-Invitrogen, Merelbeke, Belgium). Slides were incubated with mAb 25-2B to stain fAPN, or with pAb anti-DC-SIGN antibodies to stain DC-SIGN. The mAb DH59B was used to visualize CD172a (VMRD). As a conjugate, Texas red-labelled goat anti-mouse antibodies were used (Molecular Probes). Coverslips were mounted onto microscope slides and analyzed by confocal microscopy.

**Microscopy and statistics**
Infection assays were analyzed by a DM IRB inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany). Attachment, internalization and co-localization assays were analyzed with a Leica TCS SP2 laser scanning spectral confocal system linked to a DM IRB inverted microscope (Leica). Argon and He/Ne lasers were used for exciting FITC and Texas red fluorochromes, respectively. Leica confocal software was used for image acquisition.
Triplicate assays were performed and compared with the Mann-Whitney U test using the SPSS software package (version 12.0, SPSS Inc. Chicago, Illinois, USA). P values < 0.05 were considered significantly different.

RESULTS

Expression of the potential receptors fAPN and DC-SIGN on monocytes
fAPN was present on all monocytes and it was expressed in the plasma membrane as well as in the cytosol. This was assessed by stainings with mAb 25-2B before and after permeabilization (Fig. 1). It was, however, remarkable that the R-G-4 epitope was only abundantly present extracellularly on approximately 10% of the monocytes. After permeabilization, the R-G-4 epitope could be detected in all cells (Fig. 1). In contrast, on CrFK cells, the R-G-4 epitope was extracellularly present on all cells (data not shown). This suggests that the expression pattern and/or the conformation of APN is cell type dependent. Furthermore, it was shown that the extracellular expression of the R-G-4 epitope on monocytes increased over time, from no cells with extracellular R-G-4 epitope expression on day 0, up to 16% of cells with extracellular expression at day 5 post seeding (data not shown). For DC-SIGN, practically all monocytes expressed a substantial amount of DC-SIGN in their plasma membrane. DC-SIGN was also present intracellular (Fig. 1).

Evaluation of the role of fAPN in FIPV entry
The role of fAPN as an entry mediator for FIPV was evaluated in CrFK cells and in monocytes by means of inhibition studies with mAb R-G-4 and co-localization studies between FIPV and fAPN stained with mAb 25-2B.

fAPN is the major receptor for infectious entry on CrFK cells. On CrFK cells, (pre-)treatment with mAb R-G-4 completely (and significantly) blocked binding of FIPV (Fig. 2). Further, viral particles were not observed in CrFK cells treated with this mAb due to the fact that there was no virus binding (Fig. 3). This is clear from the picture in Figure 3 where no bound particles (in red) are visible. As infection was also blocked completely (and significantly) by this antibody (Fig. 4), it is safe to say that internalization after binding to fAPN leads to infection. All the particles bound to the cell surface co-localized with the epitope bound by mAb 25-2B and therefore co-localized with fAPN (Fig. 5). It is clear that fAPN is a necessary receptor for FIPV infection in the CrFK cell line.
Figure 1: Expression of fAPN and fDC-SIGN on blood monocytes. fAPN on monocytes was stained with two mAbs on the plasma membrane and/or in the cell. DC-SIGN in the plasma membrane of monocytes was stained with a pAb.

fAPN is a receptor for infectious entry on monocytes. After incubation of cells with mAb R-G-4, attachment of FIPV was significantly reduced to 46.6 % of attachment on control cells (Fig. 2). Despite the fact that there was a big reduction by the mAb, this inhibition was not complete like observed for the CrFK cells. The internalization of bound FIPV in the presence of R-G-4 in monocytes was unaffected (Fig. 3). This means that the percentage of the virions that still bound to monocytes in the presence of mAb R-G-4 that was internalized, was similar to the percentage of particles that was internalized in the absence of inhibition. Particles that got internalized could also productively infect the monocyte as infection can be significantly reduced to 56.2 % of the control through administration of mAb R-G-4. Co-localization studies showed that 59.9 ± 16.2 % of the FIPV particles that bound to monocytes, co-localize with fAPN (Fig. 5). This amount of co-localization was significantly higher than what was expected based on coincidence (27.8 ± 5.2 %), as shown by the co-localization staining between FIPV and CD172a, an irrelevant surface protein. This confirms the involvement of fAPN in virus binding to monocytes. However, a relatively high percentage of binding and infection with FIPV is still unaccounted
Figure 2: Attachment of FIPV on CrFK cells, CHO-DC-SIGN cells and monocytes in the presence of mAb R-G-4 and/ or mannan. Confocal images of single sections through cells are shown. Green dots represent bound virus particles. Next to each image the number of particles bound per cell under
the described conditions is indicated. The graphs illustrate FIPV binding per cell in the presence of an irrelevant mAb (irr mAb), mAb R-G-4 and/or mannan relative to binding in control cells. Data represent means ± standard deviations of triplicate assays. ‘p’ stands for particles. * marks values that are significantly different from the control.

for, indicating that fAPN is a receptor for FIPV but not the sole receptor. Moreover, these results show that the entry events in CrFK cells do not reflect what occurs in monocytes.

**Evaluation of the role of DC-SIGN in FIPV entry**

The role of DC-SIGN as an entry mediator for FIPV was evaluated on wild type CHO cells, CHO cells stably transduced with human DC-SIGN and in monocytes by means of inhibition studies with mannan and co-localization studies between FIPV antigens and feline DC-SIGN stained with pAb anti-DC-SIGN.

**Human DC-SIGN (hDC-SIGN) can bind and internalize FIPV.** Wild type CHO cells do not bind or internalize FIPV (data not shown). However, after stable transduction with hDC-SIGN, virus binds efficiently to all cells (Fig. 2) and is also able to enter these cells (Fig. 3). As virus attachment on the cells can be completely (and significantly) blocked by mannan, hDC-SIGN is the virus binding receptor on these cells. This is confirmed by the full co-localization between FIPV and hDC-SIGN on these cells (Fig. 5). The small number of particles that bound to cells in the presence of mannan were not internalized in the cells, indicating that DC-SIGN is responsible for both binding and internalization in CHO-DC-SIGN cells. The cells are however not susceptible to infection, which means that hDC-SIGN can not mediate infectious entry in these cells.
Role of APN and DC-SIGN in FIPV II entry

Figure 3: Internalization of FIPV in CrFK cells, CHO-DC-SIGN cells and monocytes in the presence of mAb R-G-4 and/or mannan. Confocal images of single sections through cells are shown. All red dots
represent bound virus particles that are not internalized, while exclusively green dots represent internalized virus particles. Next to each image the percentage of internalized particles (p) per cell under the described conditions is indicated. The graphs illustrate the internalization per cell in the presence of an irrelevant Ab (irr mAb), mAb R-G-4 and/or mannan relative to internalization in control cells. Data represent means ± standard deviations of triplicate assays. * marks values that are significantly different from the control.

Role of feline DC-SIGN (fDC-SIGN) in binding and internalization of FIPV in target cells. As hDC-SIGN can bind and internalize FIPV particles, the role of fDC-SIGN, naturally present on the in vivo target cells for FIPV, was evaluated in monocytes. Figure 2 showed that blocking fDC-SIGN with mannan had no effect on virus binding. This was further confirmed by the fact that combining mannan and R-G-4 did not significantly increase the inhibition of attachment caused by R-G-4. Accordingly, internalization could not be influenced by the presence of mannan alone or a combination of mAb R-G-4 and mannan (Fig. 3). For infection, like for attachment and internalization, no inhibiting effect was observed when only mannan was added. This suggests that fDC-SIGN is not involved in the entry process of FIPV in primary cells and that the binding capacities of hDC-SIGN observed in cell lines do not reflect the situation in the natural target cells. The results of the co-localization study between FIPV and fDC-SIGN on monocytes supported this conclusion as the observed co-localization of 28.9 ± 4.5 % did not significantly exceed the level of ‘background’ co-localization (27.8 ± 5.2 %; Fig. 5). However, when both mAb R-G-4 and mannan were added to the cells, infection was reduced significantly more efficiently than when only aminopeptidase N was blocked: a reduction to 17.8 % of infection in control cells compared to 56.2 % when only APN is blocked. Based on these results, it appears that fDC-SIGN does seem to have a role in the infection process, even though the underlying mechanism remains elusive thus far.
Figure 4: Graph illustrating the percentage of infected cells in the presence of an irrelevant mAb (irr mAb), mAb R-G-4 and/or mannan relative to the percentage of infected control cells. Data represent means ± standard deviations of triplicate assays. * marks results that are significantly different from the control.
Figure 5: Co-localization of FIPV with membrane proteins. Co-localization stainings are performed after attachment of FIPV to the cells at 4 °C. FIPV was stained with biotinylated anti-FIPV antibodies and streptavidin-FITC. fAPN was stained with mAb 25-2B, and hDC-SIGN and fDC-SIGN with pAbs. All these Abs were visualized with goat anti-mouse-Texas Red antibodies. The figure shows confocal images of single sections through cells.
DISCUSSION

The main goal of this study was to evaluate the role and interplay of two described receptors for FIPV, aminopeptidase N (APN) and DC-SIGN, in its natural host cell, the monocyte. This was pursued through a combination of inhibition assays at different stages of the entry process, infection inhibition assays and co-localization studies.

Feline aminopeptidase N (fAPN) was shown before to be a receptor for type II FIPV on cell lines (Tresnan et al., 1996; Hohdatsu et al., 1998; Dye et al., 2007). Our results confirmed and extended these findings showing that fAPN is a necessary receptor for FIPV II on CrFK cells and the major attachment receptor on these cells. Although it was not possible to confirm that fAPN is also involved in the subsequent internalization of the virus in CrFK cells, as virus did not bind in the presence of mAb R-G-4 (directed against fAPN), it is most likely as FIPV was found to co-localize with fAPN inside these cells (data not shown). For human coronavirus 229E, that uses human APN as a receptor, it was also indirectly shown that APN is involved in internalization. The virus was shown to co-localize with caveolin inside human fibroblast cells, and caveolin was shown to co-localize with APN inside the cells (Nomura et al., 2004).

On feline monocytes, fAPN also acts as a virus binding receptor. However, it is not the only receptor as virus binding could not be completely blocked by anti-fAPN antibodies (mAb R-G-4). The internalization experiments indicated that the fraction of the virus bound to the other unknown receptor, that is internalized, is similar to the fraction of bound virus, that is internalized when fAPN is available. Further, binding to fAPN can lead to infection as infection was reduced by mAb R-G-4. Because blocking fAPN did not completely prevent infection, it is most likely that internalization through the other receptor also leads to infection.

Hence, entry in CrFK cells provides useful information about the FIPV-fAPN interaction but does not reflect the complete picture of what happens during virus entry in monocytes. This is in line with previous findings that indicate that CrFK cells are of limited use as a model cell line to study interactions of FIPV with target cells (Dewerchin et al., 2005; Van Hamme et al., 2007).

The virus binding and internalizing capacities of human DC-SIGN (hDC-SIGN) became evident based on the fact that transduction of CHO cells with hDC-SIGN rendered them capable of binding and internalizing FIPV. However, internalization through hDC-SIGN did
not lead to infection in these cells. This might be due to the absence of a factor necessary for escape of the virions from endosomes as internalization through hDC-SIGN targets the endosomal/lysosomal pathway (Engering et al., 2002). Unfortunately, these experiments could not be performed with cells transduced with fDC-SIGN, as cloning and characterization of the feline homologue has yet to be achieved. This also has hampered research on another feline virus, feline immunodeficiency virus (FIV), where interactions between FIV surface glycoproteins and hDC-SIGN were shown and the authors remained cautious with conclusions towards fDC-SIGN (de Parseval et al., 2004). Nevertheless, the experiments with the CHO-hDC-SIGN cells provide a positive control for the set-up of the inhibition and co-localization assays.

Even though it would be very interesting to evaluate the FIPV binding and internalizing capacities of fDC-SIGN by expressing this protein in non-susceptible cells, there are already strong indications that fDC-SIGN is not necessary for virus binding and internalization in its natural host cell, the monocyte. Blocking fDC-SIGN with mannan on monocytes did not affect FIPV binding and internalization. Also infection of monocytes was not affected by blocking DC-SIGN with mannan. Additionally, when fAPN is blocked, FIPV binding does not transfer to fDC-SIGN because even then virus binding is not reduced by mannan. It seems clear that fDC-SIGN is not the unknown receptor for FIPV that is responsible for the fraction of binding and infection that remains after blocking fAPN. However, treating fAPN-blocked cells with mannan, did cause a supplemental reduction of infection. The involvement of DC-SIGN is most likely situated in a step after internalization because when both fAPN and fDC-SIGN are blocked, there is still efficient internalization of bound particles.

Having listed the results from this study, a comparison can be made with the results obtained by Regan & Whittaker (2008). They induced susceptibility to infection in unsusceptible cells (mouse 3T3 cells) after transfection with hDC-SIGN. In our study, virus internalization could be induced in transfected CHO cells, but infection could not be. A possible explanation is that CHO cells lack a factor necessary to release the FIPV genome from intracellular vesicles, while this factor is present in the mouse cells used by Regan & Whittaker. Further, Regan & Whittaker found that transfection of hDC-SIGN in CrFK cells enhanced infection of these cells. This could be explained by increased virus binding and internalization. Infection of monocytes could also be blocked with mannan, according to Regan & Whittaker. In our hands, no inhibition of infection was observed after treating monocytes with mannan. There is no obvious explanation for the different outcome of this experiment. Maybe multiple passaging in the laboratory, induced culture adaptations in the virus that influence virus-receptor interactions.
The data obtained in this study provide the following insights in FIPV type II entry in monocytes. Virus can bind to fAPN and will probably be internalized into the cell via this receptor. A particle internalized via this pathway can lead to infection of the cell. A second, unknown receptor can also bind and internalize FIPV. This pathway probably also leads to infection. fDC-SIGN is not the unknown receptor, but can fulfil a role in infection via this unknown receptor in a post-internalization step. Hypothetically, fDC-SIGN might be involved in genome release of virus that enters cells via the unknown receptor.

The experiments showed that blocking fDC-SIGN did not affect infection. This might suggest that the fAPN-mediated pathway can compensate for fDC-SIGN malfunction or unavailability.

The receptor for serotype I FIPV in monocytes is still unknown. Probably, FIPV type I does not use APN (Hohdatsu et al., 1998; Dye et al., 2007). Possibly, the pathway for type II using the unknown receptor with/without DC-SIGN might also be the pathway used by type I FIPV. This will be studied in the future by comparing binding of FIPV type I to monocytes, with binding of FIPV type II in the presence of antibodies against APN on these monocytes. Further, the effect of blocking DC-SIGN with mannan, on infection with FIPV type I in monocytes will be studied.

An interesting observation was that the epitope recognized by mAb R-G-4 was extracellularly present on all CrFK cells, but only on a small fraction of monocytes. Some possible explanations might be that the epitope could no longer be recognized by mAb R-G-4 on the majority of monocytes because the epitope is masked by glycosylation of sites near the R-G-4 epitope or by the presence of (other) proteins interacting with APN.

Because the R-G-4 binding epitope might be different between monocytes and CrFK cells, the R-G-4 mAb could be less capable of blocking potential virus binding to monocytes. However the virus binding sequences might be intact. This could explain the difference in blocking potential of the mAb between CrFK cells and monocytes. In that case, virus binding to fAPN would be underestimated on monocytes. However, the co-localization assay seems to confirm that not all bound virus is attached to fAPN.

It would be very interesting to identify the differences between APN expressed on cell lines and on primary monocytes and to determine if the FIPV-APN interaction occurs at the same epitopes of APN in these different cell types.

Taken together, in this study, the role of aminopeptidase N and DC-SIGN as receptors for FIPV were analysed for the first time in the in vivo target cell, the monocyte, at different
stages of entry and infection. fAPN is capable of binding and internalizing FIPV in these cells and fAPN-mediated entry leads to infection. However, this is not the exclusive receptor for FIPV on monocytes, like it appears to be in CrFK cells. DC-SIGN can also play a role during FIPV entry in monocytes. However, DC-SIGN is not directly required for attachment or internalization, but is probably involved in infection via an alternative pathway independent of fAPN. Besides elucidating some aspects about FIPV entry in monocytes, these new insights reveal how much is unknown about FIPV entry. This study is again a reminder that results of studies obtained in cell culture should be analysed with care, knowing that viruses can use different receptors and a variety of cellular proteins to gain entry into different cells.

ACKNOWLEDGEMENTS

We thank Dr Geijtenbeek for providing the CHO cell lines. We are grateful to Dr Rottier and Dr Egberink for supplying the polyclonal antibodies and the virus strain, and Dr Hohdatsu for the repeated gifts of mAb R-G-4. We thank Nele Dennequin and Chantal Vanmaercke for excellent technical assistance. E. V. H. was supported by a doctoral grant from the special research fund of Ghent University (01D29005) and H. L. D. and E. C. by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen).
REFERENCES


THE MECHANISM OF FELINE INFECTIOUS PERITONITIS VIRUS
TYPE II INTERNALIZATION IN MONOCYTES

Evelien Van Hamme, Hannah L. Dewerchin, Els Cornelissen, Bruno Verhasselt & Hans J.
Nauwynck

Journal of General Virology (2008), 89, 2147-2156
ABSTRACT

Feline infectious peritonitis virus (FIPV), a coronavirus that causes a lethal chronic disease in cats, enters feline monocytes via endocytosis. In this study, the pathway of internalization is characterized by evaluating the effect of chemical inhibitors and/or expression of dominant-negative (DN) proteins on the percentage of internalized virions per cell and infection. Further, co-localization studies were performed to determine the involvement of certain cellular internalization proteins. FIPV is not internalized through a clathrin-mediated pathway, as chlorpromazine, amantadine and DN eps15 did not influence virus uptake and FIPV did not co-localize with clathrin. The caveolae-mediated pathway could be excluded based on the inability of genistein and DN caveolin-1 to inhibit virus uptake and lack of co-localization between FIPV and caveolin-1. Dynamin inhibitory peptide and DN dynamin effectively inhibited virus internalization. The inhibitor strongly reduced uptake to 20.3 ± 1.1 % of uptake in untreated cells. In the presence of DN dynamin, uptake was 58.7 ± 3.9 % relative to uptake in untransduced cells. Internalization of FIPV was slightly reduced to 85.0 ± 1.4 % and 87.4 ± 6.1 % of internalization in control cells by the sterol-binding drugs nystatin and methyl-β-cyclodextrin, respectively. Rho GTPases were inhibited by Clostridium difficile toxin B, but no effect was observed. These results were confirmed with infection studies showing that infection was not influenced by chlorpromazine, amantadine and genistein but was significantly reduced by dynamin inhibition and nystatin. In conclusion, these results indicate that FIPV enters monocytes through a clathrin- and caveolae-independent pathway that strongly depends on dynamin and is slightly sensitive to cholesterol depletion.
INTRODUCTION

Viral entry occurs through a number of successive steps allowing the virus to bring its genome inside the cell. The virus either fuses with the host cell membrane or utilizes the endocytosis machinery of the cell. Endocytosis can be divided in two categories: phagocytosis of large cargo and pinocytosis of smaller cargo (Conner & Schmid, 2003). Phagocytosis is an active and highly regulated process involving specific cell surface receptors and signalling cascades mediated by Rho GTPases (Hall & Nobes, 2000; Conner & Schmid, 2003). Pinocytosis can occur through several pathways. The cargo and its receptor determine which pinocytic pathway will be used (Conner & Schmid, 2003). A first possible route for pinocytosis is ‘macropinocytosis’ (Swanson & Watts, 1995). Other pathways are named after the main structural compound involved: ‘clathrin-mediated endocytosis’ (Brodsky et al., 2001) and ‘caveolae-mediated endocytosis’ (Pelkmans & Helenius, 2002). Finally, there is a group called ‘clathrin- and caveolae-independent pathways’. They are differentiated based on their dependency on cholesterol and/or association with lipid rafts, dynamin and Rho GTPases (Nichols & Lippincott-Schwartz, 2001; Conner & Schmid, 2003). Viruses are specialized in misusing these endocytic pathways to gain entry into the cell (Sieczkarski & Whittaker, 2002a; Pelkmans & Helenius, 2003).

Recently, we have demonstrated that feline infectious peritonitis virus (FIPV), a devastating coronavirus in cats, enters its host cell, the monocyte, via endocytosis (Van Hamme et al., 2007). The pathway used is unknown. Transmissible gastro-enteritis virus (TGEV), canine coronavirus and human coronavirus 229E (HCoV-229E) are coronaviruses that - like FIPV - belong to phylogenetic group 1. They have all been shown to enter cells via endocytosis (Hansen et al., 1998; Savarino et al., 2003; Nomura et al., 2004). The pathways used for internalization have not been studied, except for HCoV-229E that enters human fibroblast cells through the caveolae-mediated pathway (Nomura et al., 2004). Severe acute respiratory syndrome (SARS), an emerging disease in humans, is caused by a coronavirus belonging to phylogenetic group 2 (Kim et al., 2006). Due to its threat, many studies have been done to better understand how the virus interacts with its host and host cells. It was shown that SARS virus enters HepG2 cells expressing ACE2 via pH-dependent endocytosis through clathrin-coated vesicles (Yang et al., 2004; Inoue et al., 2007). More recently, SARS virus was shown to enter Vero E6 cells through receptor-mediated, clathrin- and caveolae-independent endocytosis, likely involving lipid rafts (Wang et al., 2008). The entry of murine coronavirus, also belonging to group 2, is extensively studied. Although entry via non-endosomal routes has been suggested, recent publications assign a major role for
cholesterol-dependent endocytosis, possibly through clathrin-coated pits, in murine cells (Thorp & Gallagher, 2004; Choi et al., 2005; Eifart et al., 2007).

In this study, the mechanism of internalization of FIPV in monocytes was determined through chemical inhibition of internalization, transduction of monocytes with constructs to induce expression of dominant-negative (DN) proteins that hinder some pathways and co-localization studies. Our results indicate that FIPV is internalized through a clathrin- and caveolae-independent pathway that strongly depends on dynamin and is slightly cholesterol depletion sensitive.

METHODS

Cells and virus
Monocytes were isolated from blood, collected from feline coronavirus-, feline leukaemia virus- and feline immunodeficiency virus-negative cats as described previously (Dewerchin et al., 2005) and seeded on glass coverslips in medium [RPMI 1640 enriched with 10 % fetal bovine serum, 0.3 mg glutamine ml⁻¹, 1mM sodium pyruvate and 1 % non-essential amino-acids 100x (GIBCO-Invitrogen)]. Cells consisted of 86 ± 7 % monocytes. FIPV serotype II strain 79-1146 was kindly provided by Dr Egberink (Faculty of Veterinary Medicine, Utrecht University, The Netherlands) and passaged in a feline cell line (CrFK) (McKeirnan, et al., 1981). Batches of culture fluids were purified by ultracentrifugation and purified virus was biotinylated as described previously (Van Hamme et al., 2007). Purified viral particle suspension (200 µg) was applied to 10⁴.4 monocytes throughout the experiments. This amount of suspension contains 5.0 x 10¹⁰ virus particles of which 1.9 x 10⁵ particles are infectious (Van Hamme et al., 2007). This suspension was used exclusively in entry assays, not in the infection and co-localization studies.

Entry inhibition assay
Monocytes were washed extensively at 68 h post-seeding and pre-incubated at 37 °C for 30 minutes with one of the following compounds dissolved in RPMI 1640 (Gibco-Invitrogen) (all products were purchased from Sigma-Aldrich; unless stated otherwise): 0.1 µM wortmannin, 20 µM latrunculin B (ICN Biochemicals), 2 µM chlorpromazine, 500 µM amantadine, 50 µg nystatin ml⁻¹, 10 mM methyl-β-cyclodextrin, 50 µg genistein ml⁻¹, 40 and 80 µM dynamin inhibitory peptide (dip) (batch 5 - Tocris Cookson) or 0.74 nM Clostridium difficile toxin B. Working concentrations were optimized qualitatively in internalization assays with control
ligands while insuring that viability of the cells was always over 99%. After pre-treatment, monocytes were inoculated with biotinylated FIPV in the presence of the compound used for pre-treatment. Cells and virus were incubated at 37 °C for 1 h. Then, cells were briefly washed with ice-cold RPMI 1640 and fixed with formaldehyde (1 %). Bound particles were stained with streptavidin-Texas red (Molecular Probes) and after permeabilization with Triton X-100 (0.1 %) internalized particles were stained with streptavidin-fluorescein isothiocyanate (FITC) (Molecular Probes). After mounting of the coverslips, internalization was quantified per cell as the ratio of internalized virus particles to the total number of cell-associated particles. At least ten cells were analysed and all particles over the entire volume of the cell were monitored. The procedure described above, from seeding of the cells up to the analysis, was performed three times.

To assess the effectiveness of all agents, internalization of biotinylated transferrin (Sigma-Aldrich), FITC-labelled albumin and fluorescent 1µm FluoSpheres (Molecular Probes) was studied in the presence of appropriate inhibitors. After fixation and permeabilization, biotinylated transferrin was visualized with streptavidin-FITC and in the cells incubated with fluorescent beads, cortical actin was stained using falloidin-Texas red (Molecular Probes). Coverslips were mounted on microscope slides and analysed by confocal microscopy. Cells were scored as internalizing cells if all control ligands were internalized. For each experiment 50-100 cells were analysed and experiments were performed three times.

**Plasmid constructions and production of lentiviral supernatants**

Transfer vectors were prepared by deletion of green fluorescent protein (GFP) from the TRIPΔU3-CMV-GFP-WPRE vector (=TRIPΔU3-CMV-WPRE). The enhanced GFP (EGFP) tagged DN eps15 construct, named DIII and the EGFP tagged control construct D3Δ2, a kind gift from Dr Benmerah (Benmerah et al., 1998), were excised from pEGFP-C2 and cloned into TRIPΔU3-CMV-WPRE. EGFP tagged wild type (WT) and DN caveolin-1, a kind gift from Dr Helenius (Kurzchalia et al., 1992; Pelkmans et al., 2001), and WT and DN dynamin 2(aa), a kind gift from Dr McNiven (Cao et al., 1998; 2000) are also cloned into TRIPΔU3-CMV-WPRE. Biological activity of the constructs in the original plasmids and after transfer into pTRIPΔU3-CMV-WPRE was tested in CrFK cells.

pMD.G and p8.91 were used as envelope and packaging plasmids, respectively, as described previously (Stove et al., 2005). At 70 % confluency, 293FT cells (Invitrogen) were co-transfected with 1.66 µg packaging plasmids, 3.33 µg envelope plasmids and 3.33 µg transfer plasmids using a calcium phosphate transfection kit (Invitrogen). Lentiviral supernatants were harvested after 40 h (Stove et al., 2005).
Inhibition of virus internalization pathways through lentiviral gene transfer

At 3 h post-seeding, cells were washed and medium was replaced by lentiviral supernatants. At 24 h post-seeding, cells were washed and fresh medium was added. Internalization assays were performed at 68 h post-seeding. After washing the cells, biotinylated FIPV was added and incubated with the cells for 1 h at 37 °C. Then, cells were briefly washed with ice-cold RPMI 1640 and fixed with formaldehyde (1 %). Bound particles were stained with streptavidin-Alexa Fluor 350 (Molecular Probes) and after permeabilization with Triton X-100 (0.1 %) internalized particles were stained with streptavidin-Texas red. Coverslips were mounted and the level of internalization was quantified as described above.

For the controls, transduced cells were incubated with biotinylated transferrin or biotinylated cholera toxin B (Sigma-Aldrich). After fixation and permeabilization, ligands were visualized with streptavidin-Texas red. Coverslips were mounted onto microscope slides and analysed by confocal microscopy. Cells were scored as internalizing cells if all control ligands were internalized.

Co-localization with clathrin

At 68 h post-seeding, cells were washed with RPMI 1640 (37 °C) and incubated with non-biotinylated FIPV at an m.o.i. of 5 for 0, 5, 15 and 45 minutes at 37 °C. Then, cells were washed with RPMI 1640 and fixed. Cells were washed again, first with RPMI 1640 followed by Tris-buffered saline (TBS; 20 mM Tris/HCl, 150 mM NaCl, pH 7.5) with 4.5 % sucrose and 2 % inactivated goat serum (TBS-GS) and permeabilized with methanol for 30 s at -20°C (Racoosin & Swanson, 1994). Clathrin was stained with anti-clathrin heavy-chain IgM antibodies (ICN Biochemicals), diluted 1 : 50 in PBS supplemented with 0.3 % gelatine (PBS-G) (Van de Walle et al., 2001; Misinzo et al., 2005). Afterwards, cells were washed in TBS-GS and incubated for 1 h at 37 °C with biotin-labelled goat anti-mouse IgM antibodies (Santa Cruz Biotechnology) diluted 1 : 100 in PBS-G. Then, cells were washed and incubated with streptavidin-Texas red (Molecular Probes) diluted 1 : 50 in PBS-G. After washing, FIPV was stained with anti-FIPV-FITC [Veterinary Medical Research Development (VMRD)]. Coverslips were mounted on microscope slides and analysed by confocal microscopy.

Co-localization with caveolin-1

At 68 h post-seeding, cells were washed with RPMI 1640 (37 °C) and incubated with non-biotinylated FIPV at an m.o.i. of 5 for 0, 5, 15 and 45 minutes at 37 °C. Then, cells were washed with RPMI 1640 and fixed. Cells were permeabilized with Triton X-100 (0.1 %) and
washed with PBS. Caveolin-1 was stained with polyclonal rabbit anti-caveolin-1 antibodies (Abcam), diluted 1 : 200 in PBS, by incubation for 1 h at 37 °C. Afterwards, cells were washed and incubated for 1 h at 37 °C with Texas red-labelled goat anti-rabbit antibodies (Molecular Probes) diluted 1 : 100 in PBS. After washing, FIPV was stained with anti-FIPV-FITC. Coverslips were mounted onto microscope slides and analysed by confocal microscopy.

**Infection inhibition assay**

At 56 h post-seeding, cells were washed with RPMI 1640 and pre-incubated for 30 minutes at 37 °C with inhibitory compounds (wortmannin, latrunculin B, chlorpromazine, amantadine, nystatin, genistein, dip and toxin B) dissolved in RPMI 1640. Then, cells were inoculated with non-biotinylated FIPV (m.o.i. of 1 except for dip and the corresponding control: m.o.i. of 0.1 of FIPV grown in serum-free medium) in the presence of the inhibitors in RPMI and incubated at 37 °C. After 1 h the inoculum was washed off and cells were treated with a trypsin/EDTA (0.25 %/0.02 % in RPMI) solution for 5 minutes at 37 °C to remove bound, non-internalized virus particles from the plasma membrane. Figure 1 shows the effective removal of non-internalized virus particles by this method. Thereafter, cells were extensively washed with RPMI 1640 and medium was added. After 11 h of incubation at 37 °C, cells were washed, fixed and permeabilized. Permeabilization was followed by 1 h of incubation at 37 °C with anti-FIPV-FITC and 10 minutes with Hoechst 33342 (Molecular Probes). Coverslips were mounted onto microscope slides and analysed by confocal microscopy. Cells with cytoplasmic expression of viral proteins were scored as infected cells. All cells on the coverslips were evaluated.

![Figure 1: Confocal images of single sections through monocytes. Green signals represent attached FIPV virions without and with trypsin/EDTA treatment.](image)

**Microscopy and statistics**

Internalization and infection assays were analysed by a DM IRB inverted microscope (Leica Microsystems). Images of internalization assays were obtained with a Leica TCS SP2 laser scanning spectral confocal system linked to a DM IRB inverted microscope (Leica). Argon
and He/Ne lasers were used for exciting FITC and Texas red fluorochromes, respectively. Leica confocal software was used for image acquisition. Triplicate assays were performed and compared using the Mann-Whitney U test from the SPSS software package (version 12.0, SPSS). \( P \leq 0.05 \) were considered significantly different.

**RESULTS**

**FIPV entry does not occur via phagocytosis nor macropinocytosis**

Wortmannin and latrunculin B interfere with phagocytosis and macropinocytosis through their action on phosphatidyl-inositol-3 kinases and actin respectively (Spector et al., 1983; Araki et al., 1996). The influence of these compounds on the internalization of FIPV in monocytes was studied. Wortmannin and latrunculin B reduced the uptake of control ligands (fluorescent beads) significantly to 36.6 ± 4.0 % and 17.2 ± 3.8 %, respectively, relative to the untreated controls. The internalization of FIPV was unaffected: 104.7 ± 9.9 % for wortmannin and 100.1 ± 9.0 % for latrunculin B relative to the untreated controls (Fig. 2).

![Figure 2: The effect of various inhibitors on the internalization of control ligands and biotinylated FIPV in monocytes. Cells were pre-treated with the inhibitors for 30 minutes at 37°C. Respective control ligands ('c-lig') or FIPV were added to the cells and subsequently incubated with the cells in the presence of the inhibitor for 1h at 37°C. After fixation and staining, internalization was quantified. Percentages shown are relative to internalization of control ligands or FIPV without inhibitor (control). Data represent means ± standard deviations of triplicate assays. * marks values that are significantly different from the control.](image-url)
FIPV entry is mediated by a clathrin-independent pathway

The internalization of several ligands into the cell occurs through clathrin-coated pits. To determine whether FIPV enters monocytes through this pathway, cells were treated with chlorpromazine and amantadine, both are potent inhibitors of clathrin-mediated internalization (Phonphok & Rosenthal, 1991; Wang et al., 1993). Transferrin uptake occurs constitutively via clathrin-mediated endocytosis, and was therefore used as a control (Harding et al., 1983). After treatment of monocytes with chlorpromazine and amantadine, transferrin uptake was reduced significantly to 28.9 ± 0.4 % and 13.0 ± 15.4 % respectively, of the control. The internalization of FIPV, however, remained at the same level (94.0 ± 5.0 % and 99.3 ± 9.2 % of the control for chlorpromazine and amantadine, respectively), despite the presence of inhibitors (Fig. 2).

Secondly, monocytes were transduced with a control construct (D3Δ2) or with DN eps15 (DIII). Eps15 protein is crucial for clathrin-mediated endocytosis (Benmerah et al., 1998). To assess the effectiveness of the constructs, internalization of transferrin was studied in transduced cells: in cells with D3Δ2, the uptake was 103.3 ± 21.7 % relative to the uptake in untransduced control cells; in DIII transduced cells, the uptake was 47.9 ± 8.5 % relative to the control. Thus, the uptake of transferrin was reduced significantly relative to the uptake in D3Δ2 transduced cells. The internalization of FIPV showed no reduction: in cells with D3Δ2, the uptake was 98.3 ± 0.7 % relative to the uptake in untransduced control cells; in DIII transduced cells, the uptake was 90.3 ± 10.6 % relative to the control. Thus, transduction with dominant negative eps15 did not influence the cell’s ability to internalize FIPV (Fig. 3, 1A-B).
Figure 3: Internalization of control ligands and biotinylated FIPV in transduced monocytes. After transduction, cells were incubated with control ligands or FIPV for 1h at 37°C. Finally, cells were fixed, permeabilized and stained. The results depicted in panel 1 were obtained in untransduced cells and in cells transduced with constructs D3Δ2 and DIII, for non-functional and functional eps15. The results depicted in panel 2 were obtained in untransduced cells and in cells transduced with wild type (WT) and dominant-negative (DN) constructs for caveolin-1 (‘cav’). The results depicted in panel 3 were obtained in untransduced cells and in cells transduced with WT and DN constructs for dynamin 2(aa) (‘dyn’). Panels A show the graphs in which the quantified internalization for both control ligands (transferrin ‘c-Tfn’ and Cholera toxin B ‘c-Chol tox B’) and FIPV is represented by percentages relative to internalization in untransduced cells. Panels B represent confocal images of monocytes. Single optical sections through the cell are depicted. The green signal indicates expression of the transferred gene and the red signal represents control ligands or FIPV inside the cell. * marks values that are significantly different from the control.
Finally, no co-localization between clathrin molecules and FIPV proteins was detected between 0 and 45 minutes after the start of virus uptake (Fig. 4). Taken together, the experiments clearly show that clathrin is not involved in the internalization of FIPV in monocytes.

Figure 4: Visualization of FIPV and clathrin during internalization. Confocal images of single sections through cells are shown. Green signals represent FIPV stained with anti-FIPV-FITC and red signals represent clathrin stained by anti-clathrin heavy-chain IgM antibodies, biotin-labelled goat anti-mouse IgM antibodies and streptavidin-Texas red.

**FIPV entry is mediated by a caveolae-independent pathway**

Another well characterized pathway is caveolae-mediated endocytosis. Like lipid rafts, caveolae are rich in cholesterol and sphingolipids (Brown & London, 1998; Simons & Toomre, 2000). Therefore, sterol-binding drugs, like nystatin and methyl-β-cyclodextrin, disrupt the caveolar function (Rothberg et al., 1992). Genistein blocks caveolae-mediated internalization through inhibition of protein tyrosine kinases. The effect of these drugs on FIPV internalization was investigated. Albumin is internalized through caveolae and was used as a control ligand (Schnitzer et al., 1994). Nystatin and methyl-β-cyclodextrin reduced the uptake of albumin to 54.9 ± 14.5 % and 22.2 ± 4.4 %, respectively, of the control. The uptake of FIPV was reduced slightly to 85.0 ± 1.4 % and 87.4 ± 6.1 %, respectively, of the
control (Fig. 2). Genistein reduced internalization of albumin significantly to $32.6 \pm 5.3 \%$ of the control. However, internalization of FIPV was unaffected ($107.1 \pm 10.7 \%$ of the control) (Fig. 2). Thus, despite the slight effect of sterol-binding drugs, caveolae are probably not involved in FIPV entry as it is not affected by genistein.

Another experiment was performed to confirm that caveolae do not play a role in the internalization of FIPV. The most important protein compounds of the caveolae are caveolins. The presence of DN caveolin-1 directly inhibits the endocytic process through caveolae (Pelkmans et al., 2001; Pelkmans & Helenius, 2002). Monocytes were transduced with either WT or DN caveolin-1. To confirm the effectiveness, the uptake of Cholera toxin B was studied in transduced cells (Montesano, et al., 1982; Parton et al., 1994): in cells with WT caveolin-1, the uptake was $105.1 \pm 3.2 \%$ relative to the uptake in untransduced control cells and in cells with DN caveolin-1, the uptake was $34.8 \pm 7.8 \%$ relative to the uptake in untransduced control cells. For FIPV, no reduction was observed: in cells with WT caveolin-1, FIPV uptake was $102.1 \pm 3.4 \%$ and in cells with DN caveolin-1, FIPV uptake remained at $100.1 \pm 7.1 \%$ relative to the untransduced control (Fig. 3, 2A-B). These results indicate that caveolin-1 is not involved in FIPV entry.

Further, most FIPV protein clusters ($93.1 \pm 4.1 \%$) did not co-localize with caveolin-1 between 0 and 45 minutes after the start of virus uptake (Fig. 5). Only occasionally, particles were found in the proximity of caveolin-1. A co-localization study between caveolin-1 and an irrelevant protein (transferrin) showed that the observed level of co-localization does not exceed the expected level for coincidental co-localization (data not shown).
The mechanism of FIPV II internalization in monocytes

Figure 5: Visualization of FIPV and caveolin-1 during internalization. Confocal images of single sections through cells are shown. Green signals represent FIPV stained with anti-FIPV-FITC and red signals represent caveolin-1 stained by rabbit polyclonal anti-caveolin-1 antibodies and goat anti-rabbit-Texas red. The arrows indicate the few sites of co-localization. In the first picture (5min) FIPV and caveolin-1 completely co-localize, in the last picture (45min) they only partly co-localize.

Thus, both clathrin- and caveolae-mediated pathways are not involved in FIPV entry in monocytes. The sterol-binding inhibitors, nystatin and methyl-β-cyclodextrin, slightly influenced the uptake of FIPV in monocytes.

**FIPV entry depends on dynamin**

Dynamin is a GTPase that is involved in many internalization pathways: phagocytosis, clathrin-mediated internalization, caveolae-mediated internalization and some clathrin- and caveolae-independent pathways (Gold et al., 1999; Hinshaw, 2000; Mayor & Pagano, 2007). Dynamin is thought to pinch off formed vesicles from the plasma membrane (Hinshaw, 2000). Cells were treated with dynamin inhibitory peptide (dip) and analysed for internalization of the control ligand transferrin and FIPV (Grabs et al., 1997). Dip (40 µM) reduced transferrin uptake significantly to 27.4 ± 8.4 % relative to the uptake in untreated cells. For FIPV, a strong, significant reduction was observed to 40.1 ± 9.6 % and 20.3 ± 1.1 % of the uptake in control cells for 40 and 80 µM, respectively, of dynamin inhibitor (Fig.2).
To confirm these results, the uptake of FIPV was studied in cells transduced with WT and DN dynamin 2(aa) (Cao et al., 1998; 2000). The effectiveness of transduction was studied by monitoring the uptake of transferrin in transduced cells: in cells with WT dynamin 2(aa), the uptake was 86.5 ± 13.4 % relative to the uptake in untransduced control cells and in cells with DN dynamin 2(aa), the uptake was 39.0 ± 12.2 % relative to the uptake in untransduced control cells. Internalization of FIPV was reduced significantly in cells expressing DN dynamin 2(aa), compared with cells expressing WT dynamin 2(aa): in cells with WT dynamin 2(aa), FIPV uptake was 105.6 ± 6.3 % and in cells with DN dynamin 2(aa), FIPV uptake was 58.7 ± 3.9 % relative to the uptake in untransduced control cells (Fig. 3, 3A-B). Clearly, dynamin plays an important role in the internalization of FIPV in monocytes.

**Rho GTPases are not involved in FIPV entry**

Several independent internalization pathways have been characterized by their dependency on Rho GTPases (Mayor & Pagano, 2007). Rho GTPases are a subfamily of the Ras superfamily of small GTPases. They play an important role in regulating the actin cytoskeleton and in a broad range of aspects of endocytic traffic (Hall, 1998; Ellis & Mellor, 2000). Rho GTPases are involved in phagocytosis and macropinocytosis and also in clathrin- and caveolae-mediated internalization pathways (Ellis & Mellor, 2000; Grimmer et al., 2002). To determine whether they are involved in the internalization of FIPV in monocytes, cells were treated with Clostridium difficile toxin B, a general Rho GTPase inhibitor (Just et al., 1995). The activity of the inhibitor was confirmed by its effect on the internalization of fluorescent beads: a significant reduction to 10.0 ± 2.2 % of the uptake in untreated cells (Fig. 2). The internalization of FIPV was not significantly affected: internalization remained at the level of 89.2 ± 11.1 % of the control. These results were confirmed by less general Rho GTPase inhibitors like Rac1 inhibitor (Calbiochem), secramine A [inhibits Cdc42 activation (Pelish et al., 2006)] and Y-27632 (selective inhibitor of the Rho associated protein kinase ROCK; Sigma-Aldrich) (data not shown).

**The effect of entry inhibitors on FIPV infection**

After establishing the effect of inhibitors on the uptake of virus, the effect on infection was studied. Therefore, cells were inoculated and incubated with FIPV in absence and in presence of entry inhibitors. Bound, non-internalized virions were removed from the cell surface by trypsin wash. Viral replication was stopped after 1 cycle of replication, i.e. at 12 h post inoculation. Figure 6 shows that the inhibitors that did not significantly influence FIPV entry, had no effect on infection rates. The actual influence of the inhibitors on percentages
The mechanism of FIPV II internalization in monocytes

of infected cells were from 2.1 to 1.9 % for wortmannin, 1.9 to 1.7 % for latrunculin B, 2.1 to 2.1 % for chlorpromazine, 1.9 to 2.3 % for amantadine, 1.9 to 1.9 % for genistein and 1.9 to 2.4 % for toxin B. However, inhibition of FIPV internalization by dynamin inhibitory peptide is reflected in significantly reduced infection (45.7 ± 10.3 % and 23.0 ± 9.5 % of infection of control cells for 40 and 80 µM, respectively, of dynamin inhibitor or reductions from 0.48 to 0.22 % and 0.32 to 0.065 % infected cells). Nystatin treatment during entry led to a reduction to 61.7 ± 5.2 % of infection of control cells or absolutely from 1.9 to 1.2 % infected cells.

**Figure 6: The effect of various entry inhibitors on infection of monocytes with FIPV.** Cells were pre-treated with the inhibitors for 30 minutes at 37°C. FIPV was added to the cells in the absence ('control') or presence of inhibitor and subsequently incubated with the cells for 1h at 37°C. After trypsin wash, cells were further incubated for 11h. Then, cells were fixed and stained and infection was quantified. Percentages shown are percentages of infected cells in the presence of a certain inhibitor, relative to the percentage of infected 'control' cells. Data represent means ± standard deviations of triplicate assays. * marks values that are significantly different from the control.

**DISCUSSION**

Previously, we showed that FIPV enters its target cell via endocytosis and not via direct fusion with the plasma membrane (Van Hamme et al., 2007). In the present study, the mechanism of endocytosis involved in FIPV entry was determined. Multiple strategies were combined: internalization pathways were blocked by use of chemical inhibitors and expression of DN mutants, and co-localization assays were performed.
FIPV is not phagocytosed nor macropinocytosed as the inhibitors wortmannin and latrunculin B did not affect the entry and Rho GTPases were not involved in the internalization. Independency from clathrin was proven based on the facts that inhibition with chlorpromazine and amantadine was ineffective and that expression of DN eps15 had no effect on FIPV internalization. FIPV and clathrin did not co-localize either. Further, it was shown that caveolae are not involved in FIPV internalization as genistein and expression of DN caveolin-1 had no effect on FIPV internalization, and FIPV and caveolin-1 did not co-localize inside the cell. In conclusion, FIPV enters monocytes through a clathrin- and caveolae-independent pathway. This pathway is further characterized by its dependency on dynamin and independency from Rho GTPases.

Further, the sterol-binding drugs nystatin and methyl-β-cyclodextrin slightly affected FIPV internalization. Cholesterol depletion affects internalization pathways associated with lipid rafts. The association with rafts can be crucial for initiating and proceeding signalling cascades necessary for internalization. However, requirement for cholesterol is not necessarily related to lipid rafts. For example, cholesterol depletion disturbs clathrin-mediated internalization, which is not associated with lipid rafts (Subtil et al., 1999; Nichols & Lippincott-Schwartz, 2001). As the observed decrease in internalization of FIPV is much smaller than the decrease in internalization of the control ligand and as the observed reduction due to methyl-β-cyclodextrin is smaller than those described in literature (ranging from 30 to >90 % for different pathways) (Rodal et al., 1999; Subtil et al., 1999; Grimmer et al., 2002; Sanchez-San Martin et al., 2004; Barrias et al., 2007), it seems likely that the pathway is not dependent on cholesterol. Possibly, a fraction of the virus binding receptor is present in lipid rafts. Disturbance of rafts could then cause a decrease in receptor availability. Reduced virus binding subsequently leads to a drop in the number of internalized virions. Further research is needed to confirm the effect of sterol-binding drugs and to enlighten the underlying cause.

To our knowledge, no identical physiological internalization pathway has been described. However, the characteristics of the internalization of the β-chain of interleukin 2 receptors (IL-2R-β) are very similar to those of FIPV internalization (Lamaze et al., 2001). Like FIPV, IL-2R-β is internalized via a clathrin- and caveolae-independent pathway and is dependent on dynamin and sensitive to cholesterol depletion. The sensitivity to cholesterol depletion is caused by raft-association of the receptor. A clear difference with the uptake of FIPV, is the dependency on Rho GTPases. The internalization of the common cytokine receptor γ (γc) is categorized in the same group as the IL-2R-β-pathway (Kirkham & Parton, 2005; Sauvonnet et al., 2005). The γc receptor is a subunit shared by several cytokine receptors, namely the
The mechanism of FIPV II internalization in monocytes

IL-2, -4, -7, 9, -15, and -21 receptors (Schluns & Lefrancois, 2003). When expressed by itself, the γc receptor is rapidly and efficiently endocytosed (Morelon & Dautry-Varsat, 1998). Clathrin- and caveolae-independent pathways have also been linked to the entry of many viruses (Marsh & Helenius, 1989; Sieczkarski & Whittaker, 2002a; Sanchez-San Martin et al., 2004). Like FIPV, SARS virus is internalized through a clathrin- and caveolae-independent pathway that is sensitive to treatment with methyl-β-cyclodextrin (Wang et al., 2008). The involvement of dynamin and Rho GTPases has however not been studied. Rotavirus cell entry resembles FIPV entry as it is also internalized via a clathrin- and caveolae-independent pathway that depends on dynamin, but the pathway is highly cholesterol depletion sensitive. The role of Rho GTPases in this endocytic process has not been studied either. In addition, there are similarities between the entry pathways used by influenza virus and FIPV. Influenza virus enters HeLa cells via a clathrin- and caveolae-independent pathway that is not associated with lipid rafts. It is not known whether this pathway depends on dynamin (Sieczkarski & Whittaker, 2002b). Influenza virus entry in Mv-1 lung cells has been shown to depend on dynamin but further characterization has not been performed (Roy et al., 2000). As the route of entry depends on the host cell type, it is impossible to predict whether influenza virus entry in HeLa cells will also depend on dynamin. Thus, for both FIPV and influenza virus, the internalization pathways need further characterization to compare them.

HCoV-229E belongs to the same phylogenetic group as FIPV and is the only member of the group of which the internalization process has been characterized. It was shown that HCoV-229E binds to its receptor, human aminopeptidase N (APN), in rafts and enters human fibroblasts through caveolae (Nomura et al., 2004). Human APN has been reported to be a component of rafts in various cell types (Danielsen, 1995; Santos et al., 2000; Riemann et al., 2001; Nomura et al., 2004). For TGEV, that is endocytosed after binding to porcine APN, it has been suggested that clathrin might be involved in the internalization (Hansen et al., 1998). For type II FIPV, feline APN is the receptor for entry in cell lines. Whether this is also a receptor in primary target cells is not known. Even if APN would be the internalizing receptor, no conclusions can be made based on the entry mechanisms of HCoV and TGEV as these coronaviruses already use two different mechanisms of internalization through APN.

Despite the low number of infected cells, which is an inevitable obstacle for FIPV research in target cells, infection assays in the presence of entry inhibitors qualitatively confirmed the results from the internalization assays and show that virions infect their host cell via the described pathway. Inhibition of dynamin function and nystatin treatment reduced infection. The reduction in infection caused by nystatin is larger than expected based on the reduction
of internalization. Possibly, cholesterol binding by nystatin affects post-entry events, e.g. intracellular transport, despite the trypsin wash.

In this study, the mechanism of internalization for FIPV 79-1146 in monocytes was determined. The pathway is clathrin- and caveolae-independent, strongly depends on dynamin and is slightly cholesterol depletion sensitive. The identified pathway proceeds similarly, though not exactly like IL-2R-β endocytosis and SARS- and rotavirus entry. Gaining insights in the initial virus-cell interactions is valuable in the search for an effective treatment or prevention of FIP. Obviously, the pathway should be further characterized and its components should be identified in order to obtain well-defined targets for antiviral therapy.

ACKNOWLEDGEMENTS

We are grateful to Dr H. F. Egberink for supplying the virus strain and to Dr A. Benmerah, Dr A. Helenius and Dr M. McNiven for the constructs. We also would like to thank the Kirchhausen laboratory (Harvard Medical School) and the Hammond laboratory (University of Louisville) for the kind gift of secramine A that was synthesized by B. Xu and G. B. Hammond of the University of Louisville. E. V. H. was supported by a doctoral grant from the special research fund of Ghent University (01D29005) and H. L. D. and E. C. by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen). Dr B. V. is a senior clinical investigator supported by the Research Foundation Flanders (FWO), grant G.0061.05.
REFERENCES


The mechanism of FIPV II internalization in monocytes


GENOME RELEASE AFTER ENDOCYTOSIS OF FELINE INFECTIOUS PERITONITIS VIRUS TYPE II IN PRIMARY MONOCYTES

Evelien Van Hamme, Hannah L. Dewerchin, Els Cornelissen & Hans J. Nauwynck
ABSTRACT

Upon entry via endocytosis, feline infectious peritonitis virus (FIPV) particles are ‘trapped’ in intracellular vesicles. To initiate viral replication, transcription and translation, the virus needs to release its genome into the cytosol. This uncoating process occurs through fusion of the viral envelope with membranes of the intracellular vesicles. In general, such a process can be initiated by low pH, cleavage by proteases, conformational changes by receptor interaction or a combination of these factors. In this study, the process of serotype II FIPV uncoating was visualized in time by specifically staining nucleocapsids that have been released from intracellular vesicles into the cytosol. To perform this staining, the plasma membrane was selectively permeabilized without affecting intracellular membranes. At each time point, the percentage of cells with genome release was determined. Further, the requirement for endosomal low pH for FIPV infection was checked. The results indicate that the percentage of cells with genome release increased over time to a maximum (8.4 % of the cells) at 35 minutes after the start of internalization, and then decreased again. This release did not depend on a low pH as infection could not be blocked by lysosomotropic agents. In conclusion, despite the uptake of FIPV in practically all monocytes, release from vesicles appears to be restricted to a subpopulation. These findings suggest that the presence of uncoating mediators may be a determining factor in cell susceptibility for FIPV type II.
**INTRODUCTION**

Entry of enveloped viruses via endocytosis results in intact virions ‘trapped’ in intracellular vesicles. Most internalized vesicles travel through the endosomal/lysosomal pathway and the virus needs to escape before lysosomal degradation is completed. To escape from intracellular vesicles, the viral envelope has to fuse with the membrane of the intracellular vesicle. This process is mediated by viral fusion proteins. The viral envelope is left behind in the membrane of the intracellular vesicle while the nucleocapsid is released in the cytosol so that genome replication, transcription and translation can be initiated.

Based on structural similarities, there are two classes of viral fusion proteins (Lescar *et al.*, 2001). Class I viral proteins contain 4,3 hydrophobic (heptad) repeat (HR) regions and an N-terminal or N-proximal fusion peptide. Class II viral fusion proteins lack HR regions and have an internal fusion peptide. The fusion peptide is the actual mediator of fusion. The initiation of membrane fusion occurs upon induction of conformational changes in the viral fusion protein. These changes bring HR regions in class I fusion proteins in a conformation that inserts the fusion peptide into the cell membrane during the fusion event. As a result, the cellular and viral membrane are brought closely together for the actual fusion event (Eckert & Kim, 2001).

The viral spike protein is the main protein involved in coronavirus entry. This protein was extensively studied for the group 2 coronavirus, mouse hepatitis virus (MHV). The fusion core complex was structurally and functionally characterized and the data indicated that this coronavirus spike protein is a class I virus fusion protein (Bosch *et al.*, 2003). Sequence alignments of HR regions in spike proteins among coronaviruses, including feline coronavirus spikes, show significant similarity, suggesting that they all are class I fusion proteins (Xu *et al.*, 2004). To bring spike proteins into a fusogenic state, conformational changes in the S-protein are required. These conformational changes can be induced in several ways (Smith & Helenius, 2004). Certain viruses require protonation and depend on the pH drop in late endosomes for the initiation of fusion activity. Dependency on low pH in endosomes can be shown by inhibiting virus entry by lysosomotropic weak bases like chloroquine or ammonium chloride. Other viruses undergo a conformational change through the interaction with a certain receptor. A third group requires cleavage by proteases to reveal the fusogenic domains. Possibly there are more, still unknown, triggers for fusion.

There are some data available on uncoating of group 1 coronaviruses. It has been suggested that canine coronavirus entry depends on low pH in endosomal organelles (Savarino *et al.*, 2003). For human coronavirus 229E, both pH drop and proteases, more specifically
cathepsin L, are necessary to mediate genome release into the cytosol (Kawase et al., 2009). For the group 2a coronavirus MHV, binding of viral spikes of the strains MHV-A59 and MHV-4 to their receptor induces a conformational change into a fusogenic state (Matsuyama & Taguchi, 2002; Zelus et al., 2003; Miura et al., 2004). On the other hand, infection by MHV-3 is sensitive to lysosomotropic agents and therefore depends on the endosomal pH drop (Krzystyniak and Dupuy, 1984). Protease activity is not required. However, for strain MHV-2, low pH is not required but cathepsins B and L are (Qiu et al., 2006). For severe acute respiratory syndrome virus, a human coronavirus belonging to group 2b, both low pH and cathepsins mediate viral entry via endocytosis (Huang et al., 2006; Wang et al., 2008). Recently it has been reported that sequential cleavage by trypsin at the S1/S2 boundary and inside S2 might prime the spike protein for direct fusion (Belouzard et al., 2009). Avian infectious bronchitis virus, a group 3 coronavirus, undergoes a conformational change after exposure to low pH, probably inducing membrane fusion after endocytosis (Chu et al., 2006).

Studies on uncoating of feline coronaviruses have resulted in many contradictory statements. Takano et al. claimed that the entry of feline infectious peritonitis virus (FIPV) strain 79-1146 depends on acidification of the endosome (2008), while Regan et al. claimed that this is not true for FIPV strains 79-1146 and DF2, but only for enteric feline coronavirus (eFCoV) strains like 79-1683 (2008). Further, Regan et al. stated that FCoV spikes are cleaved by cathepsins, more specifically by cathepsin B for the FIPV strains and both cathepsins B and L for the eFCoV strains (2008). However, de Haan et al. claimed that cathepsins are refractory for FIPV infection (2008). To provide more insights on these contradictory statements, we performed the present study. Therefore, a kinetical study was performed to situate uncoating in the entry and infection process. In addition, the effect of pH drop inhibitors on FIPV infection was investigated.

**METHODS**

**Cells and virus**

Feline blood monocytes were isolated from blood collected from feline coronavirus-, feline leukaemia virus- and feline immunodeficiency virus-negative cats and cultured as described before (Dewerchin et al., 2005). FIPV serotype II strain WSU 79-1146 was kindly provided by Dr Egberink (Department of Infectious Diseases and Immunology, Utrecht, The Netherlands) and passaged on CrFK cells (McKeirnan et al., 1981).
Antibodies
The monoclonal antibody (mAb) against FIPV nucleocapsid (N) protein was produced in the laboratory as described previously by Lefebvre et al. (2008) after immunization of Balb/c mice with FIPV serotype II strain WSU 79-1146 infected cells. Polyclonal anti-FIPV antibodies labelled with FITC were purchased from Veterinary Medical Research and Development (VMRD).

Lysosomotropic agents
The lysosomotropic weak base ammonium chloride and bafilomycin A1, a specific inhibitor of vacuolar type H\(^+\)-ATPase (Sigma-Aldrich) were used to prevent acidification of endosomal vesicles. Ammonium chloride was used at a concentration of 5 mM and bafilomycin A1 at a concentration of 10nM.

Kinetics of uncoating
At 68 h post seeding, cells were chilled on ice and incubated with virus at 4 °C. After 2 h, when the maximal number of virions was bound to the cells as determined previously (Van Hamme et al., 2007), cells were shifted to 37 °C. At different time points (after 15, 25, 35, 45, 55 and 65 minutes), cells were fixed with formaldehyde (1 %). After washing with phosphate buffered saline (PBS), cells were put at 4 °C and washed with ice-cold buffer that consisted of 110 mM KOAc, 20 mM Hepes at pH 7.2 and 2mM MgCl\(_2\) in ultra pure H\(_2\)O (KHM buffer). Then, the plasma membrane was permeabilized with 30 µg digitonin ml\(^{-1}\) KHM buffer for 4 minutes without affecting intracellular membranes. After washing with PBS, released nucleocapsid proteins were stained with anti-nucleocapsid mAbs for 1 h at 37 °C. Cells were washed and permeabilized with 0.1 % Triton X-100. Finally, virus particles were stained with FITC-labelled anti-FIPV antibodies (Molecular probes).

Infection inhibition assay
At 56 h post-seeding, cells were washed with RPMI 1640 and pre-incubated for 1 h at 37 °C with pH drop inhibitors. After pre-treatment, cells were inoculated with FIPV in the presence of the inhibitors used for pre-treatment. Cells were infected at an moi of 5. Then, after 1 h the inoculum was replaced by medium supplemented with the inhibitors used for pre-treatment. The cells were incubated for another 11 h at 37 °C. Finally, cells were washed, fixed and permeabilized. Permeabilization was followed by 1 h of incubation at 37 °C with anti-FIPV polyclonal antibodies labelled with FITC and 10 minutes with Hoechst 33342 (Molecular Probes). Coverslips were mounted onto microscope slides and analyzed by
confocal microscopy. Cells with cytoplasmic expression of viral proteins were scored as infected cells. All cells on the coverslips were evaluated.

**Microscopy and statistics**

All assays were analyzed by a DM IRB inverted microscope (Leica Microsystems GmbH). Triplicate assays were performed and compared using the Mann-Whitney U test from the SPSS software package (version 12.0, SPSS). P values \( \leq 0.05 \) were considered significantly different.

**RESULTS**

**Kinetics of uncoating**

Kinetics of uncoating were determined by evaluating the presence of ‘free’ nucleocapsids in the cytosol at different time points after internalization. To visualize these nucleocapsids that are released from intracellular vesicles into the cytosol, nucleocapsid protein (N) was stained after selectively permeabilizing the plasma membrane (with digitonin), leaving the intracellular vesicular membranes intact. At each time point, the percentage of cells with released genomes, was determined. The first cells with released genomes in the cytosol, appeared immediately after internalization as shown in the kinetics presented in Figure 1. The maximum percentage of cells with uncoating of endocytosed particles was observed at 35 minutes after the start of virus uptake. Then, in 8.4 ± 3.0 % of the cells, nucleocapsids were observed in the cytosol. From 35 minutes onwards, that percentage of cells with uncoating decreased. This might be due to the release of nucleocapsid protein from the RNA genome for translation, transcription and replication. Possibly, single N-proteins are not visible under the microscope or they become incorporated in replication/transcription complexes and are therefore no longer accessible for antibodies.

**Effect of lysosomotropic agents on FIPV infection of monocytes**

Figure 2 shows the influence of treatment of monocytes with ammonium chloride and bafilomycin A1 on FIPV infection. None of these pH drop inhibitors had a significant effect on FIPV infection. It seems that release from FIP virions out of endosomal/lysosomal vesicles does not depend on a drop in pH.
Figure 1: (A) Visualization of genome release in monocytes. Virus particles are stained with anti-FIPV-FITC and released N-protein by a mAb followed by Texas Red labelled goat anti-mouse antibodies. The arrows indicate sites of genome release. (B) Kinetics of internalization (open squares) and kinetics of uncoating of the FIP virions after endocytosis (filled squares). The percentage of monocytes with internalized virions and the percentage of cells with uncoated particles released in the cytosol, are represented in function of time after the start of virus uptake. Data represent means ± standard deviations of triplicate assays.
DISCUSSION

In this study, the process of uncoating of endocytosed FIP virions was monitored by determining the kinetics of uncoating. To selectively visualize uncoated viral genomes in the cytosol, the plasma membrane was permeabilized with digitonin that leaves intracellular membranes intact. Digitonin permeabilizes membranes by complexing with membrane cholesterol, producing holes in the membrane (Schulz, 1990). The selectivity of this process is due to the relatively high cholesterol content of the plasma membrane (Adam et al., 1992). The digitonin-based membrane permeabilization method has been previously applied in macrophages by Diaz et al. (1989) and LeDoan et al. (1999).

Uncoating apparently starts immediately after internalization and at 35 minutes, the maximum number of cells in which nucleocapsid is detected in the cytosol, is reached. This number decreases after 35 minutes. These kinetics can be interpreted in two ways. Possibly the population of cells that is capable of mediating uncoating is restricted to approximately 8.4%, or alternatively, released genomes only remain visible for a short period of time. In that case the number of cells actually mediating release, is the total of the number of cells with uncoating visualized at each time point. In the future, this will be studied by visualizing genome release in Crandell feline kidney cells, to determine how long uncoated
nucleocapsids can be detected in the cytosol. In these cells, release is expected to occur in all cells as they are all susceptible to infection. Because we know that experiments with cells from cell lines can give indications about processes in target cells but need to be confirmed in the target cell itself, release in monocytes should be studied in an alternative assay to check the results obtained in CrFK cells.

Using our assay, it seems that only a subpopulation of monocytes released the FIPV genome in the cytosol. This suggests that the capacity of a cell to mediate FIPV uncoating, might be a factor that determines if a cell is susceptible to infection with FIPV. This would explain (partially) why infection in monocytes is restricted to approximately 1% of the cells, while virus uptake occurs in the majority of cells (Dewerchin et al., 2005; Van Hamme et al., 2007). It is evident that there might be other limiting factors that characterize the subpopulation of monocytes susceptible for FIPV infection.

In literature, there are conflicting data regarding the dependency of FIPV genome release on the pH drop in endosomal vesicles (Regan et al., 2008; Takano et al., 2008). Our results suggest that low pH is not required to initiate uncoating of FIPV 79-1146 in monocytes. This could have been expected as genome release seems to be a selective process while acidification of endosomes is likely to occur in all cells. Regan et al. also suggested that entry of serotype II FIPV occurs independently from a low pH (2008). Their results were obtained solely in feline cell lines but they did use a variety of type II FIPV strains. The concentrations of inhibitor used in this study lie in the range of concentrations used in the study performed by Regan. In contrast, Takano et al. claim that genome release of FIPV in monocytes does depend on low pH (2008). Their study was performed in monocytes. The effect of the inhibitors was evaluated by comparing virus titres after three days of cultivation instead of counting infected cells after one cycle of replication as done by Regan and us. Incubation of monocytes with lysosomotropic agents for several days at relatively high concentrations (500 nM of bafilomycin A1) might have side effects that could influence the result of the assay.

Another possible trigger for uncoating is cleavage by proteases. There are four main categories of proteases, named serine proteases, cysteine proteases, aspartyl proteases and metalloproteases (Barrett, 1994). Preliminary experiments suggest that a serine and/or cysteine protease might be necessary for FIPV infection of monocytes (data not shown). In the future, the involvement of each class of proteases in FIPV infection will be studied by using specific inhibitors: 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), trans-epoxysuccinyl-L-leucylamide-(4-guanidino)butane (E-64), pepstatin A and
phosphoramidon. Then, the specific involvement of these proteases in the process of genome release, will be studied. Because we want to identify proteases necessary for uncoating, it needs to be checked if the observed protease activity is not due to the virus-encoded proteins necessary for processing of the polyproteins pp1a/pp1ab in the early steps of virus replication (Hegyi & Ziebuhr, 2002). When the exact class(es) of proteases involved in the process of genome release is determined, inhibitors can be applied to specify which protease(group) is involved. Identification of a specific protease may increase the chance of finding an inhibitor that is able to reduce infection. Involvement of protease activity can be explained by a necessity for cleavage of the spike to reveal a fusion peptide (Bosch et al., 2008). After identification of a certain protease, it should be confirmed and checked if and how the viral spike is cleaved by this protease. Further, it would be interesting to verify whether the expression pattern of the protease in the population of monocytes may correlate with the apparent restriction on genome release to a limited number of cells. If not, this implies that another factor is crucial for efficient uncoating, for example the presence of another receptor that induces a conformational switch into a fusogenic protein. It is clear that the available data and knowledge need to be extended, before a model for feline coronavirus uncoating can be proposed.

This study reveals that uncoating of endocytosed FIP virions may not occur in all cells. Possibly, the cellular capacity to mediate uncoating could be an important determinant for cell susceptibility. A low pH seems not necessary to enable uncoating. The involvement of proteases will be studied in the future.

**ACKNOWLEDGEMENTS**

We are grateful to Dr Egberink for supplying the virus strain and we would like to thank Nele Dennequin and Chantal Vanmaercke for excellent technical assistance. E. V. H. was supported by a doctoral grant from the special research fund of Ghent University (01D29005) and H. L. D. and E. C. by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen).
REFERENCES


Chapter 7

GENERAL DISCUSSION
Feline infectious peritonitis virus (FIPV) causes a progressive vasculitis in cats that cannot be treated. The current knowledge on the pathogenesis of FIPV is an unsound basis for the development of effective antivirals. In this thesis, the entry process of FIPV was studied to add to the current knowledge and to evaluate the presence of possible viral and/or host targets for antiviral therapy.

Characteristics of FIPV serotype I and II entry in monocytes and Crandell feline kidney cells
Feline infectious peritonitis virus causes a monocyte-derived viremia (Weiss & Scott, 1981). Therefore, virus entry was studied in feline primary monocytes. Because it is laborious to obtain primary feline monocytes, Crandell feline kidney (CrFK) cells were also included in the study to evaluate if they could be used as a model cell line to study FIPV entry. Unfortunately, FIPV interacted differently with CrFK cells than with monocytes at the level of virus entry. Both attachment and internalization of FIPV were slower and less efficient in CrFK cells than in monocytes (Chapter 3). This confirms what was reported before by Nash & Buchmeier (1997), namely that one should be careful when generalizing data obtained in different cell types because entry can depend on the host cell type. Our studies made it clear that for FIPV, all data that were previously obtained with cell lines, for example the use of receptors for FIPV, should be verified in primary monocytes. Therefore, primary feline monocytes were included in all following experimental work.

FIPV strains are divided in two serotypes: serotype I (FIPV I) and the less prevalent serotype II (FIPV II) (Pedersen et al., 1984; Hohdatsu et al., 1994). In Chapter 3, kinetics of virus binding were determined for one strain of each serotype. It was clear that virus binding to monocytes differed between the serotype I and II strain. This could suggest that serotype I and II strains use different receptors in monocytes, as has been shown by others in cell lines. In those cell lines, type II strains use feline aminopeptidase N (fAPN) as a receptor, while type I strains do not (Hohdatsu et al., 1998; Dye et al., 2007). Further, the kinetics of the serotype II strain showed that virus binding was different between monocytes of two cats. This could be due to differences in expression levels of receptor protein(s) involved in FIPV entry. More virus strains and more cats will need to be included to come to general conclusions.

In general, viruses can enter a cell via two pathways: direct fusion with the plasma membrane or receptor-mediated endocytosis. The pathway that is used, can vary depending on the virus strain or the cell type (Nash & Buchmeier, 1997). Some viruses even use both
pathways in one single cell type (Schaeffer et al., 2004). Based on observations for murine coronavirus, FIPV was supposed to enter cells via direct fusion at the plasma membrane (Krzystyniak & Dupuy, 1984). Nevertheless, the kinetic experiments performed in Chapter 3, showed that both serotypes are internalized via endocytosis and not via direct fusion at the plasma membrane. Direct fusion could be excluded because biotinylated envelopes were present in the cytosol and not left behind in the plasma membrane. Other group 1 coronaviruses, like human coronavirus 229E (HCoV-229E), transmissible gastroenteritis virus (TGEV) and canine coronavirus (CCoV), also enter cells via endocytosis (Hansen et al., 1998; Savarino et al., 2003; Nomura et al., 2004). The kinetics of internalization in Chapter 3 show that internalization of FIPV in monocytes via endocytosis was very efficient for both serotypes. Comparing these results with data on virus entry of TGEV in Madin-Darby canine kidney (MDCK) cells and HCoV-229E in human fibroblasts (Hansen et al., 1998; Nomura et al., 2004), shows that they all occur with comparable efficiency.

It was observed that at 15 minutes after the start of FIPV internalization, envelopes started to accumulate in endosomes. Possibly, these are sites where fusion with endosomal membranes occurs to release the nucleocapsid into the cytosol. Data for TGEV indicate that accumulation in endosomes starts at 10 minutes after virus uptake and genome release is situated around 1 hour after the onset of uptake (Hansen et al., 1998).

In Chapter 3, the efficiency of FIPV internalization is not only noticeable in the quantity and velocity of particle uptake, it is also reflected by the fact that a large majority of the cells takes up virus particles. However, this is in contrast to the low percentage of infection that was previously seen in monocytes (Dewerchin et al., 2005). Combining these observations, we hypothesize that there is a cellular mechanism to resist viral replication in monocytes after virus internalization. This mechanism would restrict infection at the level of genome release, transcription or translation.

Virus-receptor interactions during the entry of FIPV II in monocytes
As mentioned above, cell lines and more specifically CrFK cells interact differently with FIPV during entry compared to monocytes. The two potential receptors described for type II FIPV, fAPN and dendritic cell (DC)-specific intercellular adhesion molecule (ICAM) grabbing non-integrin (DC-SIGN), were studied mainly in cell lines (Tresnan et al., 1996; Hohdatsu et al., 1998; Dye et al., 2007; Regan & Whittaker, 2008). Therefore, the role and interplay between these two proteins during the entry process of FIPV, were evaluated in monocytes and compared with results obtained in cell lines, under the same experimental conditions (Chapter 4).
In our assays, virus binding to CrFK cells was completely blocked by APN-specific antibodies and there was complete co-localization between FIPV II and APN. These data confirmed once more that fAPN is the exclusive virus binding receptor in CrFK cells. Virus bound to fAPN is most likely internalized by APN itself (as FIPV and fAPN also co-localized inside the cell). Entry through fAPN leads to infection of CrFK cells as in our study, infection could also be completely blocked with APN-specific antibodies. However, in monocytes, the entry process seems to occur differently. APN-blocking antibodies only reduced virus binding by half. Therefore, it can be suggested that FIPV binding partly depends on fAPN and partly on another unknown receptor. The internalization assays in Chapter 4 showed that the fraction of virions that is internalized by the unknown receptor, was similar to the fraction of virions that was internalized when all receptors were available. Thus it is clear that both receptors contribute to the efficiency of internalization observed in Chapter 3. Furthermore, infection could not be blocked completely by shutting down one pathway, so entry via each of both receptors can lead to infection of monocytes. The involvement of a second receptor, besides APN, has also been described for the porcine coronavirus TGEV. TGEV uses porcine APN for entry into cells (Delmas et al., 1992; 1993), but Weingartl & Derbyshire described an additional receptor of approximately 200 kDa, that was not further identified (1994). Possibly the feline variant of that protein is involved in FIPV entry.

Regan & Whittaker reported DC-SIGN as a mediator of feline coronavirus entry into host cells (2008). Therefore, the role of DC-SIGN and potential interplay with APN was studied in the entry process of FIPV. Because feline DC-SIGN (fDC-SIGN) is not completely characterized yet, a human DC-SIGN (hDC-SIGN) construct was used to see if FIPV interacted with hDC-SIGN-expressing cells. Expression of hDC-SIGN in Chinese hamster ovary (CHO) cells enabled the cells to bind and internalize virus, but infection could not be established. It is known that DC-SIGN can target the endosomal/lysosomal pathway (Engering et al., 2002), so probably virus particles are degraded because they lack a factor necessary for genome release. These experiments demonstrated the capacities of hDC-SIGN to bind and internalize FIPV. Knowing this, the presence of FIPV-fDC-SIGN interactions was also studied in monocytes, and this was done by assessing the effect of blocking fDC-SIGN on virus binding, internalization and infection. In monocytes, no role could be attributed to fDC-SIGN in binding and internalization of FIPV as non of these processes were influenced by incubation.
with mannan, a competitor for binding to DC-SIGN. Also when fAPN was blocked, blocking binding to fDC-SIGN did not cause a supplemental inhibition of FIPV binding. Therefore, we can conclude that fDC-SIGN in monocytes is not important for virus binding and internalization and hence, fDC-SIGN cannot be the unknown receptor X that binds and internalizes FIPV. Moreover, these results suggest that FIPV has a relatively low affinity towards fDC-SIGN compared to fAPN and the unknown receptor, and maybe even towards hDC-SIGN. Besides in binding and internalization, we also checked the role of fDC-SIGN in infection by evaluating if mannan could reduce infection. No effect on infection was observed when fDC-SIGN was blocked with mannan. However, when fAPN was blocked, fDC-SIGN did seem to have a role in the infection process. Because fDC-SIGN does not contribute to binding and internalization, the role in infection will most likely be in a step following internalization. Further studies are needed to further elucidate the role of fDC-SIGN in infection.

Having listed the results from this study, a comparison can be made with the results obtained by Regan & Whittaker (2008). They induced susceptibility to infection in unsusceptible cells (mouse 3T3 cells) after transfection with hDC-SIGN. In our study, virus internalization could be induced in transfected CHO cells, but infection did not take place. A possible explanation is that CHO cells lack a factor necessary to release the FIPV genome from intracellular vesicles, while this factor is present in the mouse cells used by Regan & Whittaker. Further, Regan & Whittaker found that transfection of hDC-SIGN in CrFK cells enhanced infection of these cells. This could be explained by an increase of virus binding and internalization. Infection of monocytes could also be blocked with mannan, according to Regan & Whittaker. In our hands, no inhibition of infection was observed after treating monocytes with mannan. There is no obvious explanation for the different outcomes between these studies, but maybe the FIP viruses have a different passaging history. And since it is known that multiple passaging can induce adaptations in viruses, these adaptations might have had an effect on virus-receptor interactions.
Figure 1: Schematic representation of hypothetical receptor use by FIPV type II upon entry in monocytes. The virus can enter the monocytes via two pathways. ‘Rec X’ stands for a yet unidentified receptor that can be used by FIPV to gain entry into the cell.
All the data we obtained on interactions between FIPV II and fAPN, the unknown receptor ‘rec X’, and fDC-SIGN led to the hypothetical model on receptor use in monocytes, depicted in Figure 1. Infection can be mediated by fAPN after virus binding to and internalization via this protein. This is pathway 1 in Figure 1. The unknown rec X can bind and internalize FIPV, but by itself, it can probably not (efficiently) induce infection. Possibly, rec X mediates infection through association with fDC-SIGN or fAPN after internalization to mediate genome release. This is pathway 2 in Figure 1. The association with fDC-SIGN or fAPN can result from vesicle fusion between the internalized FIPV-containing vesicle and a recycling fDC-SIGN-containing or fAPN-containing vesicle. Based on the experimental data, it cannot be excluded that fDC-SIGN or fAPN associate with rec X in the plasma membrane after binding of FIPV to rec X and that fDC-SIGN or fAPN co-internalize with rec X.

Going even one step further, the possibility cannot be excluded that rec X might also associate with fAPN in the plasma membrane in pathway 1. This way, rec X could determine the mechanism of internalization in both pathways.

A potentially interesting observation on the side, was that visualization of a certain epitope on fAPN, recognized by mAb R-G-4, resulted in different staining patterns between cells from feline cell lines and monocytes. In all cells from the CrFK cell line, this fAPN epitope could be visualized in the plasma membrane. In monocytes, this epitope was only present in the plasma membrane of a minority of monocytes, while the full fAPN protein was expressed in the plasma membrane of all monocytes (as shown by staining another epitope of the protein). Possibly, different glycosylation patterns occur in subpopulations of monocytes, that mask the epitope. Alternatively, the epitope might be masked due to di- or multimerization, or interactions with other proteins. It would be very interesting to characterize monocytic fAPN and define the exact differences with fAPN from feline cell lines. Especially since most receptor studies have been performed with constructs expressing the APN gene isolated from such a feline cell line. This would allow to compare interaction sites and binding affinities between FIPV and fAPN from monocytes on the one hand and from feline cell lines on the other hand. For example, it would be interesting to see if affinity for monocytic APN is higher than that for APN from feline cell lines. This can be assumed based on the kinetics obtained in Chapter 3, which indicate that binding of FIPV II to CrFK cells is less efficient than binding to monocytes. Evidently, the presence of the ‘extra’ receptor X might also contribute to the higher efficiency, by providing a secondary route to deliver virus particles to intracellular vesicles.
To date, the receptor for serotype I FIPV in monocytes is not known. It has been proposed that fAPN is not important for serotype I FIPV (Hohdatsu et al., 1998; Dye et al., 2007). Therefore we would like to suggest that the unknown receptor X, with or without DC-SIGN, might be important for type I FIPV infection. Type I FIPV would then use receptor X for entry, while type II FIPV could use both receptor X as well as fAPN. This hypothesis is in accordance with the observation that type I FIPV cannot bind to CrFK cells which presumably do not express receptor X, as type II FIPV only binds to fAPN on CrFK cells.

Upon the recombination event between serotype I FIPV and CCoV from which serotype II arose (Herrewegh et al., 1998), type II FIPV might have acquired affinity for APN from CCoV (that uses canine APN as a receptor), next to the ‘existing’ affinity for the type I receptor X. In the kinetics of virus binding (Chapter 3), there were significant differences between type I and type II FIPV, which could be explained if fAPN is not a receptor for type I FIPV while it is for type II FIPV (Chapter 4 - model Fig. 1). A future experiment will evaluate if type II FIPV binding, gives similar results as seen for type I FIPV binding when APN is blocked on monocytes from the same cat. If affinity for APN is a supplemental feature for type II, compared to type I that can only bind receptor X, then blocking APN in the kinetics of type II would result in the kinetics obtained for type I. This could be possible for the second cat included in the study, where binding of serotype II FIPV reaches slightly higher levels in a shorter period of time than binding of serotype I FIPV. However for the first cat, there was less type II FIPV binding than type I FIPV binding, which does not fit the hypothesis. The low level of type II FIPV binding might be due to a lack of or ‘different’ expression of APN on the monocytes of that cat, what would imply that pathway 1 (in Figure 1) is not used intensely in monocytes of that cat. The small amount of type II virus that did bound, would have bound to receptor X and follow pathway 2 (in Figure 1). The reason that this level of FIPV II binding is lower than the binding observed in the kinetics for type I, could be that type I FIPV has a higher affinity for receptor X than type II FIPV. If this is true, one could hypothesize that the price for type II to gain affinity for fAPN upon the recombination event, was a loss in affinity for receptor X. In the future, it will be studied if pathway 1, where only APN is used, is indeed less available in monocytes of this cat. This could be studied by evaluating if blocking infection of type II FIPV with APN-specific antibodies has less effect on infection of monocytes in this cat compared to the second cat.

In addition, it will also be studied in the near future if type I FIPV infection depends on DC-SIGN.
Taken together, this study obviously provided data on the entry of FIPV II which could be very useful for studying entry of FIPV I.

The mechanism of internalization of FIPV II in monocytes
In Chapter 3, FIPV II was shown to use the endocytosis machinery of the cell to gain entry into monocytes. In Chapter 5, this pathway was further characterized by identifying which cellular proteins are necessary for FIPV internalization. Several strategies were applied: blocking entry with inhibitors, transduction with dominant-negative mutants of internalization proteins and co-localization studies looking at FIPV and internalization proteins. The combination of different strategies guaranteed a reliable result. Including co-localization assays prevented us to draw wrong conclusions due to shifting to another pathway when a certain pathway is blocked.

The experiments showed that the entry of FIPV is independent of phagocytosis and macropinocytosis, clathrin-mediated endocytosis and caveolae-mediated endocytosis. Blocking dynamin function by an inhibitor and expression of a dynamin dominant-negative mutant strongly reduced virus uptake. Inhibition of Rho GTPases did not. In conclusion, the pathway used by FIPV II to enter monocytes is clathrin- and caveolae-independent and depends on dynamin.

Sterol binding drugs (nystatin and methyl-β-cyclodextrin) slightly reduced FIPV entry in our assay. Reduction by sterol binding drugs could imply the involvement of lipid rafts in the entry process. However, the reduction obtained in virus entry by these drugs was rather small and probably too small to conclude that the entry process is associated with lipid rafts and depends on them to initiate and sustain the necessary signalling cascades. Perhaps, one of the receptor(s) or components that needs to be recruited for the internalization process is located in lipid rafts. Disturbing rafts might hereby reduce the availability of that receptor/protein and slightly influence the efficiency of internalization, possibly by reducing virus binding.
Another possibility is that the pathway requires cholesterol, like for example clathrin-mediated internalization requires cholesterol independent from lipid rafts (Subtil et al., 1999; Nichols & Lippincott-Schwartz, 2001).

In accordance with the model from Chapter 4, there might be two internalization pathways. If this is true, it would be most likely that both pathways are independent from clathrin and...
caveolae. The rather low inhibiting effect of cholesterol binding drugs, could be explained if one of the two pathways is linked to rafts. The moderate effect could be due to a pathway shift or by a bigger contribution by the raft-independent pathway in the internalization process. In pathway 1, fAPN might be present in lipid rafts because its human homologue is localized in rafts (Nomura et al., 2004). For pathway 2, fDC-SIGN or a fraction of fDC-SIGN, might also be localized in rafts. In human monocytes, hDC-SIGN is not localized in rafts immediately after they are brought in culture, but during culture in the presence of IL-4 and GM-CSF a relocation to rafts is observed (Cambi et al., 2004). Of course, nothing is known about possible raft-association of the unknown receptor X. Even if the receptors are located in rafts, it remains uncertain if the association with rafts is necessary for the internalization process. For example, TGEV enters cells through porcine APN (presumably localized in rafts) via clathrin-mediated internalization and this process does not depend on rafts. Possibly, the small effect of the sterol binding drugs, we observed for FIPV, is just due to the localization of the receptors in rafts. Further, it is also not certain that both internalization pathways depend on dynamin as internalization could not be completely blocked by dynamin inhibitors. However, reductions by dynamin inhibitors are much larger than those with sterol binding drugs. Therefore, it seems most likely that both pathways depend on dynamin. Another internalization pathway that is mediated by hAPN, the internalization pathway of HCoV-229E, depends on dynamin (Nomura et al., 2004). However this does not imply that all pathways via APN recruit dynamin. In general, there is no direct interaction between dynamin and the internalizing receptor.

All monocytes internalize FIPV II virus particles, while only a very limited number gets infected. Therefore it might be questioned if the internalization pathways studied, lead to infection. After treatment of monocytes with entry inhibitors, infection of monocytes was reduced to similar levels as virus entry. This suggests that the internalization pathways studied, indeed lead to infection. However, for the sterol binding drugs, the reduction of infection was larger than expected based on the reduction of entry. Therefore, other post-internalization processes are probably also hampered by the inhibitor, like for example intracellular transport. Another possibility is that the small effect of the sterol binding drugs was due to involvement of rafts in one of the two entry pathways or for one of the two receptors. The larger reducing effect on infection would imply that the only pathway that is involved in infection is the one linked to rafts. However, this would contradict earlier results from Chapter 4 that indicate that both pathways are important for infection.
As far as we know, the entry pathway of FIPV II, namely the clathrin- and caveolae-independent pathway that depends on dynamin and is slightly cholesterol depletion sensitive, has no physiological equivalent. However, there are pathways that resemble the entry pathway of FIPV. The β-strain of interleukin 2 receptors (IL-2R) is internalized via a clathrin- and caveolae-independent pathway. The pathway depends on dynamin and is sensitive to cholesterol depletion due to raft-association of the receptor. The pathway depends on Rho GTPases (Lamaze et al., 2001). The internalization of the common cytokine receptor γ (γc) follows the same route as the IL-2R (Kirkham & Parton, 2005; Sauvonnet et al., 2005).

Clathrin- and caveolae-independent pathways are also used by several viruses, including a coronavirus (Marsh & Helenius, 1989; Sieczkarski & Whittaker, 2002; Sanchez-San Martin et al., 2004). The internalization pathway of SARS-CoV in HEK293E cells transfected with ACE2, and Vero E6 cells, is also independent from clathrin and caveolae and associated with lipid rafts (Wang et al., 2008). Further characterization, however, has not been performed to date. Rotavirus entry resembles FIPV entry the most, except for the higher susceptibility for cholesterol depletion. The role of Rho GTPases in this process has not been studied (Sanchez-San Martin et al., 2004).

Not many entry pathways of group 1 coronaviruses are characterized profoundly. The characterized pathways are diverse and different from the pathway described for FIPV. HCoV-229E enters human fibroblasts via caveolae-mediated internalization (Nomura et al., 2004), while TGEV enters cells that stably express APN presumably via clathrin-mediated internalization (Hansen et al., 1998). It is clear that their common characteristics, including the use of APN as a receptor, do not lead to a shared internalization mechanism.

**Genome release after internalization via endocytosis of FIPV II**

After internalization via endocytosis, the virus is ‘trapped’ in intracellular vesicles and the genome has to be released into the cytosol for viral replication to occur. In Chapter 6, this uncoating process was visualized. Uncoating could be observed in some cells as soon as internalization started. The maximal percentage of cells with released genomes in the cytosol, was observed 35 minutes after the start of internalization. These data correlate very good with the observed accumulation of FIPV envelopes in endosomes at 15 minutes after the start of internalization in Chapter 3. Moreover we observed that the release of the FIPV genome from these vesicles appears to be restricted to a subpopulation of cells (Chapter 6). This suggests a restriction on the uncoating process which may explain (in part) the discrepancy between the number of cells with internalized particles and the number of
infected cells that was observed in Chapter 3. Still, further research is necessary to verify if there is an additional restriction besides the one on uncoating.

Possible triggers for genome release are low pH, cleavage by proteases and receptor-induced conformational changes. For FIPV type II infection of monocytes, the requirement for low pH has been the subject of contradictory literature (Regan et al., 2008; Takano et al., 2008). Our results from infection inhibition experiments in monocytes with lysosomotropic agents, suggest that low pH is not important to mediate genome release. This is in agreement with the results that Regan et al. (2008) obtained in several cell lines for several FIPV strains. In contrast, Takano et al. (2008) suggest that low pH is important for FIPV infection in monocytes. They used a different set-up by using relatively high concentrations of inhibitors (500 nM of bafilomycin A1 while we used 10 nM) for a longer incubation time (3 days compared to 6-12 hours). This might explain the different results.

The second possible trigger for genome release is protease activity. Proteases are divided in four main categories: cysteine proteases, serine proteases, aspartyl proteases and metalloproteases. The precise role of proteases in FIPV infection will be studied in the future by treating monocytes with several protease inhibitors. Preliminary experiments suggest that cysteine and/or serine proteases may be involved in FIPV II infection. In the future, it will be determined if (a) cysteine or serine protease(s) is/are important for genome release in particular, and if so, which (subclass of) protease(s). This is of great interest as both furin, a serine protease, and cathepsin B, a cysteine protease, have been suggested to play a role in feline coronavirus entry for at least some strains (Regan et al., 2008; de Haan et al., 2008). The involvement and role of the other proteases (aspartyl proteases and metalloproteases) will also be studied. Possibly, more than one protease is involved in the uncoating, as has been described for HCoV-229E (Kawase et al., 2009).

Another potential trigger is a receptor-induced conformational change. The involvement of conformational changes to initiate fusion for uncoating, was not evaluated in our study and therefore cannot be excluded. The hypothesis in Chapter 4 namely that in pathway 2 fDC-SIGN binding might be necessary to induce uncoating remains possible. However, fDC-SIGN does probably not initiate uncoating itself by inducing a conformational change, but rather targets compartments where other release factors like proteases are present.
Hypothetical model for the entry of FIPV II in feline monocytes

The work in this thesis has led to a hypothetical model of the entry of FIPV II in feline blood monocytes, the *in vivo* target cells. In Figure 2, the different steps during entry are schematically represented. The first pathway of internalization (pathway 1) results from binding to APN in the plasma membrane. Possibly APN resides in lipid rafts, but probably this association is not required for internalization. After binding, dynamin is most likely recruited and a vesicle containing the virus-receptor complex is internalized via a clathrin- and caveolae-independent pathway. To release the viral genome from the vesicle into the cytosol, cysteine and/or serine protease activity might initiate the exposure of a fusion peptide that mediates membrane fusion between the viral envelope and the membrane of the intracellular vesicle. Another, yet unknown receptor can also bind and internalize FIPV (pathway 2). It is not known if this receptor is present in lipid rafts. The internalization also occurs via a clathrin- and caveolae-independent pathway, that probably also depends on dynamin. After internalization, the internalized vesicle can fuse with a DC-SIGN- or an APN-containing vesicle to mediate genome release (unless the association between the unknown receptor and DC-SIGN or APN already took place at the plasma membrane). How genome release is mediated, is not known. The trigger might be a DC-SIGN-induced conformational change or most likely, DC-SIGN might target the virus-receptor complex to an intracellular compartment with the appropriate physiological conditions, like the presence of cysteine and/or serine proteases, to induce fusion.

The relevance of this hypothetical model and the obtained data might be questioned based on the relatively small number of animals included in the study. It would be interesting to compare similar data for other cats. However, the data presented are clearly more representative for the *in vivo* situation than previous data obtained in cell lines. Knowing that there are big differences in susceptibilities of cats, it can be questioned if the proposed model can be generalized. This could be verified in the future but it seems more likely that differences in susceptibility are caused by differences in the immune response upon infection than by different receptor use or expression.
Figure 2: Hypothetical model for the entry of FIPV type II in feline blood monocytes based on the data obtained in this thesis.
The main conclusions that can be drawn from this thesis are:
- Crandell feline kidney cells cannot be used as a model cell line to study FIPV entry.
- Serotype I and II FIPV strains might use different receptors on monocytes as they do in CrFK cells.
- FIPV serotype I and II internalization in monocytes is extremely efficient and occurs exclusively via endocytosis.
- fAPN is a virus binding and internalizing receptor for serotype II FIPV on monocytes, while DC-SIGN is not.
- fAPN is not the only receptor for serotype II FIPV on monocytes.
- FIPV serotype II internalization in monocytes is clathrin- and caveolae-independent, depends on dynamin and is slightly cholesterol depletion sensitive.
- Attachment and internalization of FIPV serotype II occurs in most cells, while genome release appears to be restricted to a fraction of the cells which might explain why most cells are not susceptible to FIPV infection.

Fundamental research, like described in this thesis, is extremely important in the search for targets that can be used in the development of new antiviral compounds. Especially in the battle against incurable diseases like feline infectious peritonitis. The studies described in this thesis already provide some ideas on how to fight this disease. For example, FIPV infection of monocytes can be prevented by blocking dynamin. However, blocking dynamin function in an organism will probably have numerous adverse effects.

A lot of questions remain to be studied in the future. First of all, several experiments can be performed to evaluate the relevance of the hypothetical models depicted in Figures 1 and 2. Further, signalling during internalization can be studied in order to find specific regulators for the independent internalization pathway that could be used as targets for treatment of FIP. And finally, it would be of interest to identify the unknown FIPV binding and internalizing receptor.

What is known now about the entry of type II FIPV, also puts us in an ideal position to start analysing the entry of type I FIPV. Knowing more about the entry of type I FIPV is of major interest because most natural infections are serotype I infections. Therefore, if a treatment is developed that targets FIPV entry, it should also be able to reduce type I FIPV entry.
REFERENCES


Feline coronaviruses occur in two virulence variants of which the feline infectious peritonitis virus (FIPV) is the most threatening. It causes a monocyte-derived viremia that leads to a progressive vasculitis and is mostly fatal for the infected cat. There is no effective treatment available. To address this matter, an improved knowledge of the pathogenesis of FIPV is needed. The process of viral entry is an attractive target for the development of new therapeutic agents. However, little is known about the entry of FIPV. It is even questioned if the virus enters cells via direct fusion with the plasma membrane or after receptor-mediated internalization.

In this thesis, the entry process of FIPV is studied to add upon the knowledge in FIPV pathogenesis and to evaluate the presence of possible targets for antiviral therapy.

In chapter 1, an introduction is given about FIPV and virus entry in general. In the first section of chapter 1, the taxonomy and pathogenesis of FIPV are described. Further, insights are provided in the structure of a FIP virion and the production of new virions upon infection of a cell. In the second section of chapter 1, the process of viral entry is discussed. The different receptors that can be used by group 1 coronaviruses are listed and their use by the different coronaviruses is described. An overview of possible internalization pathways for viruses is given. And finally, different coronaviruses are linked to their internalization pathways.

In chapter 2, the outline of the aims is given.

In chapter 3, a quantitative analysis of the different steps in viral entry, i.e. attachment and internalization, was performed. Kinetics of attachment and internalization were determined by evaluating the number of attached virions and the percentage of internalized virions at different time points after inoculation. Kinetics were determined in both the in vivo target cells, feline primary monocytes and in Crandell feline kidney (CrFK) cells, cells from a continuous cell line. This was done to evaluate if this cell line could be used as a model cell line for FIPV entry studies. Unfortunately, attachment and internalization were less efficient in CrFK cells, so entry experiments in CrFK cells cannot predict interactions of FIPV with monocytes during virus entry.

Two virus strains were included in the study, namely the serotype I strain Black and the serotype II strain 79-1146, to evaluate differences between both serotypes. Virus binding to
monocytes differed between the serotype I and II strain. This might suggest that both serotypes use different receptors in monocytes, like was shown previously in cell lines. Further, for the serotype II strain, virus binding was different between monocytes of two cats. This could be due to differences in expression levels of receptor protein(s) involved in FIPV entry. It is clear that these hypotheses should be verified by evaluating virus binding for more virus strains and more cats.

Virus internalization was very efficient in monocytes. Besides the fact that the majority of bound virions was internalized within 1 minute, internalization also occurred in the majority of cells. This was in contrast to the restricted number of cells that is susceptible to infection. It was also shown that this internalization process proceeded via receptor-mediated endocytosis and not via direct fusion at the plasma membrane.

In chapter 4, the role of feline aminopeptidase N (fAPN) and dendritic cell-specific intercellular adhesion molecule grabbing non-integrin (DC-SIGN), as receptors for FIPV serotype II strain 79-1146, has been studied in both monocytes and cells from continuous cell lines. First, the effect of blocking the potential receptor(s) was evaluated and secondly, the level of co-localization of FIPV and the receptors was determined.

It was found that blocking fAPN inhibited binding and infection in CrFKs completely and that FIPV co-localized with fAPN. In contrast, on monocytes, binding and infection were only reduced by 53 % and 44 %, respectively, and only 60 % of bound FIPV co-localized with fAPN. Thus, APN is capable of binding and internalizing FIPV in monocytes and APN-mediated entry leads to infection in monocytes. However, this is not the exclusive receptor for FIPV on monocytes, like it appears to be in CrFK cells.

To evaluate the FIPV binding and internalizing capacities of human DC-SIGN (hDC-SIGN), CHO cells were transduced with hDC-SIGN. Transduction rendered the cells susceptible to binding and internalization of FIPV but not to infection. In monocytes, blocking fDC-SIGN did not influence binding and infection and there was no co-localization. It is clear that fDC-SIGN is not the second receptor next to fAPN on monocytes. However, blocking fDC-SIGN caused a further inhibition of infection from 56 % up to 18 % infection in APN-blocked monocytes. It seems that DC-SIGN is not directly required for attachment or internalization in monocytes, but might be necessary for infection via an alternative pathway independent of APN.

In conclusion, it was clear that virus-receptor interactions on CrFK cells are not representative for the interactions on in vivo target cells. The results obtained in this chapter also led to a model for receptor interactions upon FIPV type II entry in monocytes.
In chapter 5, the mechanism of internalization of FIPV serotype II strain 79-1146 in monocytes was studied. In chapter 3, it was shown that FIPV enters cells via endocytosis and not via direct fusion at the plasma membrane. This study aimed to specify which endocytic pathway was used by FIPV in monocytes. There are two main categories of endocytic pathways: phagocytosis and pinocytosis. Pinocytosis can be divided in macropinocytosis, clathrin-mediated internalization, caveolae-mediated internalization and several clathrin- and caveolae-independent internalization pathways. To identify the pathway that was used by FIPV, three strategies were applied: internalization pathways were blocked with inhibitors or by expressing dominant-negative internalization proteins in monocytes, and double stainings were performed to analyse co-localization between FIPV and internalization proteins. Phagocytosis, macropinocytosis and clathrin-mediated internalization were clearly not involved in FIPV entry. Caveolae-mediated internalization was not involved either but sterol-binding drugs, applied to block this pathway non specifically, had a slight but significant reducing effect on FIPV uptake. Further, blocking the function of dynamin by an inhibitory peptide and expression of dominant-negative dynamin significantly reduced both the internalization and infection with FIPV in monocytes. Rho-GTPases were not involved in internalization. It was concluded that the entry of FIPV II in monocytes proceeded via a clathrin- and caveolae-independent pathway that depends on dynamin and is slightly cholesterol-depletion sensitive.

In chapter 6, the step after internalization, the release of the genome of FIPV type II strain 79-1146 from endosomes into the cytosol, was studied. This process was analysed by visualizing released nucleocapsids in the cytosol at different time points after the start of internalization. At 35 minutes after this starting point, the maximum number of cells with released genomes was observed. Compared to the percentage of cells with internalization, the percentage of cells with genome release was low. It appears that there is a restriction to infection at this level. This might explain why only a small fraction of the cells is susceptible to infection.

The release of nucleocapsids from endosomes occurs via fusion between viral envelopes and endosomal membranes. This process can be triggered by a number of factors such as the pH drop in late endosomes, protease activity, a receptor-induced conformational change or other unknown factors. By using inhibitors, it was shown that genome release of FIPV is not induced by low pH. Preliminary data suggest a role for serine and/or cysteine protease(s). In the future, the involvement of proteases will be further studied to identify the exact protease(s) that are involved in FIPV entry.
As a **general conclusion**, it can be stated that the process of FIPV entry in monocytes does not resemble FIPV entry in CrFK cells. However, serotype I and serotype II strains probably use different receptors in both cell types.

FIPV serotype II entry in monocytes occurs in a large majority of cells and proceeds exclusively via endocytosis. Based on the results obtained in chapters 3 to 6, a model for FIPV type II entry in monocytes was proposed. This is shown in Figure 1. The first pathway of internalization (pathway 1) results from binding to APN in the plasma membrane. Possibly APN resides in or is transported to lipid rafts. After binding, most likely, dynamin is recruited and a vesicle containing the virus-receptor complex is internalized via a clathrin- and caveolae-independent pathway. To release the viral genome from the vesicle into the cytosol, cysteine and/or serine protease activity might be necessary. Another, yet unknown receptor can also bind and internalize FIPV (pathway 2). It is not known if this receptor (rec X) is present in lipid rafts. The internalization also occurs via a clathrin- and caveolae-independent pathway, that probably also depends on dynamin. After internalization, the internalized vesicle might fuse with a DC-SIGN- or an APN-containing vesicle (this association between rec X and DC-SIGN or APN may also occur at the plasma membrane). How genome release is mediated, is not known but possibly cysteine and/or serine proteases induce fusion.

It seems like only a fraction of the cells that internalize virus, release free nucleocapsids from endosomes. This might explain - at least in part - the discrepancy between the fraction of cells that internalize virus and the fraction that is susceptible to infection.
Figure 1: Hypothetical model for the entry of FIPV type II in feline blood monocytes based on the data obtained in this thesis.
The main conclusions that can be drawn from this thesis are:

- Crandell feline kidney cells can not be used as a model cell line to study FIPV entry.
- Serotype I and II FIPV strains might use different receptors on monocytes as they do in CrFK cells.
- FIPV serotype I and II internalization in monocytes is extremely efficient and occurs exclusively via endocytosis.
- fAPN is a virus binding and internalizing receptor for serotype II FIPV on monocytes, while DC-SIGN is not.
- fAPN is not the only receptor for serotype II FIPV on monocytes.
- FIPV serotype II internalization in monocytes is clathrin- and caveolae-independent, depends on dynamin and is slightly cholesterol depletion sensitive.
- Attachment and internalization of FIPV serotype II occurs in most cells, while genome release appears to be restricted to a fraction of the cells which might explain why most cells are not susceptible to FIPV infection.
SAMENVATTING

Binnen de feliene coronavirussen bestaan er twee virulentie varianten. Het feliene infectieuze peritonitis virus (FIPV) is de meest bedreigende. Het virus veroorzaakt een monocyt-geassocieerde viremie die leidt tot een progressieve vasculitis. De infectie kent meestal een fatale afloop en er is geen effectieve behandeling beschikbaar. Om hierin verandering te brengen, is er een verbeterde kennis van de pathogenese van FIPV nodig. Vele nieuwe antivirale middelen zijn gericht tegen virusopname. Voor FIPV, is er echter weinig gekend over dit proces. Het is zelfs niet duidelijk of FIPV zijn doelwitcel, de monocyt, binnendringt via directe membraanfusie of via receptor-gemedieerde endocytose.

In deze thesis, is de opname van FIPV bestudeerd met als doel een deeltje van de pathogenese op te helderen en zo een stap dichter te komen bij een effectieve behandeling.

In hoofdstuk 1, worden het FIP virus en het proces van virus opname beschreven. Het eerste deel van hoofdstuk 1 handelt over de taxonomie en pathogenese van FIPV. Verder worden de structuur van het virion en de productie van virale partikels bij infectie van een cel, beschreven. Het tweede deel van hoofdstuk 1 handelt over virus opname. De verschillende receptoren van coronavirussen in groep 1 worden opgesomd en de binding aan deze receptoren wordt besproken. Daarnaast worden alle mogelijke opnamewegen beschreven en worden verschillende coronavirussen gelinkt aan de opnameweg die hen in hun doelwitcel brengt.

In hoofdstuk 2 wordt de doelstelling van deze thesis toegelicht.

In hoofdstuk 3, werd een kwantitatieve analyse gemaakt van de verschillende stappen in het proces van virusopname, namelijk binding en internalisatie. De kinetieken van binding en internalisatie werden bepaald door het aantal virusharompsonkels dat gebonden is aan een cel en het percentage van partikels die opgenomen zijn per cel, te kwantificeren op verschillende tijdstippen na inoculatie met virus. Deze kinetieken werden bepaald in de in vivo doelwitcel van het virus, feliene bloedmonocyten, en in cellen van een continue cellijn, ‘Crandell feline kidney’ (CrFK) cellen. Deze cellijn werd ingesloten in de studie om te evalueren of ze gebruikt kon worden als model cellijn voor de studie van opname van FIPV in monocyten. Binding en internalisatie bleken helaas minder efficiënt te verlopen in de CrFK cellijn dan in monocyten, dus kunnen opname experimenten met deze cellen niet voorspellen hoe het virus met monocyten zal interageren.
Er werden twee virusstammen gebruikt in deze studie, een serotype I stam Black en een serotype II stam 79-1146, om zo eventuele verschillen tussen serotypes te bekijken. Virus binding was verschillend voor beide stammen, dit zou kunnen betekenen dat beide serotypes verschillende receptoren gebruiken in monocyten, zoals ze doen in CrFK cellen. Voor binding van het serotype II virus, werden ook verschillen opgemerkt tussen monocyten afkomstig van twee verschillende katten. Dit zou het gevolg kunnen zijn van verschillende expressie van een receptor die betrokken is bij virus opname. Deze hypothesen moeten nog verder onderzocht worden door meer stammen en meer katten in te sluiten in de studie.

Virus internalisatie was een zeer efficiënt proces in monocyten. Niet alleen werd de meerderheid van de gebonden partikels binnen 1 minuut geïnternaliseerd, dit proces voltrok zich ook in de meerderheid van de cellen. Dit staat in contrast met het beperkte aantal cellen dat gevoelig is voor infectie. Er werd ook aangetoond dat internalisatie gebeurde via receptor-gemediaerde endocytose en niet via directe fusie met de plasma membraan.

In hoofdstuk 4, werd de rol van felien aminopeptidase N (fAPN) en ‘dendritic cell-specific intercellular adhesion molecule grabbing non-integrin’ (DC-SIGN), als receptoren voor de serotype II FIPV stam 79-1146, bestudeerd in monocyten en in cellen van continue celllijnen. Eerst werd het effect bepaald van het blokkeren van deze proteïnen, en vervolgens werd de colokalisatie van FIPV en de receptoren bepaald.

Er werd vastgesteld dat het blokkeren van fAPN, binding en infectie in CrFK cellen verhindert en dat het virus volledig colokaliseert met deze receptor. In monocyten werden binding en infectie ‘slechts’ gereduceerd met respectievelijk 53 % en 44 %. Colokalisatie tussen FIPV en fAPN was beperkt tot 60 % van de viruspartikels. Virus kan dus via fAPN binden en opgenomen worden in monocyten en opname langs deze weg kan tot infectie leiden. Toch is er naast fAPN nog een receptor voor binding en internalisatie, wat niet het geval is in CrFK cellen.

Om te evalueren of humaan DC-SIGN (hDC-SIGN) FIPV kon binden en internaliseren, werden CHO cellen met hDC-SIGN getransduceerd. De transductie zorgde ervoor dat deze cellen virus konden binden en opnemen, maar de cellen konden niet geïnfecteerd worden. Het blokkeren van fDC-SIGN in monocyten had geen effect op virus binding en infectie. Verder was er ook geen colokalisatie tussen FIPV en fDC-SIGN. fDC-SIGN bleek duidelijk niet de tweede receptor, naast fAPN, op monocyten te zijn. Het blokkeren van fDC-SIGN in cellen waarin fAPN ook geblokkeerd is, veroorzaakte echter wel een bijkomende inhibitie van infectie van 56 naar 18 %. Het lijkt alsof fDC-SIGN niet nodig is voor binding en internalisatie in monocyten, maar wel een rol speelt in infectie onafhankelijk van fAPN.
Uit deze studie bleek dat virus-receptor interacties in CrFK cellen niet representatief zijn voor interacties in \textit{in vivo} doelwit cellen. Verder kon ook een model opgesteld worden van de receptor interacties bij opname van serotype II FIPV in monocyten.

In \textbf{hoofdstuk 5}, werd het mechanisme van internalisatie van FIPV serotype II stam 79-1146 in monocyten bepaald. In hoofdstuk 3 werd aangetoond dat FIPV monocyten binnendringt via receptor-gemediëerde endocytose en niet via directe fusie met de plasma membraan. Deze studie had als doel te bepalen langs welke weg internalisatie van FIPV in monocyten gebeurt. Endocytose kan opgedeeld worden in twee klassen: fagocytose en pinocytose. Pinocytose omvat macropinocytose, clathrine-gemideerde internalisatie, caveolae-gemideerde internalisatie en verschillende clathrine- en caveolae-onafhankelijke internalisatie wegen. Om de opnameweg van FIPV te bepalen, werden drie strategieën toegepast: internalisatie wegen werden geblokkeerd met inhibitoren of door expressie van dominant-negatieve internalisatie proteïnen in monocyten, en dubbelkleuringen werden uitgevoerd om de colokalisatie tussen virus en internalisatie proteïnen te bekijken. Fagocytose, macropinocytose en clathrine-gemideerde internalisatie bleken duidelijk niet betrokken bij de opname van FIPV. Caveolae-gemideerde internalisatie was ook niet betrokken maar de sterol-bindende middelen die gebruikt werden om caveolae-gemideerde internalisatie aspecifiek te inhiberen, hadden een klein, maar significant reducerend effect op de opname van FIPV. Het inhiberen van de functie van dynamine, met een dynamine inhiberend peptide en expressie van dominant-negatief dynamine, reduceerde opname en infectie met FIPV significant. Rho-GTPasen bleken niet betrokken bij opname van FIPV. Er werd geconcludeerd dat de opname van FIPV serotype II in monocyten gebeurt via een clathrine- en caveolae-onafhankelijke weg die afhankelijk is van dynamine en licht gevoelig is voor het onttrekken van cholesterol.

In \textbf{hoofdstuk 6}, werd de stap bestudeerd die volgt op internalisatie via endocytose, namelijk de vrijstelling van het genoom in het cytosol. Dit proces werd geanalyseerd door vrije nucleokapsieds in het cytosol te visualiseren op verschillende tijdstippen na de start van internalisatie. Op 35 minuten na de start van internalisatie, werd het maximaal percentage cellen met vrijgestelde nucleokapsieds gedetecteerd. In vergelijking met het aantal cellen die virus internaliseren, was het aantal cellen met vrijstelling laag. Het lijkt alsof genoomvrijstelling een stap is in de replicatiecyclus die niet in alle cellen kan doorgaan. Dit zou kunnen verklaren dat slechts een laag percentage cellen geïnfecteerd kan worden.
De vrijstelling van nucleokapsieds uit endosomen resulteert uit fusie van de virale envelop met de membraan van endosomen. Deze fusie kan geïnduceerd worden door verschillende factoren zoals de verlaagde pH in late endosomen, protease activiteit, een receptor-geïnduceerde conformatie verandering of andere onbekende factoren. Aan de hand van inhibitoren werd aangetoond dat de verlaagde pH in endosomen niet noodzakelijk is voor de vrijstelling van FIPV. Volgens preliminaire experimenten, zouden serine en/of cysteïne proteasen echter wel betrokken zijn bij de genoomvrijstelling van FIPV. In de toekomst zal de rol van proteasen in de genoomvrijstelling van FIPV verder onderzocht worden zodat de proteasen geïdentificeerd kunnen worden die de vereiste membraanfusie induceren.

Als algemene conclusie, kan gesteld worden dat de opname van FIPV in monocyten niet vergelijkbaar is met opname in CrFK cellen. Toch gebruiken serotype I en II stammen waarschijnlijk verschillende receptoren in beide celtypes. FIPV serotype II opname in monocyten vindt plaats in de meeste monocyten en gebeurt via endocytose. Op basis van de resultaten die bekomen zijn in de hoofdstukken 3 tot 6, werd een hypothetisch model voorgesteld voor de opname van serotype II FIPV in monocyten. Dit is weergegeven in figuur 1. De eerste opnameweg (opnameweg 1) wordt gevolgd na binding aan APN in de plasma membraan. Het is mogelijk dat APN gelokaliseerd is in of getransporteerd wordt naar lipid rafts. Na binding, wordt dynamine waarschijnlijk gerecruteerd naar het internaliserend vesikel dat uiteindelijk opgenomen wordt via clathrine-en caveolae-onafhankelijke internalisatie. Serine en/of cysteïne protease activiteit zou nodig kunnen zijn om genoomvrijstelling uit de endosomen te induceren. FIPV zou ook kunnen binden aan en internaliseren via een tweede, nog onbekende receptor (opnameweg 2). Uiteraard is niet bekend of deze receptor (rec X) zich in lipid rafts bevindt. Waarschijnlijk is deze opnameweg ook onafhankelijk van clathrine en caveolae, maar afhankelijk van dynamine. Na internalisatie, zou het vesikel kunnen fusioneren met een DC-SIGN- of APN-bevattend vesikel (tenzij de associatie tussen rec X en DC-SIGN of APN reeds ter hoogte van de plasma membraan plaats vindt). Hoe de daaropvolgende genoomvrijstelling gebeurt, is niet gekend, maar mogelijks zijn serine en/of cysteïne proteasen hierbij betrokken.

Het lijkt alsof slechts een fractie van de cellen met virus opname, in staat zijn om nucleokapsieds vrij te stellen uit endosomen. Dit zou - allerminst gedeeltelijk - het verschil tussen de fractie cellen die virus internaliseren en de fractie die gevoelig is voor infectie, kunnen verklaren.
Figuur 1: Hypothetisch model voor de opname van serotype II FIPV in feliene bloed monocyten op basis van de data bekomen in deze thesis.

**OPNAMEWEG 1**

- APN
- DC-SIGN
- Rec X
- Dynamine
- Lipid rafts
- (Cysteïne en/of serine) protease

**OPNAMEWEG 2**

- APN
- DC-SIGN
- Rec X
- Dynamine
- Lipid rafts
- (Cysteïne en/of serine) protease

Vrijstelling
De belangrijkste conclusies van deze studie zijn:

- De ‘Crandell feline kidney’ cellijn kan niet gebruikt worden als model cellijn om de opname van FIPV te bestuderen.
- Er zijn indicaties dat serotype I en II stammen in monocyten verschillende receptoren gebruiken zoals aangetoond in CrFK cellen.
- Internalisatie van serotype I en II FIPV in monocyten is uiterst efficiënt en vindt uitsluitend plaats via endocytose.
- fAPN is een virus bindende en internaliserende receptor voor serotype II FIPV, maar DC-SIGN niet.
- fAPN is niet de enige receptor voor serotype II FIPV op monocyten.
- Internalisatie van serotype II FIPV in monocyten is clathrine- en caveoline-onafhankelijk, afhankelijk van dynamine en licht gevoelig voor het onttrekken van cholesterol.
- Binding en internalisatie van serotype II FIPV komt voor in de meerderheid van de cellen, terwijl genoomvrijstelling beperkt lijkt te zijn tot een fractie van cellen. Dit zou kunnen verklaren waarom de meeste cellen niet gevoelig zijn voor infectie.
Personalia

Publicaties

Publicaties in internationale wetenschappelijke tijdschriften


Publicaties in voorbereiding

Abstracts

- Belgian Society for Microbiology: 14th annual symposium, 12th December 2008, Brussels, Belgium.

- Belgian Society for Microbiology: 14th annual symposium, 12th December 2008, Brussels, Belgium.

- Belgian Society for Microbiology: 14th annual symposium, 12th December 2008, Brussels, Belgium.

- Belgian Society for Microbiology: 13th annual symposium, 23rd November 2007, Brussels, Belgium.

Clathrin- and caveolae-independent entry of feline infectious peritonitis virus in monocytes depends on dynamin.

- Belgian Society for Microbiology: 14th annual symposium, 12th December 2008, Brussels, Belgium.
Werken aan een doctoraat is in zekere zin heel individueel, je werkt aan je eigen onderzoek en bepaalt uiteindelijk zelf wat wanneer moet gebeuren. Anderzijds is het voltooien van een doctoraat niet mogelijk zonder een ‘serieuze’ achterban. Aan die achterban is dit laatste woordje gewijd...

Eerst wil ik mijn promotor bedanken, prof. dr. Hans Nauwynck. Ik herinner me nog de eerste keer dat ik in uw bureau belandde als argeloze studente op zoek naar een scriptie onderwerp. Al snel wees u me erop dat het eigenlijk een sollicitatie gesprek was. Ik wist meteen waar ik de volgende 5 jaar aan toe was ☺. Ik wil u bedanken voor het vertrouwen en voor het gerust stellen bij momenten van paniek.

Prof. dr. Herman Favoreel wens ik te bedanken voor het kritisch lezen van de eerste versie van deze thesis in relatief korte tijd ☺. Bedankt voor de waardevolle opmerkingen en suggesties en het duwtje in de rug op het juiste moment!

Prof. dr. Kristien Van Reet wil ik bedanken voor de talrijke gezellige ritjes naar de faculteit ‘s ochtends. De toffe babbels op weg naar het werk waren een zeer aantrekkelijk alternatief voor de saaie busritten.

Ik herinner me nog de vriendelijke gezichten die mij verwelkomden de eerste dag op het labo, die van mijn ‘mede-FIPpers’ Hannah en Els. Met open armen werd ik direct als volwaardig lid opgenomen in het groepje. Dat zal ik nooit vergeten. Hannah, bedankt voor de steun en de hulp gedurende al die jaren. Je stimuleerde zelfstandigheid maar was altijd beschikbaar (zelfs toen ik per se bloed wou nemen op een verlofdag). Ik heb je altijd bewonderd voor je zelfvertrouwen en de rust die je uitstraalt. Ik wens je nog vele mooie momenten met Sam, Mina en de volgende telg in jullie nieuwe huis! Els, je zal het waarschijnlijk niet geloven, maar ik mis onze (gestresseerde ☹️) afdalingen naar de stallen op maandag om bloed te nemen van de poesjes. Net als de vele ritjes naar Gent ‘s avonds en de sportieve uitspattingen. Spinning in de Ucon, joggen in het park, ... je stond altijd klaar om me te vergezellen bij iets nieuws. Ik ben heel blij voor je dat je met Tim het geluk hebt gevonden en ik wens je alles toe wat je maar wil!

Ik prijs mezelf heel gelukkig dat ik gedurende 4,5 jaar deel mocht uit maken van de legendarische 1ste bureau! De 1ste bureau uitstapjes, ‘the mission’ I en II, de steun in moeilijkere tijden, de interesse (en hulp) in elkaars werk, ... maken een doctoraat zonder 1ste

In een latere fase kwamen er nog extra 1ste bureau leden bij.. Eerst en vooral, nieuwe FIPpers Leslie en Ben. Leslie, je vond al snel je draai binnen de groep en binnen het labo. Bedankt om bloed te gaan nemen voor mij, de liftjes naar Gent en om cellen te fixeren tijdens mijn zwangerschap. Je bent een aanwinst voor de groep! Hetzelfde geldt voor jou, Ben. De enige man in ons gezelschap. We maken graag gebruik van je gestalte en spierkracht wanneer die van ons tekort schiet 😊. Ik wens jullie allebei veel succes in het onderzoek! Sjouke en Gerlinde, jullie waren de laatste aanwinsten van de ‘oude’ 1ste bureau. Sjouke, 1x deed je me enorm schrikken toen ik je op een zaterdag ochtend om 8h in je slaapzak aantrof op de grond van de 1ste bureau! Maar meestal was je verschijning minder schrikwekkend, en werkte je enthousiasme aanstekelijk. Gerlinde, in de eerste plaats bedankt voor het lezen van de eerste versie van deze thesis. Bedankt ook voor het delen van je ervaringen in de States. Ik wens je veel succes in je verdere carrière.

Een paar maand geleden brak er een nieuwe periode aan. De verhuis naar een nieuwe bureau! Mijn nieuwe bureaugenootjes Hanne, Miet, Karen en Inge zorgen opnieuw voor een opperbeste sfeer in den bureau zoals dat enkel op de virologie kan 😃!! Hanne wil ik in het bijzonder nog eens bedanken om chaperonne te spelen in het L3 labo van het UZ. Ik wens je veel succes in de komende maanden en ben er zeker van dat je een schitterend doctoraat zal afleggen. En Miet bedank ik graag voor het occasionele gezelschap op de bus en niet te vergeten, om me op te volgen als ‘voorzitster’ van de JC. Je doet het echt schitterend 😃! Karen en Inge, jullie ken ik eigenlijk nog maar pas, toch weet ik zeker dat er in de toekomst nog veel gelachen zal worden in de 1ste bureau van de para.
Heel recent traden nog 2 nieuwe leden toe tot de FIP groep, namelijk Dominique en Annelike. Dominique, jou kent ik al een beetje. Bedankt voor de leuke babbels en het bewaren van mijn geheimpje! Ik wens je een goede start toe met je onderzoek en veel succes op het IWT! Hetzelfde voor jou, Annelike!

Buiten mijn bureaugenoten zijn er nog een heel aantal mensen die me nauw aan het hart liggen. Lennert en Annelies, jullie heb ik pas het laatste jaar beter leren kennen maar die korte tijd leverde wel al veel leuke momenten op! Ik hoop dat er ook nog heel veel komen. Lennert, veel succes op het komende IWT van die van de para ☺! Ik weet zeker dat je veel in je mars hebt. Ik vind het ook super dat er eindelijk iemand is die even snel geëmotioneerd is als ik. Ik hoop dat we nog vele taartjes mogen wegpinken ☺! Annelies, bedankt voor het meermaals fixeren van celletjes voor mij de laatste maanden en om mee te gaan bloed nemen in het verlof, je was een natuurtalent! Veel succes met de verbouwingen. Mark, bedankt voor het gezelschap bij de wekelijkse afspraak met Filip op de fiets, de fatburning en/of de bodysculpt! Ik vond het fantastisch dat je steeds op de afspraak was en hoop snel terug met je aan de slag te kunnen gaan. Ook bedankt voor de hulp met de varkens voor Sebastiaan, als ‘kattenmadam’ was dat me niet alleen gelukt, vrees ik. Je had je plaatsje in mijn dankwoord dus al lang verdiend vóór je mijn chocomelkske in de pmd zak gooide ☺. Ook Wander wens ik heel hard te bedanken voor de interesse in mijn onderzoek en de vele babbels. Ook jij fixeerde mijn celletjes. Ik vind het ongelooflijk hoe je geëvolueerd bent van losbol student tot een rasecht onderzoeker! Ik wens je veel succes in de toekomst en ervan overtuigd dat je een mooie carrière wacht. Bedankt voor alle hulp en… voor het heel goed bewaren van een oud geheim ☺.

Ik ben niet de eerste en zal ook zeker niet de laatste zijn die de sfeer op de ‘Viro’ looft. De collegialiteit is uniek en de vriendschap helpt iedereen door de onvermijdelijke dipjes. Merijn, Iris, Peter D, Annick, Sabrina, Annebel, Kalina, Filip, Uladzimir, Dipo, Matthias C, Joao, … Thanks to all of you for contributing to the pleasant atmosphere in the lab! Iris, bedankt voor de gezellige babbels ‘onder de middag’. Ik wens je veel succes de komende maanden met het afronden van je doctoraat en een spetterend huwelijksfeest in 2010! Annick, bedankt voor de leuke babbels en de occasionele lift naar Gent!

En ook al delen ze een verdieping met ‘de immuno’, het blijven toch echte viro-collega’s en mogen zeker niet ontbreken in dit dankwoord: Nick, Céline, Nina en Matthias D. Nick, bedankt voor de interesse in leven en werk ☺. Ik wens je veel succes in de toekomst! Céline, bedankt voor het gezelschap bij de looptochtjes in het Zuidpark en veel succes met je
doctoraat! Matthias, bedankt voor de babbeltjes 's avonds, en vooral voor het aanbieden van je printer in tijden van crisis. Je bent altijd bereid anderen te helpen. Ik wens je veel succes bij het beëindigen van je doctoraat!


An D, je hebt het labo reeds verlaten maar toch bedankt voor het gezelschap op allerlei activiteiten buiten het labo en de leuke gesprekken bij de boterhammetjes 's middags. Ons uitstapje naar Parijs was onvergetelijk! Veel succes in je nieuwe job en veel plezier met je 2 mannen!

Ik wil ook een woordje richten aan Sebastiaan en Lowiese. Met Sebastiaan heb ik vorig jaar al veel plezier gehad in de varkensstallen, met Lowiese wordt het dit jaar vast even plezant als we beginnen worstelen met kattendarmen! Ik weet dat jullie de laatste weken niet veel
aan mij gehad hebben, hopelijk kan ik dat de komende weken goed maken vooraleer ik weer even verdwijn... 😊

Regelmatig eens stoom aflaten bij outsiders kan enorm deugd doen. Daarvoor kon ik altijd terecht bij mijn vriendinnen Evy, Ine en Valéry. Ik vind het super dat we na al die jaren nog steeds contact hebben. Al onze bijeenkomsten - vooral die zonder de mannen 😇 - werken echt therapeutisch! Dat blijven we doen hé! Ook Koker en Liesbeth en VB en Heidi, bedankt voor de interesse en de geruststellende woorden! Leentje en Eva, ook al zie ik jullie niet zo vaak, toch weet ik dat jullie er altijd zijn voor me en dat is vaak al genoeg!

Ook op het thuisfront heb ik altijd al de onvoorwaardelijke steun gekregen van mijn familie. Pepe André en al zijn nakomelingen 😊 (Christine en Ivan, Wouter en Brecht, Claudine en Johan, Ruben en Laure, Jan, Jo en Barbara met de kleine Emma) informeerden regelmatig hoe het nu ging. Ik vind het fantastisch dat er zo een sterke band tussen ons allen bestaat en hoop dat we - ondanks het steeds toenemende aantal - elke gelegenheid blijven aangrijpen om samen te komen om te vieren. Mijn broer Dieter en Lotte dank ik voor de interesse en de vele vragen - vooral van Lotte - om toch maar een beeld te krijgen van waar ik me nu eigenlijk mee bezig hou 😊. Maar belangrijker, zorgden ze altijd voor welkome afleiding en ontspanning met onze petekindjes June en Jade. Last maar allesbehalve leest dank ik mijn mama. Eerst en vooral voor het strijken van tientallen hemden in de laatste maanden, en voor de spaghettisaus en andere spijzen, de afgelopen jaren. Maar vooral bedankt voor al het niet-praktische dat je voor mij gedaan hebt, te veel om met woorden te omvatten en alles behalve vanzelfsprekend. Bedankt voor alle kansen die je me gegeven hebt, de vrijheid ook om te doen wat ik wilde, zoals ik het wilde. Ik hoop dezelfde mama te kunnen zijn voor mijn kindjes.

Ook mijn ‘schoonouders’ Marcel en Monique wens ik te bedanken voor hun interesse en steun en hun geloof in mij. Bedankt dat we regelmatig de beentjes onder tafel mochten steken en bedankt voor alles wat jullie al voor mij gedaan hebben! Thomas en An, bedank ik voor het delen van hun werkervaringen en voor het luisteren naar de evoluties in mijn onderzoek op zondagmiddag.

Mijn laatste woorden wijd ik aan jou, mijn schatteke. Want zoals je vaak gezegd hebt, is dit ook een beetje jouw doctoraat, meer dan een beetje zelfs... De avonden dat ik er niet was, er geen eten was en dat je me in de late uurtjes of midden in een spannende voetbalmatch 😊 kwam halen, het weekendwerk, de crisismomenten, mijn spullen op vrijdag gaan halen en
op zondag terug brengen naar het labo, ... niets was je te veel! Zelfs niet het voederen van de dieren en ruimen van maden in de zomervakantie 😊. Bij het schrijven van de thesis werd je zonder morren even huisman en zorgde je ervoor dat ons huisje proper was, de ‘waskes’ gedaan werden, dat er eten in huis was en de afwas gedaan werd. Dit alles terwijl je het zelf op het werk ook super-druk had. Al die tijd heb je me gesteund en verbaasd met je niet aflatende geloof in mij! Zonder jou was dit niet mogelijk geweest! Bedankt voor alles! Ik kijk uit naar al wat komen zal samen met jou! Later in ons eigen huis, maar vooral heel binnenkort, met ons drietjes...

Evelien